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Abstract 
A key feature of chronic heart failure (CHF) is an inability of the heart rate 
(HR) to increase in proportion to the level of physical exertion, known as 
chronotropic incompetence (CI). Increases in HR during exercise contribute 
to an increase in cardiac output and hence greater blood supply to 
exercising peripheral muscles. It is generally assumed therefore that a 
limitation to heart rate rise might contribute to exercise intolerance. Whether 
CI is a causal factor in CHF has been a long-standing topic of debate and 
conflicting opinions. 
 
This thesis comprises a series of studies aiming to clarify the role of HR on 
exercise capacity in CHF. 
 
The observational study demonstrated a relationship between exercise 
capacity and heart rate rise, both of which are reduced in the context of 
heart failure. I have identified an association between the degree of CI and 
the extent of exercise capacity reduction in CHF, however this relationship is 
weaker with more severe CHF. 
 
I have also shown in two randomised controlled interventional double-blind 
crossover trials that increasing or decreasing the heart rate response in 
patients with CHF, does not result in any changes in exercise capacity.  
 
- vii - 
Finally, in a double blind case-control study, I have demonstrated a marked 
difference in heart rate related contractility in CHF compared to controls. 
This suggests that correcting CI may improve exercise capacity in controls 
by increasing cardiac output via increases in contractility, and this might not 
be the case in CHF.  
 
Based on these novel findings, I conclude that in patients with CHF, CI is a 
marker of reduced exercise tolerance in CHF, and cannot be considered to 
be a causal factor. Aggressively correcting CI should therefore not be 
pursued as part of the the symptomatic treatment of patients with moderate 
to severe heart failure in either sinus rhythm or atrial fibrillation. Instead the 
chronotropic adaptation seen with worsening heart failure should be 
optimised, with the aim to maintain the exertional heart rate rise between 50 
to 110 beats per minute. 
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Preface 
 
The close relationship between heart rate and exercise capacity, and limited 
techniques to detach one from the other means that published data are 
inconclusive. The purpose of this series of investigations is to determine the 
role of the heart rate on exercise capacity in heart failure.  
Chapter 1: Introduction to Heart Failure and Treatment  
 
1.1 Introduction 
 
The term heart failure (HF) refers to a common clinical syndrome that is the 
consequence of reduced cardiac pump function. This syndrome incorporates 
certain non-specific signs and symptoms, and can occur as a result of any 
mechanical, structural or electrical abnormality of the cardiac tissue. 
Impaired pump action also leads to myriad secondary consequences 
affecting various organs including kidneys, bone marrow and muscle.(1)  
 
The pathophysiology of chronic heart failure (CHF) and the basis of 
treatment are incompletely understood. There is a complex interaction 
between the reduced perfusion of organs and systemic neuro-hormonal 
processes, which is believed to contribute to and exacerbate the systemic 
organ dysfunction that exists in established HF. 
 
Thus ‘heart failure’ is a clinical syndrome in which the patient exhibits the 
typical HF signs and symptoms, along with objective evidence of impaired 
cardiac output at rest. 
 
The term ‘heart failure’ encompasses any structural or functional impairment 
of either left ventricular filling in diastole or emptying during systole. Thus HF 
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can range from those with impaired ventricular filling but normal LV size and 
ejection fraction (EF), referred to as heart failure with preserved ejection 
fraction (HFpEF), to those with reduced EF and/or ventricular dilatation, 
known as heart failure with reduced ejection fraction (HFrEF). Most 
randomised controlled trials have enrolled patients with HFrEF, also known 
as systolic heart failure or left ventricular systolic dysfunction (LVSD).  
 
At the time of writing, effective proven therapies are only available for the 
treatment of systolic heart failure. Furthermore, making the diagnosis of 
HFpEF is often challenging and relies on both the exclusion of non-cardiac 
causes for the HF symptoms, as well as multiple testing modalities to 
demonstrate LV wall stiffness and impaired diastolic LV function.  
 
Chronic dysfunction of ventricular function results in abnormal remodelling 
which varies depending on the HF type, although often elements of both 
HFrEF and HFpEF co-exist. In pure HFpEF, LV cavity size is usually normal, 
however LV wall thickness and stiffness are both increased. In contrast, 
patients with predominant HFrEF usually develop LV dilatation.  
 
Cellularly this represents a reduction in both cardiomyocyte density and 
diameter compared to HFpEF.(2) A difference in the extracellular matrix 
(ECM) has also been reported, with increased ECM synthesis due to 
enhanced inhibition of matrix metalloproteinases (MMPs) leading to 
increased LV wall stiffness and fibrosis, seen in HFpEF. Conversely, an 
increased in MMP function has been reported in the context of LV volume 
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overload and LV dilatation, seen in HFrEF.(3)  All types of HF are associated 
with an increased myocardial cell death rate and abnormal cytoplasmic 
calcium cycling.(4)(5) 
 
Using the current guidelines, it would have been difficult to accurately and 
confidently identity a group of patients with pure HFpEF. Thus this 
investigation in to the role of the heart rate will focus on those patients with 
symptoms that are predominantly due to HFrEF, defined as symptoms of 
HF, either at rest or on exertion, with objective evidence of LVSD.(6)  
 
 
1.2 Epidemiology  
 
HF affects 2% of the adult population in developed countries,(7)(8) and 
approximately 10% of over 65 year olds. The incidence has remained stable 
for the past 20 years,(9)(10) but the prevalence of the condition is 
increasing, partly as a result of decreasing mortality from ischaemic heart 
disease, advances in effective treatment regimens for CHF and an ageing 
population.(11)(12)  
 
HF is the most common cause for hospital admission in those over 65 years 
old, and accounts for 5% of all hospital admissions.(12)(13) In addition to 
this, approximately 40% of patients die within one year of being newly 
diagnosed with heart failure.(14) Current overall mortality from CHF is 50% 
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in four years, worse than the long-term prognosis following myocardial 
infarction or for most cancers.(15)  
 
Features suggestive of particularly poor prognosis include increased age, 
reduced functional capacity, male sex, coronary artery disease, low blood 
pressure, renal function impairment, hyponatraemia, and high plasma brain 
natriuretic peptide levels. 
 
HF also results in more primary care consultations than angina, reflecting 
the impact of the syndrome on the overall quality of life of those affected.(16) 
It greatly impairs physical functioning as a result of persistent fatigue and 
dyspnoea.(17) This negative impact on exercise capacity exceeds that of 
other major chronic conditions such as chronic lung disease, diabetes or 
arthritis.  
 
Better treatment of heart disease and an increase in cardiovascular risk 
factors such as diabetes and obesity, especially pertinent as healthy 
lifestyles continue to decline in countries with emerging economies, means 
that a new increase in global incidence of CHF is underway.  
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1.3 Aetiology 
 
HF is a symptomatic syndrome resulting from any structural, electrical or 
mechanical cardiac abnormality that affects ventricular function occurring 
due to a multitude of causes. HF in developed countries is usually due to 
ischaemic heart disease,(18) with LVSD occurring as a result of myocardial 
infarction (MI) or severe coronary artery disease (CAD). Hypertension is the 
largest contributor to CAD, and together these two conditions form the most 
common causes of cardiac dysfunction.(19) The most important global risk 
factors for ventricular dysfunction are therefore hypertension, diabetes and 
obesity.(19)(20)(21) 
 
Valvular disease can also lead to pump failure, due to cardiac pressure and 
volume overload. The most common causes for this are rheumatic valvular 
disease in developing countries, and degenerative valvular disease 
elsewhere.(22) Exposure to toxins, including chemotherapy agents, and 
excessive alcohol consumption can also result in a dilated 
cardiomyopathy.(23) Idiopathic cardiomyopathies account for a significant 
minority of cases.(24)  
 
Arrhythmias such as atrial fibrillation (AF) are frequently associated with 
CHF, but these are more commonly due to cardiac structural changes, 
rather than the cause thereof.(25)  
- 6 - 
1.4 Systolic Heart failure and diastolic heart failure 
 
The focus of this thesis is exploring the relationship between heart rate and 
exercise capacity in the context of chronic stable left ventricular systolic 
dysfunction (LVSD). Diastolic left ventricular dysfunction is often found to 
varying degrees in association with hypertension, valvular dysfunction, 
ischaemic heart disease, and as a normal part of the ageing process.(26) It 
is characterised by left ventricular hypertrophy and abnormal 
echocardiographic Doppler parameters, which frequently co-exist with 
systolic dysfunction.(27)(28)  
 
Definitions for diastolic impairment vary, especially across research studies. 
There is also often an apparent mismatch between the degree of diastolic 
impairment and patient symptoms.(26) Nonetheless, this is in important 
condition, as the subgroup of patients with diastolic functional abnormalities 
has worse outcomes than those with normal cardiac function.(29) Whether 
this is purely a reflection of the underlying causal pathology remains unclear.  
 
As a result, the clinical management of patients with diastolic HF continues 
to be both a diagnostic and a therapeutic challenge.(30) There is a lack of 
clarity and poor current understanding of diastolic heart failure, and how it 
impacts functional capacity. Thus, isolated diastolic heart failure is 
considered outside the scope of this discussion and the investigations that 
will follow. Henceforth, the term ‘heart failure’ will refer exclusively to chronic 
LVSD.  
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1.5 Pathophysiology 
 
1.5.1 Acute compensatory changes 
The pathophysiology of the cardiac response to an acute cardiac injury is 
well understood. In the face of a myocardial infarction for example, stroke 
volume is initially maintained through the Frank-Starling mechanism.(31)(32)  
 
Stroke volume and ventricular function depend on a combination of preload, 
myocardial contractility and afterload. In the ischaemic model of HF, the 
sudden fall in stroke volume due to cardiac damage results in a rise in end 
diastolic volume, and hence, pressure. The abrupt rise in preload results in 
increased cardiac muscle fibre stretch. This results in increased contractile 
force due to augmented calcium ion sensitivity in response to the reduction 
in lateral interfilament spacing as a consequence of sarcomere stretch.(33) 
Similar maladaptive changes also occur as a result of valvular, hypertensive 
and idiopathic cardiomyopathies, however the onset is usually more 
insidious, with end-diastolic pressure usually being the first parameter to 
alter. 
 
Thus, the preload and the end-diastolic pressures play a crucial role in 
maintaining adequate stroke volumes in the failing heart regardless of 
aetiology.(34) The degree of contractile force can also vary due to intrinsic 
factors such as the levels of intracellular ions, especially calcium and also as 
a consequence of pharmacological therapies.  
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1.5.2 Chronic structural remodelling 
Cardiac output is also regulated by a complex interplay of humoral, 
autonomic and intracardiac regulatory mechanisms, which can become 
compromised as a consequence of the maladaptive changes in all types of 
CHF.(35)  Afterload also plays a role, and increases in this due to arterial 
constriction and stiffening will result in greater impairment of ventricular 
function, and reduction in the stroke volume.  
 
The rise in afterload and the increases in preload due to volume expansion 
and higher venous return are compensated for initially, through the 
development of concentric ventricular hypertrophy in order to maintain 
normal systolic wall stress.  
 
Prolonged pressure overload will eventually cause this adaptation to be 
insufficient, and ventricular dilatation will occur. This may also cause 
functional mitral regurgitation due to changes in the shape of the mitral 
annulus, thus exacerbating the problem and causing further progression of 
the ventricular dysfunction.  
 
1.5.3 Neurohormonal adaptation and adverse long term effects 
The reduction in cardiac output over time triggers various neurohormonal 
pathways, such as the sympathetic nervous system and renin-angiotensin-
aldosterone system, in order to maintain vital organ perfusion. These 
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compensatory mechanisms attempt to maintain systemic pressure and 
organ perfusion via vasoconstriction, and improve cardiac output by 
increasing myocardial contractility, heart rate and volume expansion through 
sodium retention and renin release.  
 
Renin release leads to increased angiotensin II production, which in turn 
contributes to increased plasma aldosterone levels and vasopressin release, 
resulting in sodium and water retention, and enhanced myocardial 
remodelling.   
 
Volume expansion is initially effective as the increase in end diastolic volume 
results in an increase in stroke volume via the Frank-Starling principle in 
response to the increased preload. However, the elevated diastolic pressure 
is transmitted into the venous circulation and can lead to pulmonary 
congestion or peripheral oedema.(36) 
 
Although initially compensatory, the sarcomere stretch due to increased 
pressure can eventually reach a suboptimal stage such that contractile force 
is reduced. This becomes most pronounced with exertion, leading to 
exercise related decreases in ejection fraction and cardiac output. (37)  
 
Sympathetic system activation initially results in maintained organ perfusion 
through increased heart rate and peripheral vasoconstriction. However, 
these changes result in increased afterload, which depresses cardiac 
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function, and increases myocyte ischaemia, resulting in damage. Apoptotic 
myocyte loss results in fibrosis, hypertrophy, cardiac chamber dilatation and 
remodelling, with associated electrical instability.(38)(39)  
 
Thus sustained activation of neurohormonal mechanisms will result in a net 
worsening of the heart failure over time due to progressive loss of cardiac 
function and direct effects on myocardial remodelling, along with systemic 
maladaptive changes.(40)(41) These are a result of chronic oxidative stress, 
inflammation and loss of tissue, leading to muscle wasting, cachexia and 
osteoporosis.(42) 
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1.6 Diagnosis 
 
The characteristic feature of heart failure is impaired cardiac pumping 
function. However, patients present with non-specific signs and symptoms, 
which have poor sensitivity and poor specificity, most commonly, fatigue and 
shortness of breath (table 1.1 and table 1.2).(43) Accurate diagnosis 
requires clinical evaluation, along with relevant investigations in order to 
demonstrate signs, symptoms and objective evidence of a cardiac 
abnormality that would be consistent with a diagnosis of heart failure. 
Further investigations are sometimes needed in order to determine the 
underlying aetiology.(44) 
 
Symptom Sensitivity (%) Specificity (%) 
dyspnoea 66 52 
orthopnoea 21 81 
paroxysmal nocturnal dyspnoea 33 76 
history of oedema 23 80 
Table 1.1 Sensitivity and specificity of symptoms in diagnosing chronic heart failure 
 
1.6.1 Signs 
Heart failure signs occur due to the reduction in cardiac output at rest, and 
impaired increase with exertion. Tissue perfusion is also reduced as a 
consequence of this, leading to a variety of signs such as resting sinus 
tachycardia, narrow pulse pressure, diaphoresis, peripheral constriction with 
cool, pale peripheries and reduced urine output.(45)  
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Reduced cardiac output also triggers the neurohormonal adaptations that 
lead to volume expansion and fluid retention. This manifests itself as 
pulmonary congestion, peripheral oedema and raised jugular venous 
pressure (table 1.2).(43) (46) Left ventricular dysfunction and enlargement 
can also result in a third heart sound on auscultation and a laterally 
displaced apex beat, which are both strong predictors of heart failure. One 
study has shown a combination of past history of myocardial infarction and 
displaced apex beat have the best combined specificity and sensitivity, with 
high positive and negative predictive value.(47) 
 
Sign Sensitivity (%) Specificity (%) 
raised JVP 10 97 
third heart sound 31 95 
peripheral oedema 10 93 
tachycardia 7 99 
crepitations 13 91 
Table 1.2 Sensitivity and specificity of diagnostic signs in individuals with suspected heart 
failure  
 
 
1.6.2 Symptoms 
In advanced heart failure, patients often present with symptoms of fatigue, 
dyspnoea in a recumbent position (orthopnoea) and acute episodes of 
paroxysmal nocturnal dyspnoea.(48) The low cardiac output leads to 
lethargy and poor exercise tolerance. Once such symptoms are present 
(table 1.1), a physical examination (table 1.2) and further investigations are 
needed in order to confirm the diagnosis. 
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1.6.3 Investigations 
An electrocardiogram (ECG) is useful in supporting the diagnosis of heart 
failure and also to investigate the presence of any co-existing arrhythmias or 
evidence of ischaemic heart disease. A normal ECG has a 98 percent 
negative predictive value for systolic dysfunction.(49) A chest radiograph can 
also be useful for confirming a diagnosis of heart failure, as the presence of 
cardiomegaly or pulmonary oedema have high specificity (>90%), however it 
is important to recognise that both findings have poor sensitivity.(50)(51) 
 
Various further laboratory tests are recommended to aid diagnosis and guide 
treatment. These include full blood count, serum electrolytes (including 
calcium and magnesium), blood urea, serum creatinine, fasting blood 
glucose, lipid profile, liver function tests, serum thyroid-stimulating hormone 
and urinalysis.(1)(52)  
 
The measurement of either brain natriuretic peptide (BNP) or the N-terminal 
fragment of its prohormone (NT-proBNP) is also currently recommended in 
various guidelines.(1)(52) Studies indicate that measuring BNP or NT-
proBNP can assist in the diagnostic process, with BNP levels below 
100pg/mL having a very high negative predictive value for heart 
failure.(44)(46)(53) Elevated levels need to be interpreted in context and 
cannot be used to diagnose heart failure in isolation, given their high 
sensitivity but low specificity.(1)(44) Intermediately raised BNP or NT-
proBNP levels are neither specific nor sensitive for diagnosing heart failure, 
thus limiting BNP usefulness as a stand-alone test.(54)(55)   
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Echocardiography is a non-invasive diagnostic test around which the 
diagnosis of HF is usually based. It can be used to measure ventricular size, 
global function, regional wall motion abnormalities and the presence of any 
pericardial disease. This investigation is indicated when a patient presents 
with dyspnoea and the initial evaluation suggests that a cardiac cause is 
likely, or to assess for potential valvular abnormalities.(1)(52)(56)  
 
The sensitivity of two-dimensional echocardiography is around 80 percent 
and the specificity is almost 100 percent for detecting left ventricular 
dysfunction.(57) The key measure of left ventricular systolic function is 
determination of the left ventricular ejection fraction (LVEF), with values 
below 55% considered to represent reduced function. Diastolic dysfunction 
is more subtle, and is identified when there is abnormal left ventricular 
relaxation or diastolic stiffness.(6)(27)     
 
Heart failure and reduced cardiac output can occur as a result of either 
systolic or diastolic function. However symptomatic patients with normal left 
ventricular function and no echocardiographic abnormalities, including no 
evidence of restrictive or obstructive cardiomyopathies, often have an 
alternative diagnosis than diastolic dysfunction, such as coronary ischaemia, 
respiratory disease, intermittent arrhythmia, detraining or obesity.(58)  
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Investigations such as coronary angiography, cardiac magnetic resonance 
imaging and endomyocardial biopsy may be indicated once a diagnosis of 
dilated cardiomyopathy is made following an echocardiogram, in order to 
confirm the aetiology. Further investigations should also be considered if the 
underlying aetiology is not apparent from the history or if the disease 
progression and response to treatment are atypical (table 1.3).(1) 
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Class I - Evidence and/or general agreement that initial evaluation should include the following 
assessment: 
• History and physical examination to identify disorders associated with development or progression of HF. 
• Use of alcohol, illicit drugs, standard or "alternative" therapies, and chemotherapy drugs. 
• Ability to perform routine and desired activities of daily living. 
• Volume status, orthostatic blood pressure changes, height, weight and calculation of body mass index. 
• Laboratory studies including full blood count, urinalysis, serum electrolytes (including calcium and 
magnesium), serum urea, serum creatinine, fasting blood glucose, lipid profile, liver function tests, and 
serum thyroid-stimulating hormone. 
• A twelve-lead electrocardiogram and chest radiograph. 
• Two-dimensional echocardiography with Doppler to assess left ventricular ejection fraction, left ventricular 
size, wall thickness, and valve function.  
• Coronary arteriography if there is a history or angina or significant ischemia unless the patient is not 
eligible for revascularization of any kind. 
Class IIa - Evidence or opinion in favour of performing the following studies: 
• Coronary arteriography in patients who have chest pain that may or may not be of cardiac origin who 
have not had a prior evaluation of their coronary anatomy and are eligible for coronary revascularization. 
• Coronary arteriography in patients with known or suspected coronary artery disease who do not have 
angina and are eligible for revascularization. 
• Noninvasive imaging to detect myocardial ischemia and viability in patients with known or suspected 
coronary artery who do not have angina and are eligible for revascularization.. 
•, Maximal exercise testing with measurement of respiratory gas exchange: to identify candidates for 
cardiac transplantation or other advanced treatments, or when contribution of HF to exercise limitation is 
uncertain. 
• Screening for hemochromatosis, sleep disturbed breathing, or human immunodeficiency virus infection, if 
indicated. 
• Diagnostic tests for rheumatologic disease, amyloidosis, or pheochromocytoma, if suspected clinically. 
• Endomyocardial biopsy when a specific diagnosis is suspected that would influence therapy. 
• Measurement of serum B-type natriuretic peptide (BNP) in the urgent care setting if the clinical diagnosis 
of HF is uncertain. Measurement of natriuretic peptides (BNP and NT-proBNP) can be useful in risk 
stratification. 
Class IIb - Evidence or opinion less well established for the following tests: 
• Noninvasive imaging to define the likelihood of coronary artery disease in all patients with left ventricular 
dysfunction. 
• Holter monitoring in patients who have a history of myocardial infarction and are being considered for 
electrophysiologic study to document the inducibility of ventricular tachycardia. 
Class III - Evidence and/or general agreement that the following tests are not useful or may be 
harmful: 
• Routine endomyocardial biopsy in the absence of suspicion of a specific diagnosis that would influence 
therapy. 
• Routine signal-averaged electrocardiography. 
• Routine measurement of serum neurohormones other than BNP (eg, norepinephrine or endothelin). 
Table 1.3 Adapted from ACC/AHA guidelines: Initial evaluation for heart failure (HF) 
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1.7 Classification 
 
The functional classification developed by the New York Heart Association 
(NYHA) is most commonly used to provide an estimate of physical 
limitation.(59) This is based on symptoms alone, and can thus reflect either 
an improvement or deterioration in clinical state.  
1. Class I — symptoms of HF only at activity levels that would limit 
normal individuals. 
2. Class II — symptoms of HF with ordinary exertion  
3. Class III — symptoms of HF with less than ordinary exertion  
4. Class IV — symptoms of HF at rest  
 
The American College of Cardiology/American Heart Association 
(ACC/AHA) classification system is also used, but less commonly than the 
NYHA classification. It provides information on the status of disease 
progression.(60)  
1. Stage A – Multiple risk factors for heart failure but no structural heart 
disease  
2. Stage B – Asymptomatic with evidence of structural heart disease  
3. Stage C – Structural heart disease and symptoms consistent with 
heart failure 
4. Stage D – Refractory heart failure 
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1.8 General treatment 
 
Ischaemic heart disease, particularly a history of myocardial infarction, and 
diabetes are the main risk factors for the development of systolic CHF. 
Others include hypertension, obesity, smoking, high resting heart rate and 
atrial fibrillation.(61)(62)(63) Thus, addressing these aspects through lifestyle 
changes, patient education and appropriate timely pharmacological 
interventions could reduce the incidence of CHF.(64) 
 
The aim of treatment in a heart failure patient is to control symptoms, reduce 
hospital admissions and improve mortality. Patient education on the 
aetiology, importance of adherence to treatment, benefits of medication 
dosage optimisation, early detection and promptly reporting any symptoms 
of deterioration can improve outcomes.(65) Structured aerobic exercise may 
also improve functional capacity and quality of life.(66) Fluid and sodium 
restriction may be indicated during episodes of decompensation, however 
there is no supporting evidence for these interventions from clinical trials.(1) 
Smoking is considered to be detrimental in heart failure, primarily due to its 
peripheral vasoconstrictive effects.(1) 
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1.9 Pharmacological treatment  
 
Pharmacological therapy is the mainstay of treatment, with the key goals 
being symptomatic relief, slowing progression of the disease process and 
increasing survival. Current pharmacological treatments are aimed at 
inhibition of the two major neurohormonal pathophysiological mechanisms 
that underlie the progression and development of CHF, namely the renin-
angiotensin-aldosterone system and the sympathetic nervous system.  
  
1.9.1 Diuretics 
The mechanism of action of diuretics is to block sodium reabsorption in the 
renal tubules resulting in increased urinary sodium and water excretion. 
Diuretic therapy has minimal effect on mortality or morbidity, but provides 
rapid and effective symptomatic relief.(67) The aim is to use the lowest 
dosage possible in order to maintain a euvolaemic asymptomatic state. 
 
Thiazide diuretics can be used when there is mild heart failure with normal 
renal function. These work by inhibiting sodium re-absorption at the 
beginning of the distal convoluted tubules. Loop diuretics, which inhibit 
sodium and chloride reabsorption from the ascending limb of the loop of 
Henle in the renal tubules, are more potent and their effect is preserved in 
the presence of renal impairment.   
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Thiazide and loop diuretics may be used in combination, but the resultant 
profound diuresis usually requires close monitoring of electrolyte levels. 
Effective diuresis can be measured with the use of daily patient weight 
assessment when performed in a standardised way.(1)(68) 
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1.9.2 Angiotensin converting enzyme inhibitors 
Angiotensin converting enzyme inhibitors (ACEi) competitively inhibit the 
conversion of inactive angiotensin I to the active angiotensin II. ACEi also 
inhibit the kininase enzyme, which is involved in bradykinin degradation.(72) 
This inhibition results in kinin accumulation, which might be an important 
secondary action, since bradykinin is a potent endothelium-dependent 
vasodilator, and causes natriuresis. It is also responsible for a dry persistent 
cough in around 10%-20% of patients.(69)(70)  
 
ACEi lead to lower levels of angiotensin II and aldosterone. Angiotensin II 
causes systemic and coronary vasoconstriction, increased sympathetic 
activity and catecholamine release, increased aldosterone and vasopressin 
release, inhibition of endothelial nitric oxide synthase and cardiac myocyte 
hypertrophy.(71) These effects are a potent stimulus for adverse cardiac 
remodelling.(72) Aldosterone causes sodium and water retention, 
sympathetic activation and also leads to cardiac fibrosis. 
 
As a result, ACEi therapy reduces mortality and hospitalisation rates, as 
demonstrated in multiple large prospective randomised controlled trials 
(CONSENSUS, V-HeFT-II and SOLVD trials).(77)(73)(78) Randomised 
controlled trials have also demonstrated that ACEi usage increases survival 
in patients who develop systolic dysfunction following a myocardial infarction 
(SAVE, AIRE, TRACE trials).(74)(75)(76) 
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These benefits have been demonstrated regardless of the presence of 
symptoms, thus all patients with any grade of systolic dysfunction should be 
initiated on low dose ACEi therapy.(77)(78)(79)(80)  This should be 
uptitrated to either the target doses used in relevant RCTs or the maximum 
tolerated dosage, whichever is lower, over several weeks in order to 
maximise efficacy (ATLAS trial).(81) Possible side effects are cough, 
hypotension and renal function impairment. 
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1.9.3 Angiotensin II Receptor Blockers 
Angiotensin II receptor blockers (ARB) block the binding of angiotensin II to 
the AT1-receptor (Angiotensin II receptor, type 1), which mediates the 
vasoconstrictor and left ventricular remodelling effects of angiotensin II, with 
no effect on kininase function.(82) Based upon the CHARM study series, 
current guidelines consider ARBs to be a suitable alternative to ACEi in 
those patients with heart failure who are intolerant of ACE inhibitors or have 
developed a persistent cough secondary to kinin accumulation.(52)(83)  
 
1.9.3.1 Combining ACEi and ARB 
ACEi and ARBs can be combined, but although this probably reduces 
hospitalisation rates, there is no benefit on mortality and an increased side 
effect rate.(84) In addition, a Cochrane review of outcomes comparing ACEi 
monotherapy to ACEi and ARB combination revealed no statistically 
significant difference in mortality.(85) Similar results were seen in the 
VALIANT post-infarction heart failure trial where there was an increase in the 
occurrence of adverse events with combined therapy and no additional 
benefit in comparison to monotherapy with either drug group.(86)  Thus, 
ARB agents are only used in addition to ACEi in those patients who have not 
had a recent MI, remain symptomatic despite optimal treatment with ACEi 
and are intolerant of beta blockers and aldosterone antagonists. 
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1.9.4 Beta-blockers 
Beta-receptor antagonists (known as beta-blockers) inhibit the effects of 
adrenaline and noradrenaline on beta-receptors, and as such are capable of 
reducing activation of the sympathetic nervous system. Since this is 
chronically overactive in patients with HF, these agents are a logical choice 
and indeed data from several large randomised placebo-controlled trials 
describe improved survival and hospitalisation rates.  
 
There is often a dramatic slowing in the progression of the condition and a 
reversal of adverse remodelling especially when these agents are added to 
an ACE inhibitor, regardless of aetiology (CIBIS-II, MERIT-HF, 
COPERNICUS).(87)(88)(89)  
 
Beta-blockers should be introduced early, starting at a low dose and then 
up-titrated to the target dosage over several weeks, with regular patient 
monitoring for hypotension and bradycardia. Symptomatic worsening due to 
transient fluid retention can be resolved by temporarily increasing diuretic 
therapy rather than stopping beta-blockers.  
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1.9.5 Aldosterone antagonists 
Aldosterone is a steroid hormone with mineralocorticoid activity that is 
mostly released by the zona glomerulosa region of the adrenal cortex in 
adrenal glands, although some is also produced by myocardial tissue in 
proportion to the degree of heart failure severity. In health, aldosterone plays 
a crucial role in blood pressure regulation, by acting on the renal nephron 
distal tubule and collecting duct to promote sodium and water retention, in 
response to increases in Angiotensin II levels. It is also involved in vascular 
remodelling, inducing LV hypertrophy and renal mesangial cell 
proliferation.(90) 
 
Aldosterone levels are often increased in heart failure, leading to cardiac 
hypertrophy, fibrosis and electrical remodelling.(91) Aldosterone antagonists 
act directly to block mineralocorticoid receptors including those of the heart, 
thereby reducing salt and water retention, along with reduced progression 
and sometimes regression of myocardial fibrosis.(92)(93) 
 
Several randomised trials have shown a reduction in hospitalisation rates 
and mortality of patients with mild-moderate (EMPHASIS HF trial) or severe 
(RALES trial) HF symptoms, as well as those who develop HF following an 
MI (EPHESUS trial) with the use of aldosterone antagonists.(94)(95)(96)  
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Aldosterone antagonists have several important consequences in a heart 
failure population. They preserve serum potassium levels by reducing renal 
potassium excretion, thus counteracting the hypokalaemia associated with 
the use of loop diuretics. The use of aldosterone antagonists is also 
associated with a reduction in cardiac arrhythmias and sudden death.(97) A 
retrospective analysis of data from the SOLVD trial demonstrated increased 
arrhythmic mortality in HF patients who were treated with non-potassium 
sparing diuretics, while no such association has been demonstrated with 
potassium sparing agents.(98)  
 
Aldosterone antagonists should be considered in those patients who remain 
symptomatic despite optimal treatment with diuretics, angiotensin converting 
enzyme inhibitors and beta-blockers.(99) Treatment should be initiated at 
low doses with careful monitoring of serum potassium and renal function.  
 
Non-selective aldosterone antagonists (spironolactone) may also inhibit 
androgen receptors resulting in antiandrogenic effects such as painful 
gynaecomastia, decreased libido and menstrual irregularities.(100) 
Epleronone is more specific, and therefore avoids these side effects. 
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1.9.6 Digoxin 
Digoxin is a formulation of digitalis glycoside, which increases intracellular 
calcium and myocardial contractility by inhibiting the cell membrane sodium–
potassium adenosine triphosphatase (ATP) pump in myocardial cells.(101) 
Digoxin also has antiadrenergic effects, which result in augmentation of 
parasympathetic tone and sympathetic inhibition, leading to a decrease in 
the heart rate.  
 
In patients with heart failure in sinus rhythm, digoxin has been shown to 
reduce hospital admissions, without any reduction in mortality.(102) A recent 
systemic review and meta-analysis of RCTs and observational data has also 
concluded that digoxin use in CHF has not been shown to reduce mortality 
risk.(103)   
 
Thus, the addition of digoxin in a patient who is in sinus rhythm is only 
recommended if symptomatic heart failure remains despite therapy with ACE 
inhibitors, beta-blockers and either ARBs or aldosterone antagonists.(1) A 
loading dose of digoxin is not needed in stable patients in sinus rhythm, and 
a steady state is usually reached 7–10 days after starting treatment.(104)  
 
In patients with atrial fibrillation, digoxin can also be initiated in order to 
control the ventricular rate, if beta-blockers are contra-indicated or side 
effects limit their dose. Given its effects on heart rate and cardiac 
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conduction, digoxin should be avoided in patients who have high degrees of 
atrio-ventricular block, sick sinus syndrome and pre-excitation syndromes.  
 
Digoxin has a narrow therapeutic window so monitoring serum digoxin 
concentration is useful in guiding treatment. Hypokalaemia and renal 
dysfunction increase susceptibility to adverse effects, which include 
anorexia, nausea, arrhythmias, visual disturbances and confusion. Certain 
cardiac medications can also increase serum digoxin concentration, 
including amiodarone, verapamil and diltiazem.  
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1.9.7 Hydralazine and isosorbide dinitrate  
One of the major pathophysiological features of heart failure is persistent 
vasoconstriction. Vasodilation, usually achieved with ACEi leads to improved 
outcomes. However, some patients cannot tolerate ACEi or ARB, and others 
have such severe renal dysfunction that optimal titration of these agents is 
difficult. Another way to achieve arterial and vasodilation is with a 
combination of hydralazine and isosorbide dinitrate. Combined therapy with 
these agents reduces both preload and afterload, and is associated with 
reduced adverse cardiac remodelling.(105) 
 
These effects result in a mortality benefit that has shown to be more 
significant in the African-American population and has only been 
demonstrated with this combination of vasodilating agents (V-HeFT 
trials).(73)(106)(107)  
 
Although ACE inhibitor therapy produces a greater reduction in mortality 
compared to the hydralazine plus isosorbide dinitrate combination in an 
unselected population, ACEi are less effective in the African-American 
population. Combining ACEi with hydralazine and isosorbide dinitrate in 
African-American patients seems to have additional benefits, with reduced 
mortality, less hospital admissions and improved quality of life (A-HeFT 
trial).(99)(108)  
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The addition of hydralazine plus isosorbide dinitrate may also be considered 
as an alternative in those patients with a left ventricular ejection fraction less 
than 40 and who are intolerant of ACE inhibitors and ARBs.(1)  
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1.9.8 Selective sinus node inhibitors (Ivabradine) 
Ivabradine is a selective inhibitor of the sino-atrial ‘funny’ channels, that are 
responsible for generating the spontaneous If cardiac pacemaker current. 
The degree of activation is the key determinant of the rate of diastolic 
depolarisation.(109)  At therapeutic doses, ivabradine specifically lowers the 
heart rate in sinus rhythm, and is not known to have any additional cardiac 
or vascular effects.(110) Furthermore, the magnitude of If current inhibition 
achieved with ivabradine is proportional to the resting heart rate (RHR), 
demonstrating a plateau-dose effect. Thus severe sinus bradycardia is 
uncommon, and there is no known torsadogenic potential.  
 
Analysis of data from the BEAUTIFUL trial in which 10,917 patients patients 
with CAD and LVSD were randomised to placebo or ivabradine, suggested 
that even though HR reduction was not shown to improve outcomes in all 
patients with stable CAD and LVSD, there was a reduction in CAD outcomes 
in those with heart rates below 70 beats per minute.(111)  
 
Ivabradine was subsequently investigated in the SHIFT trial,(112) which 
demonstrated a reduction in the primary end-point of hospitalisation or 
cardiovascular death when compared to placebo. Analysis of the placebo 
arm highlighted that a higher RHR is a continuous marker of disease, and 
the study results clarified once again that RHR is a target for treatment. 
Higher heart rates were shown to be associated with significantly higher 
mortality, with an sixteen percent increase in cardiovascular death or heart 
failure hospitalisation for every five beats per minute increase in heart rate.
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1.9.9 Thromboprophylaxis: Antiplatelets and anticoagulation 
Patients with HF, even those in sinus rhythm (SR), but especially those with 
atrial fibrillation (AF), are at increased risk of thromboembolic stroke. Those 
with HF and AF should be anticoagulated, but despite multiple studies 
comparing antiplatelet and anticoagulation therapy in CHF with sinus rhythm 
there are no convincing data that patients with HF and SR should receive 
formal anticoagulation.  
 
The Warfarin versus Aspirin in patients with Reduced Cardiac Ejection 
Fraction study (WARCEF study(113): warfarin (INR aim 2.5), aspirin 325 mg, 
placebo), Warfarin/Aspirin Study in Heart failure study (WASH study(114): 
warfarin, aspirin 300 mg daily, placebo), Heart failurE Long-term 
Antithrombotic Study (HELAS Study(115): aspirin 325 mg daily or warfarin 
for patients with ischaemic heart disease and warfarin or placebo in the non-
ischaemic group) and Warfarin and Antiplatelet Therapy in Chronic Heart 
failure study (WATCH study(116): warfarin, clopidogrel 75 mg daily, aspirin 
162.5 mg daily) all failed to demonstrate any difference in all-cause mortality, 
myocardial infarction or stroke. 
 
Thus, each of these studies suggested that anticoagulation was no better 
than aspirin therapy in patients with CHF and no other indications for 
anticoagulation.(117) The paradox is that there is of course also no evidence 
for the routine use of aspirin in heart failure patients whether they have a 
history of ischaemic heart disease or not, although it is recommended in 
guidelines.(118)(119) 
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1.9.10 Other antiarrhythmic medication 
Despite the high incidence of fatal ventricular arrhythmias and sudden 
cardiac death in this patient group, there is no evidence that antiarrhythmic 
agents other than beta-blockers, improve survival in heart failure.(120) This 
is probably due to the fact that a ventricular arrhythmia most frequently 
represents a serious heart failure problem that is not reversed by treatments 
targeting the arrhythmia. 
 
No systemic reviews or RCTs have looked specifically at class 1 
antiarrythmics such as propafenone, flecanide and moricizine, however 
extrapolated evidence from post MI treatment studies suggests there may be 
increased mortality with antiarrythmic medications, other than amiodarone or 
beta-blockers, in the context of HF.(121) RCTs of amiodarone use in HF 
also do not provide strong evidence for mortality benefits, despite effective 
arrhythmia suppression.(122)(123)  
 
The best treatments for ventricular arrhythmias would seem to be those that 
target the pathophysiology of the heart failure (beta-blockers, ACEi and 
spironolactone).(82)(88)(97) 
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1.10 Cardiac pacing in heart failure 
 
Implantation of a standard cardiac pacemaker can be utilised as an adjunct 
to medical therapy in the treatment of CHF. However the impact is 
dependent on the initial indication, device type and pacemaker programming 
mode. Standard pacing also allows more aggressive heart rate reduction 
and beta-blocker therapy in CHF, as the risk of inducing significant 
bradycardia is minimised. This confidence often leads to better optimisation 
of therapy. 
 
1.10.1 Right ventricular pacing 
Right ventricular (RV) pacing is the simplest and earliest form of pacemaker 
therapy, most commonly utilised in the treatment of intermittent high level AV 
block. However, delivering a pacing stimulus from the RV apex results in an 
abnormal conduction pattern similar to that of left bundle branch block which 
results in dyssynchronous ventricular activation. This can lead to ventricular 
dysfunction due to a combination of atrio-ventricular (RV contraction not 
related to atrial contraction), inter-ventricular (RV contracts before LV) and 
intra-ventricular (septum contracts before lateral wall) dyssynchrony. The 
risk of developing left ventricular dysfunction is directly related to the degree 
of RV pacing exposure (percentage of RV pacing, %RVP).(124) High %RVP 
can also exacerbate symptoms associated with existing CHF, due to the 
reduction in cardiac pumping capability.(125) 
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1.10.2 Dual chamber pacing 
Pacing in both the right atrium and right ventricle (dual chamber pacing) has 
several advantages over RV pacing that were thought to be relevant in the 
context of CHF.  
 
In patients with underlying SR and intact atrioventricular (AV) conduction, 
atrial pacing can restore normal electrical synchrony. AV pacing has also 
been shown to be superior to ventricular pacing with regards to 
haemodynamics, improved cardiac output and optimising valve closure to 
minimise mitral regurgitation.(126)   
 
Atrial systole as a consequence of an atrial based pacing system results in 
an increase in ventricular end-diastolic volume and cardiac fibre stretching. 
This results in an improvement in the end-systolic contraction, in keeping 
with the Frank-Starling principle.(127) Thus sequential AV pacing results in 
an increase in cardiac output when compared to single-chamber ventricular 
pacing (VVI) modes, ranging from 15% to 50%.(128)(129) 
 
Several clinical trials have compared ventricular (VVI) and atrial/dual (AAI or 
DDD) pacemaker programming modes to investigate whether restoring 
atrioventricular synchrony is associated with any clinical benefits in terms of 
quality of life or outcomes.  
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In a large observation epidemiological study of >36,000 elderly Medicare 
patients with pacemaker implants (PASE study), DDD pacing was 
associated with lower mortality at 1 and 2 years compared to VVI 
pacing.(130) However observational studies such as this are limited due to 
the potential for confounding bias based on patient selection, and there were 
many differences present between the demographics of the two groups. 
However dual chamber pacing remained an independent predictor of 
survival even after adjustments were made for differences between the two 
patient groups. Several large scale randomised trials have also compared 
dual chamber with ventricular pacing, reporting the benefits of sequential 
pacing modes (AAI/DDD). 
 
Anderson et al compared AAI and VVI in a randomised trial with a cohort of 
225 patients with sinus node disease (SND), and demonstrated that atrial 
pacing was associated with more favourable long-term clinical end-points 
including improved mortality.(131)  
 
Similarly, the PAC-A-TACH trial showed mortality benefit with DDDR pacing 
when compared to VVIR in a cohort of 200 subjects with SND.(132)  
 
The Mattioli et al trial compared physiological (atrial based: AAI, DDD, VDD) 
pacing modes with VVI pacing in 210 patients. The results showed reduced 
incidence of stroke and atrial fibrillation in the physiological pacing 
group.(133) 
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The CTOPP study compared DDD(R)/AAI(R) modes with VVI(R) in 2568 
patients. The results showed a reduction in the development of atrial 
fibrillation in the atrial based pacing modes (AAI/DDD).(134) Similarly, the 
MOST study in 2002, which looked at 2010 patients with SND, demonstrated 
a reduction in AF and HF in the DDDR paced patients compared to 
VVIR.(135) 
 
Thus AV sequential pacing modes (AAI, DDD) are associated with lower 
mortality, reduction in risk of AF and HF, and improved quality of life, when 
utilised in a non-CHF population. 
 
These theoretical benefits led to a randomised trial in order to assess 
whether dual-chamber pacing could improve CHF outcomes in the absence 
of any pacing indications (DAVID trial). A comparison was made between 
dual chamber pacing (with rate adaptive pacing and resting paced HR 70, 
DDDR-70) and sinus rhythm (with RV pacing backup if the HR dropped 
below 40, VVI-40) in the context of LVSD, and no benefit was seen.(136)  
 
Similarly, post-hoc data analysis from the Mode Selection Trial (MOST), 
MADIT II, and Midas trials all revealed a proportionate increase in adverse 
HF outcomes with higher percentage of ventricular pacing therapy, 
regardless of the mode used (DDDR or VVIR).(137)(138)(139) Several 
studies have also assessed the impact of optimising atrio-ventricular delay 
- 38 - 
times (paced AV delay) in order to reduce MR severity and thus improve 
clinical outcomes in HF, with no differences seen between optimal medical 
therapy only and optimal medical therapy combined with dual chamber 
pacing.(140)  
 
Additionally, the use of pacemaker programming modes and settings to 
minimise RVP, such as long AV delays and low base rates, result in 
improved LV function without any adverse effects on symptoms, exercise 
capacity or quality of life.(141) Thus dual chamber pacing with a short AV 
delay has no role to play in the routine treatment of CHF, in the absence of 
other primary arrhythmic indications.(142) 
 
1.10.3 Rate adaptive pacing   
There has also been a focus on developing sensor technology to facilitate 
heart rate variation in response to physical activity, in patients with 
presumed chronotropic incompetence, with the aim to improve quality of life 
by reducing exertional fatigue.   
 
In the rate-adaptive pacing mode, motion sensors in the pacemaker device 
detect increasing levels of movement or activity akin to the swinging of a 
pendulum in response to increasing force. This is translated by various 
pacing algorithms to trigger a progressive increase in the rate at which the 
atria or ventricles are paced commensurate to the level of activity. 
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However, there is a paucity of research in this area with usage of rate 
adaptive pacing modes generally being based on general consensus or 
expert opinion, rather than any guidelines or class 1 evidence.  
 
The ADEPT trial in 2003 compared DDD and DDDR in 870 patients.(143) 
The primary end point was quality of life, and no differences were seen in 
the two groups. Similarly, the UKPACE study compared DDD vs VVI vs 
VVIR in 2000 patients. There was no difference in mortality between the 
groups.(144) The RAMP study also compared DDD with DDDR pacing in 
400 patients. The results of this study showed no difference in quality of life 
between the two groups.(145) 
 
1.10.4 Implantable cardioverter defibrillator (ICD) as primary 
prevention 
Ventricular arrhythmias are a major cause of mortality in HF, with almost fifty 
percent of patients dying suddenly. The relative risk of sudden death is 
greatest in patients with mild/moderate HF, and NYHA functional status of 
II/III.(146) Randomised, placebo controlled trials have demonstrated 
reductions in mortality with implantable defibrillators in patients with 
LVSD.(147)(148)  
 
Thus all patients with NYHA status II/III, good quality of life, no significant co-
morbidities and a left ventricular ejection fraction less than 35 should be 
- 40 - 
considered for an ICD, with the evidence for benefit being greatest in those 
patients with an ischaemic cause for heart failure (SCD-HeFT Trial).(1)(120) 
1.10.5 Cardiac Resynchronisation Therapy (CRT) 
Around 30% of patients with severe heart failure have some degree of 
intraventricular conduction delay (for example left bundle branch block). The 
electrical delay results in ventricular dyssynchrony, which can accelerate 
adverse remodelling. This results in wider QRS durations, which directly 
reflects the underlying electromechanical dysynchrony. Wide QRS durations 
are seen as a result of LVSD chronicity and severity, and may contribute to 
worse exercise capacity.(149)(150)  
 
Cardiac resynchronisation therapy is a form of pacemaker therapy that aims 
to improve coordination of contraction of the heart. In order to achieve this a 
ventricular electrode is paced in the right ventricular apex as usual, and 
another is placed in a coronary vein on the lateral wall of the left ventricle. By 
pacing through both electrodes simultaneously, it is possible to improve 
conduction timing, which can reduce dyssynchrony and improve cardiac 
output (CARE-HF trial).(151)  
 
CRT in LVSD improves symptoms, quality of life, hospitalisation rates, 
mortality and reverses abnormal myocardial remodelling (MIRACLE 
trial).(152) It is currently recommended in patients with severe left ventricular 
systolic impairment (LVEF<35%) and an intraventricular conduction delay 
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resulting in QRS durations greater than 120 ms on the 12 lead 
electrocardiogram.(1)(6) 
 
 
1.10.6 Left Ventricular Assist Devices (LVAD) and Heart 
Transplant 
Surgical treatment options for end-stage heart failure are limited. Left 
ventricular assist devices can improve myocardial contractility and reverse 
abnormal remodelling.(153)(154) These devices are used temporarily as 
bridging therapy prior to heart transplantation or permanently where 
transplantation is contraindicated and long-term prognosis is poor, for short-
term survival benefits (REMATCH trial).(155)(156) Cardiac transplantation is 
considered to be definitive treatment, however the limited availability is 
usually restricted to younger patients, and those with no co-morbidities.(157) 
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Chapter 2: Cardiovascular physiology in health and disease 
 
2.1 Cardiac physiological responses during exertion 
 
Maximal exercise capacity refers to the maximum degree of physical 
exertion attainable. Normally during aerobic exercise, cardiac output 
increases in order to meet the upsurge in metabolic demand within skeletal 
muscles. This is achieved through rises in both stroke volume and heart 
rate, with the major contributions provided by the latter. In health there is a 
linear relationship between rise in heart rate and oxygen uptake (Vo2) 
readings, and a hyperbolic relationship with stroke volume (figure 
2.1).(158)(159)(160) 
 
 
 
Figure 2.1 Increases in heart rate and stroke volume during 
exercise in non-competitive runners   
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2.1.1 Cardiac Output 
During exercise, cardiac output increases via the stroke volume and heart 
rate (Cardiac output (CO) = stroke volume X heart rate). There can be a 
50% increase in stroke volume through a reduction in the end-systolic 
volume, whilst maintaining the end-diastolic volume as a result of increases 
in cardiac contractility and the Frank-Starling mechanism. A four-fold 
increase in the heart rate can occur as exercise progresses, through a 
reduction in vagal tone and increase in sympathetic activation at the sino-
atrial node.  
 
Cardiac output is usually attributed as the most significant limiting factor 
during exercise, as demonstrated by the Fick principle, which states that the 
maximal skeletal oxygen consumption (peak VO2) is a product of cardiac 
output and arteriovenous oxygen difference. The latter is dependent on 
skeletal muscle vasculature and function. Thus, both peak cardiac output 
and oxygen delivery to muscles are responsible for the highest achievable 
skeletal muscle oxygen consumption, and determine aerobic exercise 
capacity.(161)  
 
2.1.2 Stroke volume 
The achieved stroke volume depends on preload, contractile force and 
afterload.(162)  
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2.1.2.1 Preload 
A rise in end diastolic left ventricular volume (EDV), the preload, will result in 
an increase in cardiac myocyte sarcomere stretching. This raises myocardial 
calcium sensitivity leading to a greater number of force generating cross 
bridges, with a resultant increase in tension and force, as expected from the 
Frank Starling mechanism. Thus cardiac contraction is augmented in 
response to the increased EDV that occurs during physical activity, due to 
constriction of splanchnic and capacitance vessels and also as a result of 
improved venous return from vessels located within skeletal muscles. 
 
2.1.2.2 Contractility 
Stroke volume also depends of the contractility of myocardial cells. The 
degree of generated tension for any given sarcomere length is dependent on 
intracellular cyclic adenosine monophosphate (cAMP) levels and calcium 
concentrations. Increasing either of these results in an increase in the force 
generated with each contraction. Contractility is discussed in more detail 
later in this chapter. 
 
2.1.2.3 Afterload 
Afterload is the resistance to ejection during each ventricular contraction, 
and constitutes the wall stress in the aorta and conduit arteries during 
systole. A negative feedback mechanism is in place that alters the stroke 
volume in accordance to the afterload and aortic impedance. Moreover, the 
Anrep effect describes how the heart responds to any abrupt increase in 
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afterload, by increasing myofilament Ca2+ responsiveness, and thus 
increasing cardiac contractility and maintaining the end-diastolic 
volume.(163)  
 
Episodic exercise leads to a reduction in systemic vascular resistance and 
systemic blood pressure, both acutely during exercise, and also for 
prolonged periods following a bout of exercise. Exercise training can also 
lead to beneficial adaptations in vascular beds resulting in persistent 
reductions in afterload. Although this is generally assumed to be a 
prognostically beneficial effect, this lower afterload requires an increase in 
stroke volume to maintain cardiac output.(164)  
 
2.1.3 Heart rate 
In health, there is a linear relationship between heart rate (HR) rise and the 
level of physical activity. HR increase during exercise is a major contributor 
to the rise in cardiac output. The maximum HR attainable is age-
dependent.(165) Although physical training and conditioning can reduce the 
resting heart rate, they do not significantly affect the peak heart rate.(166)  
 
The spontaneous rate of sino-atrial myocyte activity at rest and during 
exertion is governed chiefly by the autonomic nervous system. Cardiac 
parasympathetic outflow originates at the vagal nucleus in the medulla from 
the cardioinhibitory centre, and innervates the heart via the vagus nerve.  
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The vagus nerve regulates parasympathetic signals through acetylcholine 
release, which results in an increase in cell membrane potassium ion 
permeability and a reduction in the heart rate through inhibition of the 
hyperpolarisation dependent sino-atrial If (“funny current”). This controls the 
heart rate through its role in initiating diastolic depolarisation of sino-atrial 
myocytes at the end of every action potential.(167)      
 
The reticular formation of the brain stem provides sympathetic cardiac 
innervation from the vasomotor centre, activation of which results in an 
increase in heart rate and cardiac contractility via the release of epinephrine 
and norepinephrine, both of which act on the cardiac beta-adrenergic 
receptors. This results in an increase in intracellular calcium ion 
concentrations and activation of the If current, leading to an increase in the 
heart rate. 
 
Exertional heart rate changes are governed by multiple peripheral and 
central mechanisms. Initially there is a reduction in the parasympathetic 
tone, followed by an increase in sympathetic activation of the If, the degree 
of which depends on feedback from arterial baroreceptors and skeletal 
muscle mechanoreceptors, and is coordinated by the various brainstem 
centres.(168)  
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2.2 Cardiac myocyte contraction physiology 
 
The normal physiological processes underlying each heart-beat, and the 
relationship between the heart rate and cardiac contractility are fundamental 
to understanding the basis of this thesis, and thus a detailed discussion of 
the cellular physiology follows. 
 
2.2.1 Excitation-contraction coupling  
Cardiac myocytes differ from skeletal muscle cells in that the activation of 
one cell results in mass depolarisation of adjacent cells. This is facilitated by 
the presence of tight junctions between myocytes, which ensure the 
existence of a cardiac muscle syncytium, with no role for spatial summation 
in the development of tension.(169)   
 
The excitation-contraction coupling (ECC) of myocytes is modulated via 
receptors and channels located on the surface membrane, also known as 
the sarcolemma, and on membrane invaginations known as T-tubules.(170) 
These receptors allow compounds such as epinephrine, norepinephrine and 
acetylcholine to influence myocyte function.(171) An enclosed internal tubule 
network, known as the sarcoplasmic reticulum (SR), is also present which 
sequesters and releases calcium ions during diastole and systole, 
respectively. The cellular cytoplasm in myocytes, known as the sarcoplasm, 
contains large quantities of mitochondria and myoglobulins to ensure 
maximal aerobic metabolism.(172) 
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2.2.1.1 Excitation 
The sino-atrial node generates each action potential, which initiates myocyte 
excitation. Depolarisation of the sarcolemma results in the opening of L-type 
calcium channels (LTCC), allowing a small influx of calcium ions.(173) The 
presence of a calcium ion current in the sarcoplasm induces further calcium 
ion release from the SR via ryanodine receptors (RyR2), in a process termed 
‘calcium-induced calcium-release’.(174) This binds to contractile proteins to 
produce physical shortening of the myocyte. RyR2 mediated calcium release 
is graded in response to the magnitude of the initial depolarisation induced 
calcium influx current (ICa).(175)  
 
2.2.1.2 Contraction 
These processes result in increased calcium ion concentration in the 
sarcoplasm surrounding the myofilaments.(170) The calcium ions are then 
free to bind to troponin C (TnC) on the thin filaments. This exposes the actin 
heads, allowing cross bridges to form between the actin and myosin 
components in an ATP dependent process, which results in sarcomere 
shortening and myocyte contraction.(172)  This is discussed in further detail 
in the next section.  
 
2.2.1.3 Termination 
The process ends when the bound calcium ions are recycled in to the SR by 
the calcium activated MgATPase, SERCA2a. SERCA2a activity is 
modulated via phospholamban (PLB).(176) This proteolipid can inhibit 
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calcium ion transport. Phosphorylation of PLB via cAMP dependent protein 
kinase enhances calcium ion uptake.(177) The excess sarcoplasmic calcium 
ions which initially entered in response to the sino-atrial action potential are 
also returned to the extracellular space in exchange for sodium ions, via the 
sodium–calcium exchange protein, NCX, which is driven by the sodium ion 
gradient across the sarcolemma. This gradient is maintained by the sodium-
potassium ATPase protein.(178) Some calcium ions also exit the 
sarcoplasm via sarcolemma calcium ion pumps, or in to the mitochondrial 
spaces.  
 
2.2.1.4 Contractile reserve 
Calcium ions do not saturate the TnC binding sites on the actin filaments at 
the basal resting heart rate. Thus a thin filament reserve exists, which allows 
the force of the contraction to be increased if more calcium ions are 
present.(179) Varying the sarcoplasmic calcium ion concentration allows 
control over the resultant number of force generating cross-bridges that can 
be formed between the actin and myosin components during each ECC.  
 
2.2.2 Sarcomere physiology 
Myocyte contraction is determined by sarcomere function. The sarcomere 
consists of thick filaments, which contain the power generating myosin 
molecules, and the thin filaments, which house the actin molecules.(172) 
Contraction and shortening is mediated by the formation of cross-bridges 
between the myosin heads and the actin molecules.  
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At the initiation of systole, actin becomes exposed to the myosin binding site 
when calcium ions bind to TnC and cause tropomysin (Tm) to move off the 
actin binding sites.(180) This allows the cross bridge to form, followed by 
movement of the myosin lever arm in order to drive the actin molecule and 
the attached thin filament towards the centre of the sarcomere.(181)  
 
2.2.2.1 Sarcomere energy consumption 
This process is energy dependent and requires the hydrolysis of one 
molecule of MgATP per cycle. During diastole MgATP is hydrolysed to ADP 
and Pi, and remains bound at the cross bridge.  
 
In systole, movement of the Tm off the actin binding site allows the cross 
bridge to form, and resultant filament sliding and sarcomere shortening to 
occur.(182) ADP and Pi are release at the end of the myosin stroke, at which 
stage the actin and myosin components remain strongly bound until an 
MgATP molecule binds to the cross bridge, to allow actin release and further 
cross-bridge formation if required.(183)  
 
In diastole, the passive tone of the myocytes is determined by the presence 
of the titin protein in the sarcomeres, which extend from the mid-line to the Z 
discs.(182) Titin has elastic properties that allow it to stretch in response to 
the increased venous return and ventricular filling in diastole, and allows the 
sarcomere to be restored to its diastolic parameters at the end of each 
myocyte contraction.(184) 
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2.2.3 Contractility 
Cardiac contractility is determined by a complex interaction between the 
various sarcomere components. It relies on the number of myocardial fibres 
involved in cardiac contraction and the maximal velocity of the shortening of 
these fibres, which is determined by the concentration of calcium ions in 
myocardial cytosol.(185) The enhanced force development in response to 
greater calcium ion concentration is due to additional recruitment of cross 
bridges between the actin and myosin contractile proteins. This is further 
affected by adrenergic and cholinergic activation.(186)  
 
2.2.3.1 Modulation 
Contractile performance of the myocardium is modulated in three 
ways.(187)(188)  Firstly, increases in sarcomere length due to increased 
preload decreases the actinomysin overlap, but increases calcium sensitivity 
and calcium release. Secondly, the presence of catecholamines leads to 
increased cyclic AMP phosphorylation and thereby increased calcium influx, 
increased calcium release from the SR and accelerated calcium 
removal.(189) Thirdly the contractile force is directly related to heart rate 
through augmentation of the amount of calcium that enters the cell per unit 
of time, increasing SR loading and hence the amount of calcium that can be 
released during contraction.(186) This is known as the Bowditch effect, and 
is discussed in greater depth later. 
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PLB phosphorylation via protein kinase A (PKA), under adrenergic 
stimulation, will cause increased calcium ion uptake into the SR, resulting in 
a shortening of the contraction-relaxation cycle. PKA also acts to 
phosphorylate LTCC and RyR2 receptors, resulting in increased calcium ion 
release from the SR.(176)  
 
Cross bridge activity is also altered by PKA under adrenergic stimulation, 
due to phosphorylation of myosin binding protein C (MyBP-C) and 
phosphorylation of troponin I (TnI). This results in increased cross-bridge 
cycling and kinetics, and faster release of calcium ions from the TnC binding 
sites on the actin filaments.(190)  
 
Thus the heart normally responds to the increased venous return associated 
with adrenergic stimulation and higher heart rates through improved 
contraction and relaxation dynamics, without any significant change in the 
EDV.  
 
2.2.3.2 Mechanisms 
Normal increases in contractility during exercise require both the 
depolarisation-rate dependent (heart rate dependent), and catecholamine-
dependent mechanisms to be functioning normally.(191)   
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2.2.3.2.1 Catecholamine dependent mechanism 
The catecholamine system is chronically overactive in CHF such that there 
is down-regulation of adrenergic receptors, making the sympathetic system 
less sensitive and responsive. 
 
Adrenergic stimulation increases the heart rate and the force of contraction, 
with increased peak calcium ion concentration during an ECC. Adrenergic 
beta-receptors are linked to G-receptor proteins, which can inhibit and 
stimulate the formation of cAMP by altering activity of the enzyme adenylyl 
cyclase.(192)  
 
Adenylyl cyclase activity is increased under adrenergic stimulation and is 
inhibited by cholinergic stimulation. Elevated cAMP levels result in increased 
PKA activation, which acts to modulate calcium ion levels in the sarcoplasm. 
Phosphorylation of PLB via cAMP dependent PKA enhances calcium ion 
uptake by the SR. Dephosphorylated PLB reduces calcium ion uptake by 
reducing SERCA2a activity.(193)  
 
2.2.3.2.2 Depolarisation-rate dependent mechanism 
The depolarisation-rate dependent mechanism (catecholamine independent) 
through which increases in heart rate lead to increases in the force of 
contraction is known as the Treppe phenomenon and was described by 
Bowditch in the late 19th century.(194) This frequency-dependent up-
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regulation of contractility is both fast and intrinsic to the myocardial cell with 
no external involvement from neuronal or hormonal controls.(195)  
2.2.3.2.2.1 Treppe phenomenon  
Increases in heart rate result in an increase in the depolarisation induced Ica 
amplitude, with an associated increase in calcium ion entry into the 
sarcoplasm. A stepwise increase (‘staircase effect’ – Treppe) in the 
myocardial contractile force occurs in response to increasing HR, known as 
the Treppe phenomenon (or force-frequency relationship (FFR)).(196).  
 
Thus in controls, CO will increase by increasing the heart rate and reducing 
the end systolic volume (ESV), with little change in the EDV. Without such a 
compensatory increase in contractility, stroke volume would be reduced due 
to less filling time, significantly impairing efficiency and requiring greater 
increases in heart rate to achieve similar rises in cardiac output. The positive 
force-frequency relationship (FFR) exists to prevent a reduction in stroke 
volume at faster heart rates.(197) 
 
In humans, the increase in contractility in response to increased heart rate 
seems to occur between heart rates of 60 -180 per minute, after which 
contractility declines.(198)(199)(200)  
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2.3 Pathophysiological cardiovascular responses to exercise 
in CHF 
 
2.3.1 Introduction 
The key feature of heart failure is exercise intolerance due to fatigue, which 
has a significant impact on quality of life. However, the severity of LVSD in 
CHF correlates poorly with functional capacity.(201) This is probably due to 
the fact that exercise intolerance is influenced by abnormalities in 
cardiovascular, respiratory or skeletal muscle response mechanisms and 
function, all of which are abnormal in patients with systolic heart failure.  
 
2.3.2 Fatigue 
The diagnosis of heart failure is inextricably linked to a reduction in 
functional capacity. As heart failure progresses, exercise capacity becomes 
progressively limited due to fatigue and dyspnoea, however this does not 
correlate with measures of left ventricular function at rest, such as the 
ejection fraction or fractional shortening.  
 
Fatigue is a multifaceted symptom, which incorporates central and 
peripheral elements. Fatigue can represent either difficulty in initiating 
activity due to generalised weakness and poor concentration, or the inability 
to maintain prolonged activity.(202) The extent of the latter is dependent on 
the level and duration of physical activity, and the ability of the body to 
maintain effective oxygenation and acid-base homeostasis via adaptations in 
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the cardiovascular, respiratory and skeletal muscle systems. Thus multiple 
pathways may contribute to the increasing functional limitation that is 
pathognomonic of HF. 
 
During exercise, energy substrate levels become depleted and metabolic by-
products such as lactate accumulate. Both of these processes contribute to 
the fatigue associated with exercise and activity.(203) The lactate threshold 
(or anaerobic threshold) refers to the point at which the production of lactate 
in myocytes exceeds its metabolism via the Krebs cycle, and a sustained 
rise in serum lactate levels is detectable.(204) Thus, a steady metabolic 
state exists at VO2 levels just below the lactate/anaerobic threshold (AT), and 
sustained activity is possible with less peripheral fatigue. Sustained exercise 
will cease due to fatigue once oxygen consumption exceeds AT.  
 
The AT is a good marker for the ability to maintain prolonged activity, in 
comparison to peak VO2 measurements.(205)  AT is reduced in patients with 
heart failure compared to normal subjects, accounting for the reduced 
functional capacity, lower exercise tolerance and higher degree of 
fatigability.(206)   
 
2.3.3 Cardiovascular adaptations 
Exercise intolerance in systolic heart failure is likely to be the result of 
multiple physiological processes, but a key feature is impaired cardiac 
function due to abnormal cardiac remodelling. This results in reduced 
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cardiac output at rest because of myocyte contractile impairment, leading to 
diminished cardiac output rise with exercise.(207) There is a reduction in 
blood flow to skeletal muscle, which contributes to muscle wasting and 
dysfunction.(208)  
 
2.3.3.1 Cardiac output 
Adaptations to LVSD include an increase in sympathetic and neurohormonal 
system activity, through stimulation of the vasomotor regulatory centres in 
the medulla via aortic baroreceptors, as described previously. The role of 
increased sympathetic activity is to restore cardiac output through an 
improvement in contractility by increasing the amount of available 
intracellular cAMP and calcium, peripheral vasoconstriction and by 
increasing the heart rate, as a result of the increased plasma norepinephrine 
levels. This inotropic response may be sufficient to maintain a normal 
cardiac output in the early stages of the disease process, both at rest and 
during moderate activity.(209)  
 
2.3.3.2 Stroke volume – Preload, contractility, afterload 
2.3.3.2.1 Preload 
The neurohormonal changes result in blood volume expansion via water and 
salt retention. This increases the preload, resulting in increased ventricular 
contraction as described by the Frank-Starling principle, and mal-adaptive 
changes in the ventricular structure including left ventricular hypertrophy, in 
an attempt to compensate for the preload changes and hence maintain 
cardiac output. (210)  
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In the long term, these adaptive changes are detrimental to cardiac function 
and result in a net worsening of ventricular systolic dysfunction. Thus further 
changes in the preload do not result in proportionate increases in contractile 
tension despite a maintained Frank-Starling mechanism.(211)  
 
2.3.3.2.2 Afterload 
The most common causes of heart failure are hypertension and ischaemic 
heart disease. A sustained chronic increase in afterload, which occurs in 
hypertension, can result in cardiac remodelling and hypertrophy.(212)  
 
The increasing circulating volume that accompanies chronic renin-
angiotensin and sympathetic nervous system activation causes a pressure 
overload in the left ventricle, resulting in further remodelling, dilatation, 
fibrosis and reduced compliance.  
 
Over time, cardiac remodelling leads to an increase in EDV. This 
necessitates an increase in left atrial pressure to ensure LV filling in diastole, 
thereby raising pulmonary venous pressure. These maladaptive changes are 
responsible for the pulmonary oedema and reduced alveolar gas exchange, 
which are present in decompensated symptomatic heart failure.  
 
2.3.3.3 Contractile dysfunction in heart failure 
Another key feature of heart failure is reduced global cardiac contractility. 
Multiple mechanisms, including those described above lead to contractile 
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dysfunction, usually initiated by myocyte loss but exacerbated by efforts to 
compensate.(213)  
 
These changes are an attempt to match the cardiac output to the venous 
return. While these adaptive mechanisms can restore near normal cardiac 
output at rest, a loss of contractility reserve results.(214)  This is associated 
with a significant limitation in exercise tolerance and quality of life, as the 
cardiac output fails to increases sufficiently to meet the increased demands 
during exercise.  
 
2.3.3.3.1 Impaired calcium handling 
Myocyte structural change results in dysregulation of calcium ion control 
mechanisms and reduced phosphorylation activity. Similarly, myocardial 
ischaemia and myocardial infarction can result in cardiac remodelling due to 
reduced myocyte gas exchange and impaired local nutrient supply, which 
results in maladaptive changes affecting EC coupling and the response to 
increasing venous return. This depletes intracellular cAMP and calcium 
levels, and the abnormally remodelled cardiac tissue also has reduced 
contractility in response to sympathetic stimulation.(215) 
 
Regardless of the cause of heart failure, a reduction in the delivery of 
calcium ions to the TnC binding sites on the actin filaments is commonly 
present. This contributes to the reduced contractility and impaired response 
to exercise that are key features of this disease process. 
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The molecular and cellular changes causing the abnormal contractile 
response to increases in heart rate seen in CHF are due to abnormalities of 
calcium (Ca2+) handling.(216)(217) There is also a reduction in SERCA2a 
activity seen in CHF, which is partly due to reduced phosphorylation of 
phospholamban.(218) This leads to increased inhibition of SERCA2a and 
decreased Ca2+ sensitivity.(219)  
  
These changes lead to depletion of SR calcium stores and delayed diastolic 
Ca2+ removal especially at higher heart rates.(220) Beyond a ‘critical heart 
rate’ calcium will be extruded from the cell rather than be taken up by the SR 
and oxygen consumption is doubled for each unit of force developed such 
that there is a marked decrease in efficiency of cardiac work.(221) Hence at 
high stimulation frequencies Ca2+-lowering mechanisms play a crucial role in 
cardiac contractility and the altered functional balance between Ca2+ re-
uptake and Ca2+ extrusion, are responsible for the blunted force-frequency 
relationship (impaired Treppe effect) that is present in the failing 
myocardium.(222)  
 
2.3.3.3 Heart rate  
Patients with heart failure have a significantly lower peak heart rate and 
reduced functional capacity compared to matched controls. It has been 
suggested that this is the major cause for the reduced exercise tolerance 
seen with chronic heart failure.(223)(224) It is as yet unclear whether this 
association indicates causality.     
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It is generally assumed that a limitation to heart rate rise might contribute to 
exercise intolerance. However, heart rate is closely related to workload and 
subjects with impaired exercise capacity have a lower peak heart rate.  
Whether impaired HR rise in heart failure actually induces a reduction in 
exercise capacity remains controversial. This close relationship, and limited 
techniques to detach one from the other means that published data are 
inconclusive. A detailed discussion of this follows. 
 
2.4 Chronotropic incompetence 
Chronotropic incompetence (CI) refers to an inability of HR to increase in 
proportion to the level of physical exertion or metabolic demand. This is 
commonly seen to be present in the context of heart failure, and is also 
known to be present in patients with coronary artery disease or sick sinus 
syndrome.(225)  
 
2.4.1 Definition 
The most widely used definition for CI is a failure of HR to reach an arbitrary 
percentage (usually 80%) of the age-predicted maximum based on the 
‘220−age’ equation, obtained during an incremental exercise test.(226) The 
chronotropic index is a more objective measurement for CI, consisting of the 
ratio of HR reserve to metabolic reserve.(227) A ratio of less than 0.8 is 
indicative of CI, irrespective of age, level of fitness or functional capacity. 
Reports of the prevalence of CI in moderate to severe chronic heart failure 
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vary between 28% and 70%, depending on the definition and testing 
strategy used.(228)(229)(230)(231)  
 
2.4.2 Potential pathophysiology of CI 
The presence of CI has also been related to increased cardiovascular 
mortality.(232) In subjects with LVSD, CI has been associated with down-
regulation and de-sensitisation of myocardial beta-receptors due to 
heightened catecholamine levels as a result of neuro-hormonal 
activation.(224)(233) Structural remodelling of the sino-atrial node with 
associated impairment of electrical conduction of the sinus impulse in heart 
failure patients has also been demonstrated, which may play an additional 
role in CI.(234)  
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2.5 Literature review of HR and exercise capacity in CHF  
 
The degree of CI relates to both the severity of LVSD and the level of 
exercise limitation, although it is unclear as to whether this is merely an 
association or a causative link.(235) Over the years, numerous studies have 
looked into this area with conflicting results. 
 
2.5.1 Evidence supporting causal relationship  
Jorde et al reported a significant relationship between exercise capacity in a 
cardio-pulmonary exercise test and the presence of CI in their sample of 278 
stable CHF patients (ejection fraction <=40%) on optimal medical therapy. 
Almost half of the cohort (n=128) had CI as defined by a peak heart rate less 
than 80% of the age-predicted maximum. By stratifying their sample based 
on peak oxygen consumption measurements (pVO2; ml/kg/min), they were 
able to show that the prevalence of CI increased significantly, from 24% in 
the ‘pVO2 >20ml/kg/min’ group to 48% in the ‘pVO2 between 14.0-20.0 
ml/kg/min’ group and was the highest in those with the worst exercise 
capacity, 72% in the ‘pVO2 <14ml/kg/min’ group. This study demonstrated 
that CI was present in a significant proportion of CHF patients, and was 
associated with reduced exercise capacity.(230) 
 
Al-Najjar et al looked at the relationship between the presence of CI in CHF 
and mortality in an unselected cohort of 411 patients with CHF who 
underwent cardio-pulmonary exercise testing. They found that CI was 
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present in 42% of the study population, and was associated with significantly 
lower exercise time and pVO2. Peak VO2 was an independent prognostic 
marker, but there was no association between CI and mortality.(228)  
 
Lele et al also demonstrated some correlation between pVO2 and HR 
(r=0.45; p=0.04) using erect cycle ergometry in 20 patients with mild-
moderate CHF (mean ejection fraction 47%).(236)  
 
2.5.2 Evidence opposing causal relationship 
However, such a relationship between HR and exercise capacity was not 
seen in all studies. Roche et al performed a study to evaluate HR response 
to exercise in CHF. They performed symptom limited exercise testing with 
metabolic gas exchange measurements to determine pVO2 in 21 subjects, 
and reported no significant difference in resting heart rate, age, maximal VO2 
achieved or left ventricular ejection fraction between the subjects with and 
without CI.(231)  Similarly Clark et al tested 57 CHF subjects (mean LVEF 
30%) and 14 controls using a treadmill based symptom limited exercise 
protocol and gas exchange analysis. Peak VO2 was significantly reduced in 
the CHF group (19.6 (S.D. ±7.6) vs. 35.0 (±9.9) ml/kg/min; P < 0.001), and 
there was a correlation between peak heart rate and heart rate rise with 
pVO2 (r=0.47, 0.59; P <0.001). However, there was no difference in peak VO2 
or exercise time between those CHF subjects with CI (defined as peak heart 
rate less than 80% age predicted maximum; n=16) and those without 
CI.(229)  
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Witte et al explored this association further, in the context of submaximal 
exercise. Controls (n=9) and CHF subjects (n=11) performed steady state 
exercise tests with gas exchange analysis at 15%, 25%, 50% and 100% of 
peak workload. They found that the CHF cohort had lower oxygen 
consumption at each steady state sub maximal stage compared to the 
controls, with the same heart rate. However, peak heart rate was reduced in 
CHF, such that there was no correlation between peak heart rate and 
exercise capacity (r=0.003; p=0.98), whereas the control cohort showed a 
strong correlation (r=0.85, p<0.001). This would suggest that a lower peak 
heart rate during exercise is a consequence of the reduced functional 
capacity in CHF rather than the cause.(235) 
 
In most heart failure patients, there is an iatrogenic component to the 
impaired heart rate rise due to beta-blocker therapy. This was also 
investigated by Witte et al who demonstrated higher exercise time despite 
worse heart rate rise (exercise time: 498 vs 435 seconds; p=0.02) in a study 
of 237 patients with severe CHF (mean LVEF 30%) of whom 74 were not 
taking a beta-blocker. There was no difference in resting LVEF or baseline 
symptom class between the beta-blocked and non-beta-blocked 
cohorts.(237) However, in those with a low HRR in the presence of beta-
blocker usage, CI did not predict a poorer outcome.  Similarly, acute alpha 
and/or beta-blockade reduces sub-maximal ventilation during exercise, with 
no difference in pVO2, exertion time or perceived exertion scores.(238) 
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Hirsh et al also showed in a study on 19 CHF subjects on beta-blocker 
therapy, that acute withdrawal of beta-blockers did not result in any change 
in exercise time, pVO2 or ‘normalisation’ of the chronotropic response during 
a cardio-pulmonary exercise test.(239) 
 
2.5.3 Heart rate control in AF 
Studies of whether strict AF resting heart rate control (resting heart rate 
below 80) improves mortality and reduces hospitalisation have shown that 
lenient HR control (HR<110 at rest) is non-inferior.(240)(241) Thus stringent 
HF control does not seem to improve quality of life, symptoms, 
hospitalisation or outcomes, even in the presence of HF 
(EF<40%).(242)(243) The role of heart rate rise during exercise in AF and 
HF has hitherto not been explored in the context of any RCTs. 
 
2.5.4 Evidence for rate adaptive pacing 
The objective of rate adaptive pacing modes is to simulate the physiological 
heart rate rise that occurs in response to increasing levels of physical 
activity. Multiple studies have been carried out to assess the optimal slope 
for the relationship between heart rate and work rate.  
 
Lewalter et al looked at the heart rate response to a ramping incremental 
treadmill exercise protocol in 41 middle aged subjects. They showed 
significant heterogeneity in heart rate response of men compared to women, 
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and suggested an average heart rate increase of 5 beats per minute for 
each 10 Watt increase in workload.(244)  
 
In a further study, Lewalter et al also demonstrated a curvilinear HR 
response to minute ventilation, with a reduction in HRR at higher 
workloads.(245) Limitations for these studies include a small cohort size, no 
randomisation or blinding, and being carried out entirely using healthy 
middle aged volunteers.  
 
Early rate adaptive pacing systems were based on single sensor systems, 
which used either pendulum based acceleration sensors to detect body 
acceleration (accelerometer), minute ventilation rate detection, intrathoracic 
impedance measurements or pacing electrode sensors. Each differed with 
respect to sensitivity, specificity, effectiveness and response 
speed.(246)(247) Thus modern pacemakers utilise a multisensor pacing 
system and algorithms to alter efficacy and responsiveness, with the aim to 
match paced heart rate response to metabolic demands.(248)(249)  
 
Rate adaptive pacing with multi-sensor technology is also available in bi-
ventricular pacing systems for heart failure, however these systems aim to 
mimic the physiological heart rate response derived from previous studies 
that recruited subjects with dual chamber pacemakers, and excluded those 
with severe LVSD.(250)  
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Thus the efficacy of rate adaptive pacing to match physiological heart rate 
rise, and alter the chronotropic adaptation seen in the context of severe 
LVSD, is unknown. Tse et al assessed the potential benefit of rate adaptive 
pacing in conjunction with cardiac resynchronisation therapy on metabolic 
exercise testing parameters in a small study of 20 patients with CI and 
LVSD. The increased heart rate achieved was not associated with any 
increase in peak oxygen consumption.(251) 
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2.6 Limitations of current research  
 
Limited HRR is accepted as a contributor to exercise intolerance and the 
correction of CI as a potential target that could improve exercise capacity in 
health.  This is usually achieved through the use of an implanted pacemaker. 
Pacemakers can be programmed to deliver either fixed rate pacing or utilise 
a rate-adaptive pacing algorithm, where the heart rate is altered in proportion 
to the level of activity as detected by internal device sensors. Rate-adaptive 
pacing in people without CHF is associated with an increase in cardiac 
output during exercise,(252) better quality of life(253)(254)(255) but with 
inconsistent(256)(257) improvements in peak exercise capacity, when 
compared to fixed rate pacing. 
 
On the other hand, in patients with CHF, there is clear evidence that a high 
resting HR is a strong predictor of poor outcome.(258) Using a pacemaker to 
increase the heart rate in CHF patients worsens both the outcomes and 
cardiac function.(259)(260) Outcomes in CHF are clearly improved by 
inducing a bradycardia at rest; with the prognostic benefit increasing as the 
degree of resting heart rate reduction is increased.(111) This does lead to a 
limitation of HRR during exercise, and worsening of any CI that may be 
present.  
 
It is currently unknown whether CI, intrinsic or iatrogenic, either contributes 
to (261)(262) or is the consequence of reduced exercise capacity in 
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CHF.(229) Thus, heart rate reducing agents, for which there are clear 
prognostic indications, are used at sub-optimal doses for fear of inducing 
exercise intolerance, fatigue or lowering blood pressure. In addition to this 
there is no conclusive evidence of benefit on exercise time or quality of life in 
CHF from rate-responsive atrial pacing.(263) Despite this, rate-adaptive 
pacing remains the standard of care for most CHF patients with 
pacemakers, creating a paradox that medical therapy to reduce mean heart 
rate is aggressively applied and proven, yet those with a pacemaker are 
programmed to rate-adaptive pacing and thus may be subjected to higher 
mean heart rates.  
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2.7 Discussion 
 
CO is dependent on HR, contractility of the cardiac myocytes and end 
diastolic left ventricular volume. These three factors are interdependent, and 
continuously increasing the heart rate will affect the stroke volume by 
reducing the filling time and hence the end diastolic volume. There is a 
reduction in cardiac function and cardiac contractility in CHF. The purpose of 
the initial adaptive changes is to match CO to venous return. While these 
mechanisms can restore near normal CO at rest, a loss of contractile and 
heart rate reserve results.  
 
Limitations to either heart rate rise or cardiac contractility, or a combination 
of both might contribute to lower CO during exercise. This is associated with 
a significant limitation in exercise tolerance and quality of life, as the CO fails 
to increase sufficiently to meet the increased demands during exercise. 
Because contractility is impaired, increasing the heart rate in an attempt to 
improve the CO becomes an energy intensive response, which may result in 
increased ischaemic insult due to the reduced diastolic time, and impaired 
ventricular filling.  
 
These processes cause the CO to decrease over time, as the compensatory 
mechanisms are overwhelmed. Initially CO fails to increases appropriately 
on exertion, resulting in lower peak VO2, exercise intolerance and fatigue, but 
later in the course of the disease CO becomes limiting even at rest.  
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2.8 Clinical implications 
 
In health, HR directly influences cardiac output and is thus an important 
aspect of the biological response to increasing levels of activity and 
exercise.(63) HR is also a determinant of total body and myocardial oxygen 
consumption, and increased heart rates at rest lead to higher myocardial 
oxygen consumption at rest, with the potential to cause ischaemia.(264)  
 
The role of the heart rate rise achieved during exercise in the context of 
heart failure is less clearly understood. Myocardial tissue in chronic heart 
failure may exhibit a negative force-frequency association with inefficient 
energy expenditure to maintain or increase cardiac output during exercise. 
(35)(218)(265) In such a situation, achieving a higher heart rate during 
activity could lead to higher than expected myocardial oxygen consumption 
and thus limit exercise tolerance.  
 
In systolic dysfunction, there is a reduction in cardiac output, so the 
therapies used for treatment aim to alter the preload and afterload, in order 
to maintain or improve the stroke volume. These therapies also have a role 
in reversing the abnormal cardiac remodelling, and hence improving the 
function and contractility of the heart over time. 
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The traditional view is that chronic changes in the myocardial electrical 
conduction pathways, adrenergic sensitivity and the sino-atrial node may be 
the reason for the reduced heart rate rise seen in chronic heart failure, in 
which case CI could be a potential therapeutic target to improve exercise 
capacity. 
 
However, in a dilated heart, more ventricular filling time is necessary in order 
to allow sufficient wall tension to develop to achieve a given pressure, so 
necessitating a lower heart rate to produce the same cardiac output in the 
presence of heart failure, in accordance with the law of LaPlace (∆P = 2λh/r; 
P: Internal pressure, λ: Wall tension, h: Wall thickness, r: Radius).(266)  
 
In the presence of a higher EDV, cardiac contractility and the resulting stroke 
volume may be increased if the heart rate is lowered and the ventricular 
filling time is maximised. The greater radius of the dilated left ventricle in 
heart failure requires greater sarcomere shortening, and thus more ATP 
hydrolysis, in order to generate the same cardiac ejection pressure in order 
to maintain cardiac output. The lower heart rate would also favour these 
cardiac cellular energy kinetics, allowing greater delivery of oxygen and 
nutrients to the myocytes.(267)  
 
Thus, patients with heart failure who demonstrate CI may be able to 
maintain near normal cardiac output and peak VO2 during exercise with 
greater energetic efficiency via increases in the stroke volume in accordance 
- 74 - 
with the Frank-Starling principle.(268)  So CI may be an adaptive response 
to limit myocardial damage.  
 
Meta-analysis of trials involving beta-blockers in chronic heart failure has 
demonstrated that the reduction in baseline heart rate is of great prognostic 
significance irrespective of the beta-blocker type or dose.(269) The 
prognostic benefit of heart rate lowering is borne out by the results of trials 
involving other heart rate lowering agents, such as the BEAUTIFUL 
(morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with 
coronary disease and left ventricULar dysfunction) study and SHIFT 
(Systolic Heart failure treatment with the If inhibitor ivabradine Trial). In these 
studies the sinus node inhibitor ivabradine was used to reduce the resting 
heart rate of patients in sinus rhythm with severe chronic heart failure, 
resulting in prognostic and symptomatic improvement.(258)  
  
However, there is conflicting evidence as to whether CI contributes to, or is 
the result of, the reduced exercise capacity that is pathognomonic of 
worsening heart failure. Chronic multi-system abnormalities in the 
respiratory, skeletal and cardiovascular systems as a direct result of CHF, 
may all be contributing to the limited exercise capacity, such that simply 
increasing the heart rate rise and achieving ‘chronotropic competence’ may 
not result in any improvement in exercise capacity (Figure 2.2).(270)  
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Figure 2.2 Various physiological mechanisms that may contribute to limited exercise 
capacity and fatigue in systolic heart failure 
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2.9 Conclusion 
 
The aim of this thesis is to explore and unravel the connection between 
heart rate and the reduced functional capacity that is pathognomonic for 
heart failure. It is unclear whether the lower heart rate response to exercise 
that manifests as the heart failure syndrome progressively worsens, is a 
cardio-protective mechanism or whether exercise capacity in heart failure 
could be improved by increasing the heart rate response during activity.   
 
The close relationship between the heart rate and any measure of exercise 
capacity makes determining the causality difficult, and requires placebo 
controlled double blind studies during which the heart rate response is either 
corrected or worsened during exercise to determine whether CI is adaptive 
or maladaptive, and is either a cause or consequence of exercise 
intolerance in heart failure. 
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Chapter 3: Methodology 
 
The pathophysiological changes in CHF that lead to a reduction in exercise 
performance relate to a complex interplay between peripheral and central 
defects in the oxygen transport chain during exertion. Complete functional 
assessment requires some form of standardised exercise testing to 
objectively measure the degree and nature of the symptoms, in addition to 
appropriate cardiac imaging to assess structural changes and confirm 
aetiology. 
 
3.1 Measuring exercise capacity 
 
There are several different ways to measure exercise capacity, which can 
range from history taking to laboratory testing. While history taking and 
patient interview using activities of daily living questionnaires, NYHA status 
or six-minute walk tests, can give a valuable insight in to the extent and 
impact of any exercise limitation, they cannot accurately be used as a 
comparative marker between small populations of people, time-points or 
treatments.(271) 
 
Exertional performance is crucially reliant on the ability of the cardiovascular 
system to transport oxygen to and remove carbon dioxide from respiring 
skeletal muscles, thus increasing the level of oxygen uptake. The upper limit 
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of the cardiovascular system and an overall estimate of the exercise 
capacity can be defined by measuring peak symptom-limited oxygen 
consumption (pVO2) during an incremental cardio-pulmonary exercise test.  
 
 
3.1.1 Cardio-pulmonary exercise testing 
3.1.1.1 Introduction 
Cardio-pulmonary exercise testing (CPX) is the gold-standard for 
simultaneously measuring the cardiovascular and respiratory physiological 
responses involved in providing the skeletal muscles with an adequate 
oxygen supply to maintain and allow any increases in the intensity of the 
exercise stimulus. CPX testing also plays a vital role in prognostic and 
functional assessment, and understanding the causes for exercise 
intolerance, dyspnoea and fatigue.(272)  
 
Exertional fatigue can be objectively assessed as a reduction in pVO2 and an 
increase in the ventilatory response to exercise (VE/VCO2 slope) during 
incremental exercise testing with metabolic gas exchange analysis.(273) 
Once a familiarisation test has been performed, a peak exercise test is not a 
training stimulus, and produces reliable, reproducible results.(238) 
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3.1.1.2 Test overview 
During a CPX test, subjects breathe room-air via a face mask or mouth 
piece and nose clips, and all gaseous exchange is measured breath-by-
breath by real time high speed O2 and CO2 analysers, which adjust for 
environmental factors such as the ambient room temperature and humidity, 
while performing an incremental exercise test. Various exercise modalities 
are available such as treadmill, cycle ergometer, supine bicycle or arm 
ergometer, using a variety of different exercise protocols such as continuous 
ramp, multi-stage or constant workload. Sensors can also measure the 
minute ventilation (VE), which incorporates both the breathing rate 
(respiratory rate, RR) and the tidal volume (Vt).  
 
During higher levels of exercise, O2 and CO2 uptake and production at the 
mouth represent utilisation and production at the skeletal muscle level. 
Hence calculations derived from measuring the difference between inhaled 
and exhaled O2 and CO2 concentrations and ventilation parameters, provide 
an accurate assessment of cellular metabolic homeostasis. In this way, CPX 
can be used to identify which part of the cardiovascular-respiratory-skeletal 
triangle in responsible for causing the restriction in exercise capacity.  
 
 
3.1.1.3 Peak VO2 
Peak VO2 (normalised for body weight; mL/kg/min) is a well-established 
measure of aerobic capacity.(274) Oxygen uptake VO2 readings show a 
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linear relationship to work load.(275) This can be increased with physical 
training and is decreased in cardiovascular, pulmonary or neuromuscular 
system dysfunction.(276)  
 
Maximal exercise capacity can be reliably expressed by measuring the peak 
oxygen consumption in an incremental exercise regime, referred to as the 
peak VO2.(277) It is based on the Fick equation (Peak VO2 = Cardiac Output 
X arteriovenous O2 concentration difference at the respiring skeletal muscles 
during sustained maximal effort). Cardiac output response to exercise is 
dependent on increases in both heart rate and stroke volume.(278)  
 
Thus Vo2 is calculated as the product of VE and the oxygen fraction that can 
be utilised by the actively respiring skeletal muscles during sub-maximal 
(anaerobic threshold; AT) or maximal exercise (peak VO2).(279) Oxygen 
delivery to the respiring skeletal muscles during exercise is dependent on 
the cardiovascular system, and measuring the peak VO2 provides an 
accurate and reproducible measure of cardiovascular performance.  
 
Attaining maximal oxygen uptake is also evidenced by a plateauing of VO2 
measurements despite increasing the workload at the maximum level of 
perceived exertion. The rate at which steady state is reached is represented 
by the exponential time constant of VO2 rise, known as the mean response 
time (MRT).(280) 
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The normal value for an individual’s maximum VO2 will depend upon the age, 
sex, body size and normal level of physical ability. Conditions that reduce 
cardiac function and exertional response, or are associated with a reduction 
in pulmonary gas exchange, will lead to a reduction in VO2 
measurements.(271)  
 
 
3.1.1.4 Respiratory exchange ratio 
Whether a measured VO2 is truly reflective of a high degree of exertional 
effort can be determined by calculating the respiratory exchange ratio (ratio 
of VCO2 to VO2; RER). As the aerobic metabolic capacity of the respiring 
muscles is exceeded, there is an increase in lactate production that results 
in an increase in exhaled VCO2, so an RER greater than 1.1 is taken to 
reflect peak workload and effort, and can thus identify those subjects who 
terminate the exercise test prior to achieving peak workload due to other 
factors such as poor motivation.(281)  
 
 
3.1.1.5 VE/VCO2 slope  
Skeletal oxygen consumption results in a concomitant increase in CO2 
release, the homeostasis of which is dependent on respiratory system 
efficiency during exertion. Ventilation (VE) is normally closely matched to 
CO2 production (VCO2) but in heart failure, there is a hyperventilation 
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response to carbon dioxide production that is seen as a steeper VE/VCO2 
slope.  
 
Although a steeper VE/VCO2 slope is a strong marker of adverse prognosis, 
(282)(283) the pathophysiological stimulus is incompletely understood. It is 
likely that the increased VE/VCO2 slope is a consequence of complex 
feedback mechanisms that link skeletal muscle activity or metabolism to 
ventilatory centres.(284)(285)  
  
3.1.1.6 End tidal carbon dioxide 
The partial pressure of end tidal CO2 (PetCO2, mmHg) is also measured by 
the CPX equipment. Low PetCO2 measurements at rest and at peak exercise 
reflect a mismatch in lung ventilation and perfusion, and can be used as an 
additional marker of prognosis and disease severity.(286)(287)  
 
3.1.1.7 Sub-maximal exercise 
CPX testing can also provide information at sub-maximal effort levels, which 
is a better indicator for the level of exertional intensity during a person’s 
usual activities of daily living (ADL). Minute ventilation increases linearly at 
the onset of exercise, however an abrupt transition occurs at the point where 
aerobic metabolism reaches the maximum sustainable level and skeletal 
mitochondria have to increasingly rely on increases in the anaerobic 
metabolism in order to continue cellular respiration and ATP production.  
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The increase in anaerobic glycolysis leads to a rapid increase in blood 
lactate levels, which results in excess CO2 production via bicarbonate in 
order to buffer the sudden excess in H+ ions. At this point, there is an abrupt 
non-linear rise in the VE measurements and a sudden increase in the ratio of 
measured VCO2 to VO2. This point is known as the ventilatory or anaerobic 
threshold (VT or AT; mL/kg/min).(288)  
 
AT is a recognised measure for sub-maximal exercise capacity and can be 
used to assess the functional benefits gained from a given therapy in terms 
of increasing the person’s ability to perform ADLs.(289) AT also tends to 
occur earlier relative to the peak VO2 in CHF (<30%) and is usually normal in 
pulmonary disease (40-60% of peak VO2).(290) 
 
3.1.1.8 Oxygen pulse 
The ‘oxygen pulse’ (O2 pulse; mL/beat) can also be calculated using CPX 
testing, by dividing the peak VO2 by the peak HR (or similarly for submaximal 
exercise using the AT and the HR reached at the point of AT). This provides 
an index of stroke volume with oxygen extraction, and is reduced in 
conditions associated with cardiac output reduction.(291)(292) 
 
3.1.1.9 Oxygen uptake efficiency slope 
Analysis of the rate of increase of the VO2 in relation to the VE can be used 
to determine the effectiveness of O2 extraction and utilisation. This measure 
is known as the oxygen uptake efficiency slope (OUES). It is considered to 
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be independent of the level of effort achieved, and improves with physical 
training.(293)(294) 
 
Although the relation between ventilation and oxygen uptake is not linear, 
the OUES is derived by plotting VO2 as a function of log10VE, which is an 
approximately linear relationship.(294) This represents the effectiveness of 
oxygen extraction, demonstrated by the rate of VO2 increase during 
incremental exercise in response to a given VE. The steeper the slope, the 
more oxygen is taken up for a given unit of ventilation.(295) 
 
OUES is reduced in CHF in proportion to disease severity, and is lower in 
those with AF compared to normal sinus rhythm.(296)(297) It can be 
increased with physical training and improvements in exercise 
tolerance.(298) One advantage of the OUES as a measure is that it can be 
measured from submaximal data and does not depend upon effort levels or 
reaching peak exertion. The OUES is predictive of prognosis even from 
submaximal tests.(296)(299) 
 
3.1.1.10 Critical power 
The term ‘critical power’ refers to the highest sustainable power where both 
the VO2 and lactate are at a steady state.(300) Several studies have shown 
this to occur at around 70% peak power in young healthy 
individuals,(300)(301) with higher values in the context of aerobic 
training.(302) Critical power is a marker of the sustainable upper limit of 
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aerobic intensity levels, however it requires at least four constant-power 
exercise tests of varying intensities above the level of the AT for accurate 
determination.(300) A close correlation has been demonstrated between the 
critical power and the power at respiratory compensation point, which is 
obtainable from a single metabolic exercise test.(303) No conclusive data 
are currently available on changes in critical power in the context of CHF, 
and as such this measurement considered to be outside the scope of this 
investigation.(304)(305)(306) 
 
 
3.1.1.11 Exercise protocols 
Various incremental exercise protocols are available for both stationary cycle 
and treadmill exercise. The aim is to provide a gradual workload increase to 
allow adequate metabolic gas kinetic response, while keeping exercise time 
between six and twelve minutes, to maximise the accuracy of pVO2 
measurements.(307) 
 
3.1.1.11.1 Stationary cycle  
Stationary cycle is utilised in such circumstances where better 
haemodynamic monitoring is required, with gradual and constant workload 
increments until exhaustion is reached. A ramp protocol is most commonly 
used, whereby the resistance (watts) continuously increases, aiming for ten 
minutes of exercise time.  
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3.1.1.11.2 Treadmill   
Treadmill based protocols provide a better reflection of peak exertional 
capability, and lead to a higher peak VO2. The Bruce protocol modified by the 
addition of a ‘stage 0’ at onset, consisting of 3 minutes of exercise at 
1.61km/hr (1mile/hour) with a 5% gradient, is often used in the CHF setting 
(figure 3.1).(308) Other protocols exist with smaller speed and incline 
increments, such as the Balke protocol or the Naughton protocol, however 
these can lead to excessive exercise times.(309)(310) Faster protocols do 
not allow steady state gas exchange to occur.(311) 
 
  
  
Figure 3.1 Modified Bruce protocol 
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3.2 Measuring force-frequency relationship  
 
3.2.1 Literature review  
Cardiac contractility refers to the intrinsic capacity of cardiac myocytes to 
generate contractile force at a specific heart rate, independent of the preload 
and afterload. Thus assessment of this force-frequency relationship (FFR) in 
vivo should ideally take place independently of loading. This requires end-
systolic pressure (ESP) and end systolic LV volume (LVESV) 
measurements, which can be done either invasively or non-invasively. 
These are divided by each other (ESP/LVESV) to give an end-systolic 
pressure volume ratio (ESPVR), which has been shown to be a reliable 
representative measure of the FFR.(30)(312)(313) 
 
FFR is usually measured invasively, however this is generally complex, 
technically demanding, time consuming and exposes the patient to 
increased risk. Invasive methods include the use of exercise 
cineangiography, which requires a significant volume of nephrotoxic contrast 
agents and high radiation doses, using a high fidelity left ventricular catheter 
to measure pressure-volume loops, which is costly, or nuclear scintigraphy, 
which results in prolonged exposure to ionising radiation with limited 
temporal resolution.(314)(315)(316)  
 
FFR can also be measured noninvasively using echocardiography. This has 
been shown to be accurate, reproducible and safe.(313)(317) Contractility 
can be estimated either from 2-dimensional images or by the new technique 
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of tissue Doppler imaging. There are two main issues: accurately measuring 
subtle changes in contractility, and increasing the heart rate in predefined 
stages. Using 2D images, the ratio of systolic pressure and end-systolic 
volume can be obtained. The systolic pressure divided by the end-systolic 
volume index (LVESVi = biplane ESV/BSA) gives a surrogate of contractility 
(SP/LVESVi) that has been tested and validated against invasive 
methods.(288)(313)(318)  
 
 
3.2.2 Limitations 
A limitation of this method is using the systolic cuff pressure as a surrogate 
for end-systolic pressure in calculating the end-systolic pressure–volume 
relationship. This does introduce an approximation, however, there is a tight 
relationship between peak and end-systolic pressure (314)(316)(319) so any 
error will be systematically distributed along the whole FFR, provided the 
heart rate rise is not pharmacologically mediated. Thus this would not affect 
the comparative analysis between CHF and controls, and also within each 
cohort. 
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3.3 Thesis interventional study protocols 
 
3.3.1 Baseline visit 
Height and weight were measured at the start of each visit to allow oxygen 
consumption measures to be adjusted for body-weight and calculation of the 
body mass index (BMI, body weight (kg) divided by height squared 
(metres)). Information regarding co-morbidities, past medical history, 
medication types and dosages, pacemaker settings, NYHA symptom class 
and activities of daily living were collected during the baseline consent 
appointment, and stored in a secure anonymised electronic database.  
 
At baseline, each participant was consented for the study, underwent a full 
echocardiographic assessment, and performed a peak, symptom-limited 
treadmill-based familiarisation cardiopulmonary exercise test with breath-by-
breath metabolic gas analysis. Once a familiarisation test has been 
performed, a peak exercise test is not a training stimulus. The results from 
these familiarisation tests were not included in the final analysis. 
 
The echocardiogram images were stored on a commercially available 
database, (Echopac PC, Vingmed, Norway) and analysed offline to assess 
LV systolic and diastolic function variables, mitral regurgitation and 
pulmonary artery pressure.  
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3.3.2 Blinding protocol 
All interventional studies had a double-blind design and both the supervising 
physician and the patient were blinded to the pacemaker settings and to the 
heart rates throughout the visit. An un-blinded technician, who also 
monitored the electrocardiogram throughout the study, performed the 
pacemaker programming. 
 
The metabolic cart was separated from the electrocardiogram and heart rate 
monitors by a screen, and observed by the blinded physician. The blinded 
physician also measured the resting, peak and recovery blood pressures 
using a standard manual cuff sphygmomanometer. 
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3.3.3 Research exercise testing protocol 
After randomisation and prior to starting the test, a rest period of six minutes 
was implemented to ensure that steady-state conditions were achieved. 
Both the blinded physician and the unblinded technician constantly 
monitored the test data. A continuous 12 lead ECG was displayed on the 
screens in real-time through the rest, test and recovery phases. Standard 12 
lead ECGs were also printed out at baseline, end of each stage, at peak 
exercise and during recovery, and stored for analysis.   
 
All participants performed a symptom limited maximal CPX test on a 
motorised treadmill using the Bruce protocol, modified by the addition of a 
‘stage 0’ at onset consisting of 3 minutes of exercise at 1.61km/hr 
(1mile/hour) with a 5% gradient (figure 3.1). During each test, expired air 
was collected continuously and metabolic gas exchange analysis performed 
breath-by-breath with the MedGraphics Ultima CardioO2 equipment (Medical 
Graphics UK Limited, Gloucester, UK).  
 
The equipment was re-calibrated using manufacturer recommended volume 
and gas calibration techniques before every exercise test, and each patient 
was familiarised with the equipment prior to starting the protocol. The height 
and weight for each patient are measured at the start of the visit and entered 
into the analyser software so that the breath-by-breath VO2 values were 
calculated in mL/min/kg.  
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All test subjects were encouraged to exercise to exhaustion prior to starting 
the protocol, and no motivation or instructions were given during the 
exercise test. Procedures were in place to ensure that the test would be 
stopped if the subject developed chest pain or ECG abnormalities.  
 
At the end of each stage and at peak exercise, subjects were asked to 
indicate their score for dyspnoea or fatigue on a chart that showed a scale 
from 0 (no symptoms) to 10 (maximal symptoms) using the standardised 
Borg scoring system.(320) All subjects were rested for six minutes following 
the test, and recovery CPX and ECG data were monitored.  
 
All tests were carried out in the same exercise laboratory by trained cardiac 
physiologists who were unaware of the echocardiographic data. The 
following week the other mode was activated. At the end of each test the 
pacemaker was re-programmed back to the original settings by the un-
blinded technician. All CPX and ECG data were recorded and stored in a 
secure server for post hoc analyses. 
 
 
- 93 - 
3.3.4 CPX data analysis 
Heart rate (HR, bpm), oxygen consumption (VO2, ml/kg/min) and carbon 
dioxide release (VCO2, ml/kg.min) were recorded as 15-second averages 
taken at the start of each stage and at peak. A respiratory exchange ratio 
(VCO2/VO2; RER) of greater than 1.1 was taken to indicate maximal effort.  
 
Peak oxygen consumption was defined as the maximal fifteen-second 
average of VO2 achieved during the last 60 seconds of exercise. The AT was 
manually determined using the VO2/VCO2 slope method. Ventilatory variables 
such as tidal volume (VT), frequency (f) of ventilation, OUES, O2 pulse, 
mean response time (MRT), mean response time recovery (MRT recovery) 
and VE/VCO2 slope (at peak and AT) were determined using average values 
from 15-second intervals. The VE/VCO2 slope was measured from start to 
peak (VE/VCO2 peak) and from start to AT (VE/VCO2 AT).  
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3.3.5 Echocardiography protocol 
All echocardiographic assessments were carried out by a highly specialised 
certified echocardiographer, who collected datasets in line with the 
European Society of Cardiology (ESC) Echocardiography guidelines.(321)  
All participants underwent a full 2-dimensional transthoracic 
echocardiographic study with with grey-scale and tissue Doppler images 
recorded in the two and four chamber views using harmonics to improve 
border definition if necessary. 
 
Images were obtained using a Philips ultrasound machine (3.5 MHz 
transducer; Model 7500, Philips Medical Systems, Andover, Massachusetts, 
USA) and stored offline to allow post-hoc analysis and measurements. Left 
ventricular systolic function assessment was done both visually and using 
the modified Simpson’s bi-plane method, whereby the 2 dimensional end 
systolic and end diastolic left ventricular areas were measured in orthogonal 
planes using the apical 4-chamber and 2-chamber views. The 
echocardiographer was blinded to the study arm and protocol. All 
echocardiographic data was analysed by two independent echo-
sonographers, independently of the exercise data analysis.  
 
 
3.3.6 FFR measurement protocol 
Following the baseline echocardiogram, further images were recorded at 
each 10 beat frequency increase during the interventional FFR protocol for 
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study 3 (OPT-Rate 3 – Chapter 7).  All echocardiogram images were stored 
on a commercially available database, (Echopac PC, Vingmed, Norway) and 
analysed offline to assess LV systolic and diastolic function variables, 
contractility, cardiac output, mitral regurgitation and pulmonary artery 
pressure.  
 
This analysis included a calculation of LV end diastolic and end systolic 
volumes using the biplane discs (modified Simpson’s) method by tracing the 
endocardial border excluding the papillary muscles. An average of three 
measurements was used in the final analysis. The frame at the R-wave was 
taken as end diastole, and the frame with the smallest LV cavity, as end 
systole. This was carried out by two independent fully qualified senior echo-
sonographers, and an average was taken for each measurement or 
calculation.  
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3.3.7 Statistical analysis protocol 
All statistical analyses were performed using the IBM SPSS Statistics 
program, version 22, for Windows. The Shapiro-Wilk test was used to 
determine whether the subject demographics, CPX and echocardiogram 
parameters were normally distributed (parametric).  
 
Continuous variables within and between groups were reported as either the 
mean and standard deviation (SD) if normally distributed, or as the median 
and interquartile range (IQR) if non-normally distributed (non-parametric).  
 
Groups were compared using either the Analysis of Variance test (ANOVA) 
and unpaired student T-test for normally distributed values, or the Kruskal-
Wallis H test (one way ANOVA on ranks) for non-parametric data, adjusting 
baseline values where appropriate.  
 
The Levene statistic was used as a test of homogeneity of variances, and 
the Welch and Brown-Forsythe statistical tests for ‘equality of means’ to 
confirm the results obtained from the one way ANOVA test if variances 
differed.  
 
Where the ANOVA test was significant, post hoc analysis was performed 
using either the Gabriel test, if variances were homogeneous, or the Games-
Howell test, if variances were not homogenous. 
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Categorical variables were analysed using the Chi-squared test. The 
relationship between heart rate changes and CPX parameters was assessed 
by calculating the paired correlation coefficients and using linear regression 
techniques.  
 
Any p-value less than 0.05 was considered to be statistically significant. All 
numerical and graphical data was also visually analysed prior to statistical 
testing to ensure validity. 
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Chapter 4: Retrospective CPX data analysis study 
 
4.1 Abstract 
 
Chronic heart failure (CHF) is associated with both impaired exercise 
capacity, measured as lower peak oxygen consumption (pVO2), and a 
reduction in heart rate rise during exertion, known as chronotropic 
incompetence (CI).  
 
The aim of this study was to assess whether there is a relationship between 
the severity of resting left ventricular systolic dysfunction (LVSD) assessed 
on echocardiography ejection fraction (EF) and exercise capacity assessed 
on cardiopulmonary exercise (CPX) testing, and whether this relationship is 
influenced by the heart rate response during exercise. 
 
A retrospective analysis of clinical, echocardiographic and CPX data from 
147 CHF patients and 48 hospital based control subjects was performed. 
The CHF cohort was split in to two groups based on LVSD severity on 
echocardiography.  
 
Hospital based controls delivered the best exercise performance, and this 
group also exhibited the best heart rate rise during exercise. Both CHF 
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groups showed a similar blunting in the heart rate response. However, whilst 
the control group had a strong correlation between peak VO2 and heart rate 
rise, this correlation was much weaker in the mild/moderate LVSD group and 
non-existent in the severe LVSD group. The total CHF cohort was then re-
stratified by the presence and the degree of CI present. Those with CI had 
lower pVO2, despite similar EF, co-morbidities and medications. 
 
Thus, this study demonstrates the principle underlying the thesis. There is a 
definite association between HRR and exercise capacity in LVSD, but it is 
unknown whether the reduced HRR in CHF is an adaptive or maladaptive 
physiological response.  
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4.2 Introduction 
 
Heart failure is associated with a sustained reduction in cardiac output and 
limited ability for the cardiac output to increase appropriately during 
exercise.(322)(323) Cardiac output is a composite of the stroke volume and 
heart rate. In health both increase during activity in order to match the supply 
of oxygenated blood to the demands of respiring metabolically active 
skeletal muscles.(324)  
 
A limited adaptation to the demands of physical exercise is characteristic of 
CHF and reduced stroke volume is typical.(325) However it is unclear what 
role heart rate plays in determining exercise capacity in CHF. The aim of this 
study was to determine whether there is a reduction in heart rate rise in the 
context of heart failure, and if there is any relationship between an impaired 
heart rate response and the degree of exercise intolerance in patients with 
CHF.  
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4.3 Methods 
 
All out-patients attending the Leeds General Infirmary Cardiology 
Investigations Unit for a cardiopulmonary exercise test as part of their clinical 
assessment, between August 2011 and August 2012, were included in this 
retrospective cohort analysis. The population was a convenience cohort of 
consecutive patients referred for assessment of their heart failure syndrome. 
Control subjects were people without heart failure referred for pre-operative 
assessment.  
 
All subjects also underwent a transthoracic echocardiogram (TTE) with 
acquisition of the full minimum dataset in accordance with the ESC, and a 12 
lead ECG as part of their outpatient assessment. All subjects were instructed 
to omit heart rate limiting medications for 24 hours prior to, and on the day 
of, the CPX test, as part of routine practice with CPX testing in this 
Cardiology Investigations Unit. All the raw data from these tests were 
analysed retrospectively.  
 
Patients with primary valvular disease were excluded from the heart failure 
cohort, and subjects in the non-heart failure group were excluded if 
echocardiography revealed structural cardiac disease including left 
ventricular dysfunction or if they had musculoskeletal conditions limiting 
exercise capacity. 
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All patients underwent a cardiopulmonary exercise test as described in 
chapter 3 according to the standard protocol. Data were stored for offline 
analysis. Subsequent statistical analysis was undertaken as described in 
chapter 3 using SPSS for windows. 
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4.4 Results 
 
During the 12 month period from August 2011 to August 2012, 214 patients 
underwent outpatient clinical assessment, 12 lead ECG, CPX testing and 
echocardiography. Of these, 19 were found to have primary valvular disease 
with severe dysfunction, and were thus excluded. No patients were limited 
by extertional symptoms relating to cardiac ischaemia, evidenced by the 
presence of chest pain or ischaemic ECG changes during the exercise test.  
  
4.4.1 Groups 
The remaining 195 subjects formed the study cohort and were sub-divided 
into three groups based on their resting echocardiographic left ventricular 
ejection fraction (LVEF) and clinical diagnosis. The echocardiographic data 
showed that the left ventricular internal dimensions at both systole (LVIDs) 
and diastole (LVIDd) were significantly increased with worse LVEF (figure 
4.1 and table 4.1).  
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Figure 4.1 Cardiac function and measurements 
 
 
 Parameters (mean (SD)) 
Control Mild-Mod LVSD Severe LVSD 
Ejection Fraction (%) 60 (5) 43 (5) 27 (6) 
Left ventricular end 
diastolic diameter (mm) 50 (6) 51 (6) 62 (8) 
Left ventricular end 
systolic diameter (mm) 35 (5) 41 (7) 53 (8) 
Table 4.1 Echocardiographic parameters 
 
The hospital based control group of convenience consisted of 48 patients 
with a normal resting echocardiogram (no echocardiographic evidence of 
systolic or diastolic dysfunction, as defined by the BSE criteria; EF>55%), 
who primarily had CPX tests and echocardiograms as part of their non-
cardiac pre-operative assessment. The remainder were divided into two 
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groups based on resting EF: mild-moderate LVSD (n=57, EF between 35 
and 55 %) and severe LVSD (n=90, EF less than 35%).  
 
4.4.2 Demographics 
The characteristics of the three groups are shown in Table 4.2. The Levene 
statistical test revealed that the variances in ejection fraction, height, QRS 
duration, VO2 peak and beta-blocker dose were not homogenous (p<0.05).  
 
There were differences in the groups with regards to age (F=0.819; p<0.05), 
and QRS duration (F=23.279; p<0.05). The control group were younger (63 
± 13 years; p<0.05), had shorter QRS duration (median 90 ± 0 ms; p<0.05) 
and were not taking any heart failure medication (beta-blocker or ACEi). 
Doses of these agents were not different between the two groups with 
LVSD.   
 
The 1 year all-cause mortality was higher in the presence of heart failure 
(severe LVSD 14%, mild-moderate LVSD 12%, controls 2%), although the 
numbers were too small to be significant (n=21; χ2 = 5.169, p = 0.075). 
 
4.4.3 Aetiological factors 
Table 4.3 shows the aetiologies of the 147 heart failure subjects. The ‘other 
causes’ included chemotherapy related cardiomyopathy, postpartum 
cardiomyopathy, alcoholic cardiomyopathy, right ventricular pacing 
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cardiomyopathy and idiopathic cardiomyopathy. Cardiomyopathy due to IHD 
was found to be the most frequent cause (48% in the ‘Severe LVSD’ group 
and 56% in the ‘Mild-moderate LVSD’ group). 
 
A comparison was made of the frequency of risk factors. Ischaemic heart 
disease was present in 47%, diabetes mellitus in 15%, atrial fibrillation in 
23%, left bundle branch block in 37% and the presence of a pacemaker in 
42%. The two groups with LVSD had a higher incidence of coronary artery 
disease, diabetes mellitus and abnormal ECG changes such as atrial 
fibrillation and a left bundle branch block. The ECG abnormalities were also 
increased in the severe LVSD group compared to the mild/moderate LVSD 
group, as was the likelihood of having a pacemaker device in-situ (table 4.3). 
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Table 4.2 Group demographics 
 
 
 
Demographics 
(mean (SD)/median (IQR)*) 
Control 
(EF >50) 
n=48 
Mild-Mod 
LVSD 
(EF 35-50) 
n=57 
Severe 
LVSD 
(EF <=35) 
n=90 
F 
statistic/ 
Chi-
squared 
Significance 
Control 
vs 
LVSD 
(any) 
P value 
Mild-Mod 
vs Severe 
LVSD 
P value 
Ejection Fraction, % 60 (5) 43 (5) 27 (6) 555.993 0.000 <0.05 <0.05 
Height (cm) 171 (12) 168 (10) 171 (8) 2.478 0.087 0.453 0.116 
Weight (kg) 83 (21) 81 (18) 87(18) 1.537 0.218 0.676 0.641 
BMI (median (IQR)) 28 (25-29) 29 (26-31) 30 (26-31)  0.311   
BSA 1.99 (0.3) 1.94 (0.2) 2.03 (0.2)     
Age (median (IQR), years) 68 (55-74) 74 (66-78) 72 (63-80) 4.819 0.009 <0.05 0.688 
Male (tally) 34 (71%) 43 (75%) 72 (80%)  0.472   
Peak predicted heart rate 156 (14) 150 (12) 150 (12) 4.819 0.009 <0.05 0.967 
Heart Rate Rise 67 (28) 46 (23) 48 (26) 11.518 0.000 <0.05 0.948 
Resting Heart Rate 78 (17) 76 (15) 77 (18) 0.289 0.750 0.850 0.909 
Peak Heart Rate* 157 (39) 121 (26) 130 (53) 18.486 0.000 <0.05 0.840 
QRS duration (ms) 90 (81-94) 101 (83-129) 113 (86-137) 23.279 0.000 <0.05 0.06 
BB (bisoprolol equivalent, mg)* 0 (2.5) 5 (7.5) 5 (7.5) 28.104 0.000 <0.05 0.868 
ACEi/ARB (ramipril equivalent, mg)* 0 (3) 10 (8) 10 (7) 25.315 0.000 <0.05 0.978 
pVO2 (ml/kg/min)* 23.2 (8) 16.5 (6) 15.9 (6) 26.000 0.000 <0.05 0.481 
Chronotropic Index 0.9 (0.4) 0.7 (0.5) 0.7 (0.5) 3.891 0.022 <0.05 0.860 
Exercise Time 595 (268) 427 (212) 399 (216) 11.882 0.000 <0.05 0.840 
Anaerobic Threshold 16 (7) 13 (4) 12 (3) 8.716 0.000 <0.05 0.957 
RER 1.13 (0.1) 1.08 (0.1) 1.07 (0.1) 3.428 0.035 <0.05 <0.05 
VE/VCO2 slope (AT) 27 (6) 32 (6) 30 (7) 5.687 0.004 <0.05 0.394 
VE/VCO2 slope (Peak) 30 (6) 36 (9) 37 (12) 7.057 0.001 <0.05 0.993 
LVIDd 50 (6) 51 (6) 62 (8) 46.293 0.000 <0.05 <0.05 
LVIDs 35 (5) 41 (7) 53 (8) 45.165 0.000 <0.05 <0.05 
Resting SBP 135 (19) 130 (24) 122 (21) 6.391 0.002 0.514 <0.05 
Resting DBP 90 (99) 71 (11) 70 (12) 2.623 0.075 0.082 0.998 
Peak SBP 169 (28) 151 (28) 137 (24) 23.414 0.000 <0.05 <0.05 
Peak DBP 78 (12) 72 (11) 73 (12) 4.867 0.009 <0.05 0.996 
Non-parametric variables reported as median (interquartile range). Normally distributed variables 
as mean (SD). 
KEY: NYHA: New York Heart Association functional classification, HR: heart rate, LVIDd: left 
ventricular internal diameter in diastole, LVIDs:  left ventricular internal diameter in systole, DT: 
deceleration time, PMH: past medical history, IHD: ischaemic heart disease, CABG: coronary 
artery bypass grafting, PCI: percutaneous coronary intervention, ACEi: angiotensin converting 
enzyme inhibitor, ARB: angiotensin II receptor blocker. 
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 Control Mild-Mod LVSD Severe LVSD 
Tally % Tally % Tally % 
IHD 7 15 37 65 47 52 
DCM 2 4 12 21 39 43 
Diabetes mellitus 4 8 11 19 15 17 
Any pacing device 5 10 22 39 55 61 
Bi-ventricular CRT 0 0 16 28 52 58 
Atrial fibrillation 5 10 13 23 27 30 
LBBB (QRS >120ms) 2 4 21 37 50 56 
KEY: IHD: ischaemic heart disease, DCM: dilated cardiomyopathy, CRT: 
cardiac resynchronisation therapy, LBBB: left bundle branch block  
Table 4.3 Group co-morbidities 
 
 
4.4.4 Differences in exercise test findings and HR  
Peak VO2 and peak heart rate followed a non-parametric distribution 
(Shapiro-Wilk test, p<0.05). These are therefore reported as median and 
interquartile range.  The median peak heart rate was 127 ± 38 beats/min, 
and the mean heart rate rise achieved was 52 ± 27 beats/min. The median 
pVO2 was 17.1 ± 9.2 ml/kg/min. 
 
Peak VO2 differed between controls (23.2 ± 18 ml/kg/min; p<0.05) and the 
LVSD groups (Mild-mod LVSD 16.5 ± 6 ml/kg/min; Severe LVSD 15.9 ± 6 
ml/kg/min, p=0.481).  
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The Kruskal-Wallis H test on pVO2 showed χ2(2) = 26, p = 0.000, with a 
mean rank of 133.25 for ‘controls’, 92.78 for ‘mild-moderate LVSD’ and 
82.51 for ‘severe LVSD’, and in peak heart rate χ2(2) = 18.486, p = 0.000, 
with a mean rank of 128.23 for ‘controls’, 85.43 for ‘mild-moderate LVSD’ 
and 89.84 for ‘severe LVSD’. 
 
Oxygen consumption at AT during cardiopulmonary exercise testing was 
also significantly different between all groups, as were the calculated slopes 
of the ratio of minute ventilation to CO2 volume exhaled (VE/VCO2 slope) at 
peak exercise and at the anaerobic threshold (table 4.2, figure 4.2). Heart 
rate responses were equally limited in both LVSD groups (figure 4.3).  
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Figure 4.2 Cardio-pulmonary exercise testing results 
Figure 4.3 Heart rate comparisons 
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4.4.5 Relationship between exercise capacity and HR 
Whilst the control group had a strong correlation between peak oxygen 
consumption and heart rate rise (peak HR – resting HR), this correlation was 
much weaker in the mild/moderate LVSD group and non-existent in the 
severe LVSD group (Figure 4.4). 
 
In the entire cohort, there was a significant linear relationship between heart 
rate rise and peak VO2 where a heart rate rise of 10 bpm resulted in an 
increase in peak VO2 of 1.8 ml/kg/min (p<0.05, fitted lines represented by 
dashed lines). However, in control patients the rate of increase in peak VO2 
relative to a 10 bpm increase in HRR was 2.6 ml/kg/min (p<0.05), whereas 
this was less in patients with mild-moderate LVSD (1.6 ml/kg/min per 
increase of 10 bpm, p<0.05) and no clinically significant in those with severe 
LVSD (0.085 ml/kg/min per increase of 10 bpm, p<0.05).  
 
This relationship was further investigated using linear regression of the HRR 
as a predictor of peak VO2 in the three groups: controls R2=0.420 (ANOVA F 
value <0.01), mild-moderate LVSD R2=0.366 (ANOVA F value <0.01) and 
severe LVSD R2=0.179 (ANOVA F value <0.01).  
 
A likelihood ratio test comparing these regression lines against a single line 
for all points confirmed that there were significant differences in the HR 
relationship in control subjects and patients with mild-moderate and severe 
heart failure (χ21=4.01, p=0.035). Furthermore, comparing the regression 
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lines pair-wise suggested that there are also significant differences in the 
slopes between control and mild-moderate patients and mild-moderate 
patients and severe patients (p<0.05). 
 
  
Figure 4.4 Correlation of heart rate rise to peak oxygen consumption 
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4.4.6 Association with CI  
Patients with LVSD were then divided by the presence or absence of CI, 
defined as a chronotropic index of less than/equal to 0.8 (discussed in 
Chapter 3; (Peak HR –Resting HR)/(Peak Predicted HR – Resting HR)). The 
demographics and results from the two groups (No CI [n=43] and CI [n= 
104]) are shown in Table 4.4.  
 
Variables in both groups were tested for normality using the Shapiro-Wilk 
test. In the ‘no CI’ group, chronotropic index, peak predicted heat rate, 
height, pVO2, RER, peak diastolic blood pressure, QRS duration, bisoprolol 
dose and ACE/ARB dose were not normally distributed. In the ‘CI’ group, 
chronotropic index, pVO2, resting heart rate, resting diastolic blood pressure, 
QRS duration, bisoprolol dose and ACE/ARB dose were not normally 
distributed. All non-parametric data were therefore reported as median and 
interquartile range (Table 4.4).  
 
The Levine statistic revealed that variance differed in age, peak predicted 
heart rate, heart rate rise, resting heart rate and peak heart rate, thus 
appropriate statistical tests were used to ensure accuracy of ‘equality of 
means’ in the ANOVA test results (discussed in chapter 3).   
 
The two groups were similar with respect to age, sex, height, weight, BMI, 
EF, LVIDd, LVIDs, beta-blocker dose, ACEi dose and resting blood 
pressures. There was a higher occurrence of diabetes, coronary artery 
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disease, LBBB and pacing devices in the ‘CI’ group, and increased AF and 
DCM in the ‘no CI’ group. 
  
The ‘no CI’ group with higher HRR (73 (23) v 36 (16) beats/min), had better 
exercise time (477 (217) vs 382 (209) seconds, F(1,145) = 6.2, p<0.05) and 
AT (13.7 (3) v 12.1 (3) ml/kg/min, F(1, 81) = 4.28, p<0.05), but similar 
VE/VCO2 slope (peak), VE/VCO2 slope (AT) and RER (figure 4.5).  
 
 
Non-parametric variables were compared using the Kruskall Wallis test. This 
showed higher peak VO2 (16.3 (6) v 15.9 (6) ml/kg/min, χ2=6.4, p<0.05), CI 
index (1.07 (0.7) v 0.6 (0.3), χ2=90.6, p<0.05) and QRS duration (χ2=5.96, 
p<0.05). There were no differences in bisoprolol (χ2=0.293, p=0.588) and 
ACEi/ARB (χ2=0.130, p=0.719) dosages (table 4.4). 
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P<0.05 
P<0.05 
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P<0.05 
P<0.05 
  
Figure 4.5 Comparing CHF cohorts with and without CI 
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Demographics 
(mean (SD)/median (IQR)*) 
No CI (n=43) CI (n=104) P value 
Age 69 (30) 67 (13) 0.834 
Male 35 (80%) 80 (78%)  
Height* 172 (19) 170 (10) 0.394 
Weight 90 (22) 81 (15) 0.769 
BMI 30 (5) 28 (4) 0.636 
Ejection Fraction (%) 30 (9) 35 (9) 0.791 
LVIDd diameter (mm) 58 (9) 56 (8) 0.989 
LVIDs (mm) 48 (12) 46 (9) 0.890 
BB* (bisoprolol equivalent, mg) 5 (5) 7.5 (5) 0.475 
ACEi/ARB* (ramipril equivalent, mg) 10 (0) 10 (8) 0.569 
Peak VO2* (ml/kg/min) 16.3 (6) 15.9 (6) <0.05 
Exercise Time (s) 477 (217) 382(209) <0.05 
AT (ml/kg/min) 13.7 (3) 12.1 (3) <0.05 
VE/VCO2 slope (peak) 30 (5) 35 (7) 0.288 
VE/VCO2 slope (AT) 29 (4) 32 (7) 0.329 
RER* 1.09 (0) 1.05 (0) 0.484 
Rest HR* (bpm) 89 (16) 73 (15) <0.05 
Peak HR (bpm) 159 (28) 109 (19) <0.05 
HR rise (bpm) 73 (23) 36 (16) <0.05 
Peak Predicted HR* (bpm) 144 (19) 149 (13) 0.064 
Chronotropic index* 1.07 (0.7) 0.6 (0.3) <0.05 
Rest Systolic BP (mmHg) 125 (25) 128 (22) 0.660 
Rest Diastolic BP* (mmHg) 70 (19) 70 (20) 0.690 
Peak Systolic BP (mmHg) 141 (27) 150 (29) 0.658 
Peak Diastolic BP* (mmHg) 74 (13) 70 (20) 0.286 
Ischaemic Heart Disease 21 (48%) 54 (52%) 
 
Dilated Cardiomyopathy 17 (40%) 34 (33%) 
Coronary Artery Disease 23 (53%) 61 (59%) 
Heart Failure 43 (100%) 104 (100%) 
Diabetes Mellitus 3 (8%) 23 (21%) 
Any pacing device 14 (33%) 63 (60%) 
Bi-ventricular CRT 12 (28%) 56 (53%) 
Atrial fibrillation 22 (55%) 18 (17%) 
LBBB (QRS >120ms) 15 (35%) 56 (53%) 
QRS duration* (ms) 90 (50) 130 (50) <0.05 
All continuous variables are reported as either mean (SD) or median (IQR)*. 
Key: BMI: body mass index, LVIDd: left ventricular internal diameter in diastole, LVIDs: left ventricular internal 
diameter in systole, BB, beta-blocker, ACEi/ARB: angiotensin converting enzyme inhibitor/angiotensin II receptor 
antagonist, VO2: oxygen consumption, AT: anaerobic threshold, VE/VCO2 slope: slope relating ventilation rate to 
carbon dioxide output, RER: respiratory exchange ratio, HR: heart rate, BP: blood pressure, CRT: cardiac 
resynchronisation therapy, LBBB: left bundle branch block. 
Table 4.4 Comparison between different exertional heart rate rise groups (No CI vs CI). 
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4.4.7 Stratification of the cohort based on degree of CI 
The CI group had worse exercise capacity and lower peak VO2, despite no 
difference in BMI, ejection fraction, co-morbidities or medications.  
 
The total heart failure cohort (n=147) was then re-stratified by the degree of 
CI, as defined by the chronotropic index to assess for any link between 
worsening CI and exercise capacity, described by the peak VO2 and exercise 
time. This resulted in seven groups: 1 (Chronotropic Index > 1.2, n=16), 2 
(Chronotropic Index > 1, n=8), 3 (Chronotropic Index > 0.8, n=18), 
4(Chronotropic Index > 0.6, n=32), 5 (Chronotropic Index > 0.4, n=40), 6 
(Chronotropic Index > 0.2, n=23), 7 (Chronotropic Index < 0.2, n=10).  
 
Bisoprolol and ACEi/ARB dose were not normally distributed (Shapiro Wilk 
test p<0.05), and were examined using non-parametric tests, which 
demonstrated no difference between groups (Table 4.5, bisoprolol χ2=8.7, 
p=0.188; ACEi/ARB χ2=3.6, p=0.727).  
 
 
N Mean SD Minimum Maximum 
Percentiles 
25th 50th 75th 
Bisoprolol 146 5.6507 3.61456 0 10 2.5000 5.0000 10.0000 
ACEi/ARB 142 6.70 3.723 0 10 2.50 10.00 10.00 
Table 4.5 Bisoprolol and ACEi/ARB doses 
 
ANOVA testing was used to compare the seven groups (results data for 
each group is available in appendix A). Significance was seen in heart rate 
rise (F(6,140) = 47, p < 0.05), exercise time (F(6,140) = 4.38, p < 0.05), 
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resting heart rate (F(6,140) = 9.30, p < 0.05), peak heart rate (F(6,140) = 
101, p < 0.05), peak VO2 F(6,140) = 4.5, p < 0.05) and QRS duration 
(F(6,127) = 2.8, p < 0.05). 
 
Below an index of 0.8 (group 3), worsening heart rate response was 
associated with definite and progressive reductions in pVO2, AT and exercise 
time (figures 4.6 and 4.7).  
 
There was no difference in ejection fraction, ventricular internal dimensions, 
anaerobic threshold, VE/VCO2 slopes at AT and peak or BMI. 
 
Figure 4.6 Peak oxygen consumption with decreasing chronotropic index 
 
p	<0.05 
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Figure 4.7 Exercise time with decreasing chronotropic index 
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4.5 Discussion 
 
This retrospective analysis of a cohort of real-world subjects with heart 
failure of multiple aetiologies undergoing exercise testing for clinical 
purposes demonstrated that heart rate rise is closely related to exercise 
capacity in a linear way, but that the slope of this relationship is much 
reduced in those with severe heart failure.  
 
Furthermore, within the heart failure cohort, the presence of CI was 
associated with worse exercise capacity, despite there being no difference in 
cardiac structure or function, co-morbidities, medications, BMI and age.  
 
 
4.5.1 Cohort selection 
The cohorts were selected according to the resting EF on echocardiogram. 
Multiple studies have shown that although LVSD is associated with reduced 
functional capacity, there is poor correlation between the severity of LVSD 
and symptoms as measured by the NYHA functional classification,(326) and 
also between the severity of LVSD and CPX exercise measures.(207)(327) 
The findings from this study are in keeping with this.  
 
The degree of LV systolic impairment at rest (ejection fraction) was chosen 
as the measure by which to group these patients since mechanical 
alterations are a possible driver behind the pathophysiological changes 
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leading to impaired HRR with exertion. EF is also widely used, both clinically 
and in the research setting, to assess systolic function, influence treatment 
decisions and monitor response,(328)(329) so if in due course management 
is altered by our findings, grouping patients like this is practical and 
pragmatic.  
 
Selecting a control group for this study was also challenging, and a hospital 
based control cohort of convenience was used. This consisted of a healthy 
subset of hospital patients who underwent outpatient echocardiogram and 
CPX testing for elective non-cardiac surgery pre-operative assessment. 
Thus a higher proportion of the control cohort had co-existing IHD, AF or a 
pacing device in-situ, than would be expected in a totally healthy cohort. This 
may impact any group comparisons made, however as the presence of 
these comorbidities would limit exercise capacity, then any difference seen 
is likely to be an under-estimation. 
 
 
4.5.2 Relationship between HRR and exercise in controls and 
heart failure patients 
Our data confirm that HRR is strongly associated with peak exercise 
capacity achieved in control subjects. However, this relationship was weaker 
in patients with heart failure. There was a potential age related bias with the 
hospital based controls in that they were younger than the HF cohort. In our 
analyses we corrected for both age and level of fitness by using the ratio of 
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HR reserve to metabolic reserve, known as the chronotropic index. This is a 
more objective measurement for CI than measures that rely on achieving a 
certain percentage of the age-predicted maximum heart rate. An index of 
less than 0.8 is considered to represent CI, regardless of age, functional 
capacity or BMI.  
 
The two LVSD cohorts had lower chronotropic index measures than the 
control group, and cardio-pulmonary exercise test indices were similarly 
reduced. However, there was no difference in exercise parameter 
comparisons between the two heart failure groups.  
 
Although most of the LVSD patients were taking beta-blockers, which could 
result in an iatrogenic worsening of heart rate rise, we and others have 
previously shown that although these agents lower peak and resting heart 
rates, this does not generally adversely alter exercise capacity. Equally, 
although acute withdrawal of beta-blockers improves PHR there is no 
increase in exercise capacity or symptoms.(230) (235) Patients with LVSD 
were also taking ACEi, but ACEi are not known to restrict exercise 
capacity.(330)  In addition, all patients attending for elective outpatient CPX 
testing in this Cardiology Investigations Unit are routinely instructed to omit 
all rate-limiting medications on the day of the procedure, and 24 hours prior. 
 
Nonetheless, the data have shown that within the control cohort, there is a 
strong correlation between HRR and pVO2, and this association is weakened 
in the LVSD cohorts, who exhibit an impaired chronotropic response. 
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4.5.3 CI and LVSD 
A significant difference in exercise capacity was demonstrated when the 
combined LVSD dataset was divided into two groups based on the 
chronotropic index. The ‘no CI’ group also had a higher resting HR, which 
could either represent higher sympathetic tone in this group, or be a 
reflection of the increased prevalence of AF.  
 
The LVSD cohort was further stratified into seven groups based on the 
chronotropic index. CI commonly develops in association with cardiac 
dysfunction and seems to worsen with disease progression.  Whether this 
contributes to or is the consequence of lower exercise capacity in CHF is 
unclear. These results confirm that there is a relationship between peak 
oxygen consumption and heart rate rise, and that both are reduced in the 
context of heart failure.  
 
This forms the key principle underpinning this body of research, and the 
associated hypotheses. These results agree with previous studies that have 
shown a similar relationship.(331)(332) However, what is not clear from 
these data, and from previous studies in this area, is whether the reduced 
HR response is a causative factor in the impaired exercise capacity that is 
pathognomonic of worsening heart failure, or simply an associated incidental 
finding that reflects the reduced exertional capability.  
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4.5.4 Clinical implications 
These findings are clinically relevant because they highlight the differences 
in heart rate response with decreasing resting ejection fraction, in a large 
cohort with varied co-morbidities. It is widely believed that a limited HRR 
contributes to exercise intolerance in subjects with CHF. Hence, the 
correction of CI remains a target to improve functional capacity. This is a 
reasonable assertion in patients without CHF and as we have seen there is 
a strong relationship between heart rate rise and peak oxygen consumption.  
 
However, even our observational dataset shows that this relationship is 
weaker in patients with heart failure and essentially flat in those with the 
worst heart function. This is likely to be the consequence of the chronic 
multi-system abnormalities in the respiratory, skeletal and cardiovascular 
systems, whether directly or indirectly the result of CHF, that could all be 
contributing to the limited exercise capacity, such that simply increasing 
HRR and achieving ‘chronotropic competence’ may not result in any 
improvement in exercise capacity.  
 
Nevertheless, the uncertainty of a causative relationship might contribute to 
suboptimal use of heart rate reducing agents, for fear of inducing exercise 
intolerance. Furthermore, despite no conclusive evidence of benefit on 
exercise time or quality of life in CHF from rate-adaptive pacing,(263) this 
programming mode with high base rates remains the standard of care for 
most CHF patients with pacemakers, creating a paradoxical mix of medical 
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therapy to reduce mean heart rate with rate-adaptive pacing to increase 
heart rate. 
 
4.5.5 Study limitations 
This was a retrospective cohort analysis and prospective studies will 
necessarily be required in order to confirm these findings and explore the 
association between heart rate and exercise further. All of the patients in this 
cohort had been referred for either a clinical indication, functional 
assessment prior to undergoing vascular surgery, impaired exercise capacity 
or for heart failure prognostication. Thus, there was a wide mixture of 
aetiologies and co-morbidities present within this cohort, all of which could 
impact the overall functional capacity and exercise test results. 
 
Resting ventricular function was used to divide cohorts into controls, mild-
moderate LVSD and severe LVSD. EF has been shown to correlate poorly 
with exercise capacity and as such a better way to discriminate LVSD 
severity may have been to use questionnaires that assess the activities of 
daily living, 6-minute walk tests, NYHA status or dose of diuretics required to 
control the LVSD symptoms. Nonetheless, LVSD treatment guidelines rely 
on echocardiographic EF measurements to stratify LVSD severity and to 
guide treatment decisions. Hence, EF was chosen as the measure with 
which to separate the cohorts, as this information was readily available.  
 
Measurement of BNP would also have been useful for stratification however 
this was not available in the context of this retrospective analysis. It is also 
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noteworthy to mention that the controls were a hospital based sample of 
convenience, comprising of younger asymptomatic individuals with normal 
ejection fractions attending for elective pre-operative assessment for non-
cardiac surgery. 
 
The rationale behind using cardio-pulmonary exercise testing results, rather 
than six-minute walk tests was to increase reproducibility. The accuracy of 
the CPX tests and echocardiograms that were carried out clinically may not 
be to the same standards and rigour as required for research purposes and 
post-hoc data analysis. Different cardiac physiologists would have carried 
out the tests, thus creating the potential for errors in data recording and 
measurement. However, all cardiac physiologists are highly specialised, and 
each test was supervised and reported by two independent physiologists. All 
echocardiogram reports in this department are all routinely verified by the 
senior echosonographer on call for reporting.  
 
Also, all patients underwent an echocardiogram to quantity their ejection 
fraction, yet other imaging modalities such as cardiac magnetic resonance 
imaging can produce much more accurate and reproducible ejection fraction 
measurements, as well as give additional information with regards to cardiac 
filling and wall stiffness. However, such tests are not widely carried out on all 
patients undergoing functional assessment in the clinical setting.  
 
The groups were also not matched for height, weight, age or level of training; 
all of which can affect peak VO2. There may also have been differences in 
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the level of motivation within patients or encouragement from the technicians 
running the tests. There is a suggestion that a proportion of patients in this 
analysis may not have performed maximal tests as the mean RER for the 
entire cohort was below 1.1, however this could just be reflection of the 
multiple co-morbidities that were present within this cohort. 
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4.6 Conclusion 
 
The study has confirmed that an association exists between CI and exercise 
capacity in control subjects and albeit less strongly in patients with heart 
failure. However, a correlation does not necessarily indicate causation.  
 
The close relationship between the heart rate and any measure of exercise 
capacity makes determining a causal link between CI and poor exercise 
capacity difficult. Observational data will never be able to answer this 
question of causality, and it is therefore currently unknown whether CI, 
intrinsic or iatrogenic, either contributes to or is the consequence of reduced 
exercise capacity in CHF. 
 
In order to perform a comprehensive analysis of heart rate and exercise 
capacity in CHF, the roles of both the resting and peak heart rate will need to 
be investigated, whilst neutralising the potential effects of any contributors to 
functional capacity such as co-morbidities or medications. Double-blind 
randomised controlled trials of interventions to increase or reduce heart rate 
are required in order to determine whether CI actually causes exercise 
limitation.  
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Chapter 5: The influence of increasing the heart rate on 
exercise capacity in chronic heart failure (Opt-RATE 1 Study) 
 
5.1 Abstract 
 
As the observational cohort study has shown (Chapter 4), there is a strong 
relationship between peak oxygen consumption and heart rate rise (HRR) in 
controls. This association is decreased in chronic heart failure (CHF), and 
the presence of more severe chronotropic incompetence (CI) relates to 
lower functional capacity.  
 
Functional capacity is considered the most consistent prognostic indicator, 
and a reliable predictor for mortality. Those with reduced functional capacity 
also tend to have a blunted exertional heart rate response, however whether 
this is cause or effect has never been directly investigated before.  
 
A total of 118 subjects with pacemaker devices were enrolled into a 
randomised double blind study of rate adaptive versus fixed base rate 
pacing. The purpose of this trial was to assess whether ‘correcting’ 
chronotropic incompetence by increasing the heart rate response during 
exercise with a pacemaker device acutely alters exercise capacity in heart 
failure.    
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This was a placebo controlled cross-over study where the intervention was 
rate adaptive pacing and the control was fixed rate pacing to allow intrinsic 
rate changes. Each subject underwent two symptom-limited maximal 
treadmill-based cardio-pulmonary exercise tests, and acted as their own 
controls. Measures of oxygen kinetics were collected throughout the test 
period. Subjects with exertion-limiting co-morbidities and those who were 
known to not exhibit any intrinsic heart rate rise were excluded.  
 
Rate-adaptive pacing led to a higher mean (SE) peak HR (128 (3.0) vs 107 
(3.9) bpm) but no difference in mean peak oxygen consumption (16.6 (0.7) 
vs 15.9 (0.6) ml/kg/min, p=0.24), anaerobic threshold (11.7 (0.4) vs 11.3 
(0.4) ml/kg/min; p=0.24), exercise time (470 (34) vs 451 (31) s; p=0.33) or 
perceived exertion level scores.  
 
The study showed that correcting CI and increasing the peak HR achieved 
during a maximal exercise test did not result in any improvement in exercise 
capacity. 
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5.2 Introduction 
 
Reduced aerobic exercise capacity is the hallmark of heart failure, and it has 
been postulated that this may be to be due to an impairment in the ability of 
the heart to augment cardiac output in response to increasing physical 
activity demands. This is thought to be as a result of minimal increases in 
stroke volume and reductions in the peak achievable heart rate. However, it 
is currently unknown whether the lower peak heart rate is a limiting factor 
during aerobic exercise, or whether this is simply a reflection of the lower 
workload achieved prior to the onset of fatigue.    
 
The focus of this investigation is to examine the effects of increasing the 
heart rate rise and thus correcting CI in patients with CHF on peak and 
submaximal exercise capacity, by augmenting the heart rate profile 
throughout exercise, including peak heart rate. 
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5.3 Methods 
 
5.3.1 Study design  
This study was designed as a cross-over study of rate adaptive versus fixed 
rate pacing with subjects acting as their own controls, thus negating the 
contribution of all confounding factors except the independent variable, heart 
rate rise. All subjects were approached at routine outpatient pacemaker 
follow-up appointments and given information sheets. A pre-test consent 
appointment was attended by all participants (as described in chapter 3). 
This study was approved by the National Research Ethics Service (REC 
reference 13/YH/0144, IRAS project ID  129113, Appendix B). 
 
5.3.2 Study population 
Within this cohort of 118 subjects, 79 had CHF due to LVSD (HF group), and 
39 had pacing devices with no symptomatic or structural evidence of heart 
failure (Control group). These cohorts were further divided into those with 
n=692
•Patients attending	the	Cardiac	Investigations	Unit	for	routine	
pacemaker	check	over	6	months
n=476
•Patients	deemed	eligible	for	the	study	and	approached	for	
recruitment	and consent
n=131
• Patients consented	for	the	study	and	performed	pre-test	
familiaristion	CPX	and	echo
n=118
•Patients	completed	study	protocol	and	attended	for	two	consecutive	
double	blind	crossed exercise	tests	
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sinus rhythm (CHF n= 53; Controls n= 26) and atrial fibrillation (CHF n=28; 
Controls n = 11). All subjects had a pacing device in situ for a clinical 
indication, with stable pacemaker device and lead variables for at least six 
months. 
 
5.3.3 Inclusion and exclusion criteria 
The inclusion criteria for the test subjects were CHF due to left ventricular 
systolic dysfunction (LVSD), (moderate-severe; left ventricular ejection 
fraction <45% and symptoms of breathlessness or fatigue on exertion), on 
optimal medical therapy and stable symptoms. They must have had their 
pacemaker for at least 6 months with stable lead variables and no change in 
medication or other invasive cardiac procedures for at least three months. All 
subjects were capable of performing a peak exercise test on a treadmill, and 
informed written consent was obtained in all subjects.  
 
Subjects who were pacing dependent in the atrium and hence would not 
exhibit any rise in heart rate during activity were excluded. Other exclusion 
criteria consisted of the inability to give informed consent and co-morbidities 
that would limit exercise capacity such as uncontrolled angina, peripheral 
vascular disease, severe valvular dysfunction, severe obstructive or 
restrictive respiratory conditions, oxygen dependence and any 
musculoskeletal abnormalities or disorders that could restrict walking on a 
treadmill.  
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5.3.4 Exercise testing and randomisation 
After at least one week following the familiarisation test, subjects were 
invited back for the two maximal symptom-limited treadmill crossover 
exercise tests, which were carried out at least one week apart. Immediately 
prior to each test, the unblinded pacing technician temporarily programmed 
the pacemaker to rate-adaptive (RR on) or fixed rate pacing (RR off), with 
the maximum paced HR determined using the age-predicted peak HR 
equation (220-age).  
 
A screen was used to separate the heart rate and electrocardiographic 
monitor, which was only observed by the unblinded technician, from the 
metabolic cart, which was monitored by the blinded investigator. Resting, 
peak and recovery blood pressures were measured using a standard 
manual cuff sphygmomanometer. 
 
  
- 135 - 
5.3.5 Cohort size calculation 
The changes due to rate limitation are as yet not investigated in heart failure 
patients. This part of the study is therefore necessarily exploratory. An 
additional problem is that assessing sample size to demonstrate statistical 
equivalence is more difficult than establishing a difference between two 
groups. However peak oxygen consumption measurement is reliable and 
reproducible, with a coefficient of variation percentage of 9.73 in this 
laboratory. A mean of 15 (2) ml/kg/min was expected in CHF subjects in 
sinus rhythm, and a mean of 13 (2) ml/kg/min for CHF with atrial fibrillation 
(mean difference 15% lower), with higher peak heart rates achieved in the 
AF cohort (mean difference 23% higher).  
 
Therefore, in order to demonstrate a clinically important change of 2.0 
ml/kg/min with 80% power, and a two sided alpha of 0.05, a minimum of 22 
subjects were needed in the atrial fibrillation CHF group, and a minimum of 
38 in the sinus CHF group. To allow for drop-outs and to confidently suggest 
equivalence, the recruitment aims for the HF cohort were a minimum of 25 
patients in atrial fibrillation and 50 in sinus rhythm. As controls were 
expected to achieve higher peak VO2 readings (mean of 24 (3) ml/kg/min for 
sinus rhythm and 22 (3) ml/kg/min for atrial fibrillation) and heart rates, the 
recruitment aims were a minimum of 10 subjects with atrial fibrillation and 25 
with sinus rhythm.  
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5.4 Results 
 
5.4.1 Baseline characteristics  
5.4.1.1 Entire cohort 
The total population for this RCT consisted on 118 subjects. There were 79 
subjects with a diagnosis of CHF (symptomatic heart failure with 
echocardiographic evidence of LV systolic dysfunction), within which 53 
were in sinus rhythm and 26 had co-existent permanent atrial fibrillation. The 
remaining 39 were controls, of which 28 were in sinus rhythm and 11 had 
atrial fibrillation.  
  
Weight, resting heart rates and resting diastolic blood pressure followed a 
non-parametric distribution (Shapiro-Wilk normality test; p<0.05) and are 
hence reported as median ± interquartile range. Normally distributed 
variables are reported as mean (SD). Baseline variables are shown in table 
5.1. 
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Group 1 
Controls 
AF 
N=11 
Group 2 
Controls 
sinus 
N=28 
Group 3 
CHF-AF 
N=26 
Group 4 
CHF 
sinus 
N=53 
 
F 
statistic/ 
Chi-
Square 
 
P Value 
 
Height, cm 171 (9) 173 (9) 173 (6) 172 (7) .437 0.727 
Weight, kg 76 (16) 81 (12) 85 (17) 86 (15) 1.439 0.235 
Age, years 78 (6) 69 (13) 76 (8) 73 (8) 3.051 0.074 
NYHA class 1 1 2 2 - - 
Ejection fraction, % 54 (7) 55 (7) 31 (10) 34 (11) 34.698 0.000 
Peak predicted HR, 
bpm 142 (8) 151 (13) 144 (9) 147 (8) 3.051 0.076 
LVIDd, mm 49 (5) 48 (6) 53 (20) 53 (10) 0.408 0.748 
LVIDs, mm 35 (4) 35 (6) 46 (21) 43 (11) 2.409 0.081 
EA ratio - 0.96 (0.3) - 1.4 (1.3) 0.694 0.421 
E wave DT, ms - 234 (48) - 235 (72) 0.149 0.863 
E/E’ - 10 (5) - 8 (2) 0.903 0.462 
Furosemide dose: 
0/40/80/≥120 mg (% [n]) 
0/100/0/0 
[0/2/0/0] 
0/0/0/0 
[0/0/0/0] 
23/42/12/23 
[6/11/2/6] 
42/40/12/6 
[22/21/7/3] 26.218 0.000 
Diabetes mellitus 9% (1) 18% (5) 39% (10) 32% (17) 5.232 0.156 
IHD 9% (1) 32% (9) 39% (10) 42% (22) 4.418 0.220 
Hypertension 27% (3) 29% (8) 31% (8) 28% (15) 0.069 0.995 
PMH: CABG 0% (0) 18% (5) 27% (7) 23% (12) 3.784 0.286 
PMH: PCI 0% (0) 14% (4) 12% (3) 23% (12) 4.258 0.235 
PMH: Valve surgery 0% (0) 4% (1) 19% (5) 6% (3) 6.822 0.078 
ACEi 27% (3) 29% (8) 62% (16) 53% (28) 10.013 0.124 
ARB 0% (0) 11% (3) 35% (9) 36% (19) 15.582 0.016 
Beta-blocker 64% (7) 32% (9) 89%(23) 87% (46) 31.717 0.000 
Aldosterone antagonist 9% (1) 4% (1) 42% (11) 47% (25) 21.628 0.000 
Statin 36% (4) 32% (9) 77% (20) 70% (37) 16.729 0.001 
Ca2+ channel blocker 18% (2) 11% (3) 8% (2) 8% (4) 1.365 0.714 
Digoxin 0% (0) 0% (0) 46% (12) 6% (3) 34.260 0.000 
Normally distributed variables shown as mean (SD). 
KEY: NYHA: New York Heart Association functional classification, HR: heart rate, LVIDd: left ventricular internal 
diameter in diastole, LVIDs:  left ventricular internal diameter in systole, DT: deceleration time, PMH: past 
medical history, IHD: ischaemic heart disease, CABG: coronary artery bypass grafting, PCI: percutaneous 
coronary intervention, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker. 
Table 5.1 Baseline group demographics 
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5.4.1.2 Groups 
 
There were no differences in all four groups with respect to co-morbidities 
(table 5.1), thus making it possible to consider some inter-group 
comparisons. In particular, there were similar percentages of ischaemic 
heart disease and diabetes mellitus in all groups. 
 
The subgroups within the controls and CHF cohorts (ie: AF and sinus) 
showed no difference with respect to height, weight, BMI, age, NYHA class, 
ejection fraction, LV measurements, co-morbidities or medications. 
 
 
5.4.2 Comparing intrinsic heart rate rise (RR off) to augmented 
heart rate rise (RR on) 
Rate adaptive pacing alters the heart rate profile and cardio-acceleration in 
response to increasing levels of activity. The four groups exhibited different 
functional and symptomatic responses. 
 
5.4.2.1 CHF sinus group 
In the sinus CHF group (Group 4, n= 53) the use rate-adaptive pacing (RR 
on) resulted in correction of chronotropic incompetence, with a significant 
increase in the heart rate achieved at submaximal (HR at AT: 103 (18) v 94 
(18) bpm; p<0.05), maximal exercise (HR at peak: 125 (24) v 108 (26) bpm, 
p<0.05) and overall heart rate rise (HRR: 83 (20) v 58 (20) bpm, p<0.05).  
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There was no associated change in any CPX parameters including pVO2 
(17.0 (5.0) v 16.6 (5.4) ml/kg/min, p=0.345), exercise time (459 (240) v 464 
(249) s, p=0.706), AT (12.8 (3.4) v 12.3 (3.6), p=0.073), VE/VCO2 slopes (AT 
and peak) or reported symptoms of breathlessness and fatigue (Borg score 
(shortness of breath), 2.9 (2) v 2.7 (2), p=0.227; Borg score (leg weakness), 
3.1 (2) v 3.1 (2), p=0.856 (figures 5.1 and 5.2A-D; tables 5.2 and 5.3). 
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p<0.05 
p<0.05 
 
Figure 5.1 RR on vs RR off in sinus CHF cohort 
 
igure 5.1 RR on vs RR off in sinus CHF cohort 
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Group (CHF sinus, n=53) Mean N 
Std. 
Deviation 
Std. Error 
Mean 
 Resting HR, bpm RR on 67.151 53 11.9782 1.6453 
RR off 66.642 53 10.7024 1.4701 
Peak HR, bpm RR on 125.453 53 23.7758 3.2659 
RR off 107.849 53 26.3763 3.6231 
Resting systolic blood 
pressure, mmHg 
RR on 122.769 52 17.3958 2.4124 
RR off 119.346 52 18.6725 2.5894 
Resting diastolic 
blood pressure, 
mmHg 
RR on 66.808 52 10.7831 1.4954 
RR off 67.077 52 11.0858 1.5373 
Peak systolic blood 
pressure, mmHg 
RR on 147.154 52 28.2603 3.9190 
RR off 143.500 52 22.3865 3.1045 
Peak diastolic blood 
pressure, mmHg 
RR on 68.000 52 12.9373 1.7941 
RR off 65.808 52 11.1971 1.5528 
Exercise time, 
seconds 
RR on 458.679 53 239.9860 32.9646 
RR off 464.811 53 249.0455 34.2090 
pVO2, ml/kg/min RR on 17.030 53 5.0202 .6896 
RR off 16.645 53 5.4102 .7431 
HR at AT, bpm RR on 103.48 42 17.904 2.763 
RR off 93.83 42 18.340 2.830 
AT, ml/kg/min RR on 12.99 43 3.441 .525 
RR off 12.44 43 3.632 .554 
VE/VCO2 slope (peak) RR on 35.6728 53 9.72763 1.33619 
RR off 36.2838 53 10.69304 1.46880 
VE/VCO2 slope (AT) RR on 29.73 40 6.690 1.058 
RR off 30.70 40 8.925 1.411 
Peak RER RR on 1.1262 53 .11994 .01647 
RR off 1.1306 53 .12185 .01674 
OUE slope RR on 1702.11 51 636.7709 89.1658 
RR off 1707.28 51 721.2726 100.998 
MRT RR on 193.56 15 108.067 27.903 
RR off 187.81 15 126.239 32.595 
MRT recovery RR on 90.44 7 28.894 10.921 
RR off 106.03 7 46.827 17.699 
O2 pulse (peak) RR on 11.64 14 3.225 .862 
RR off 11.64 14 3.319 .887 
KEY:	CHF:	chronic	heart	failure,	HR:	heart	rate,	pVO2:	peak	oxygen	consumption,	AT:	
anaerobic	threshold,	VE/VCO2	slope:	slope	relating	ventilation	rate	to	carbon	dioxide	
output,	RER:	respiratory	efficiency	ratio,	OUE:	oxygen	uptake	efficiency,	MRT:	mean	VO2	
response	time.	
Table 5.2 Paired sample statistics (CHF sinus) 
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Group: CHF sinus 
 (n=53) 
Paired Differences 
t df P value 
Mean SD SE 
95% Confidence 
Interval 
Lower Upper 
 Resting HR, bpm .5094 10.115 1.3895 -2.2789 3.2977 .367 52 .715 
 Peak HR, bpm 17.603 19.622 2.6954 12.1951 23.0125 6.531 52 .000 
 Rest SBP, mmHg 3.4231 16.720 2.3187 -1.2320 8.0782 1.476 51 .146 
 Rest DBP, mmHg -.2692 11.334 1.5718 -3.4248 2.8864 -.171 51 .865 
 Peak SBP, mmHg 3.6538 23.048 3.1963 -2.7630 10.0707 1.143 51 .258 
 Peak DBP, mmHg 2.1923 14.210 1.9706 -1.7638 6.1484 1.113 51 .271 
 Exercise time, s -6.132 117.74 16.173 -38.5859 26.3217 -.379 52 .706 
 pVO2, ml/kg/min .3849 2.9386 .4037 -.4251 1.1949 .954 52 .345 
 HR at AT, bpm 9.643 15.631 2.412 4.772 14.514 3.998 41 .000 
 AT, ml/kg/min .553 1.973 .301 -.054 1.161 1.839 42 .073 
 VE/VCO2 slope (peak) -.6109 6.9987 .96135 -2.54003 1.31814 -.636 52 .528 
 VE/VCO2 slope (AT) -.979 6.328 1.001 -3.003 1.044 -.979 39 .334 
 Peak RER -.0043 .12314 .01691 -.03828 .02960 -.257 52 .799 
 OUE slope 24.835 368.32 51.575 -78.757 128.428 .482 50 .632 
 MRT 5.747 157.03 40.546 -81.217 92.710 .142 14 .889 
 MRT recovery -15.58 34.058 12.873 -47.083 15.914 -1.21 6 .272 
 O2 pulse (peak) .000 2.000 .535 -1.155 1.155 .000 13 1.000 
 KEY:	CHF:	chronic	heart	failure,	HR:	heart	rate,	SBP:	systolic	blood	pressure,	DBP:	diastolic	
blood	pressure,	pVO2:	peak	oxygen	consumption,	AT:	anaerobic	threshold,	VE/VCO2	slope:	
slope	relating	ventilation	rate	to	carbon	dioxide	output,	RER:	respiratory	exchange	ratio,	
OUE:	oxygen	uptake	efficiency,	MRT:	mean	VO2	response	time.	
Table 5.3 Paired sample T-tests (CHF sinus) 
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Figure 5.2A Heart rate profile in CHF sinus cohort 
 
Figure 5.2B Oxygen consumption profile in CHF sinus cohort 
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Figure 5.2C Symptom score (shortness of breath) in CHF sinus cohort 
 
Figure 5.2D Symptom score (leg fatigue) in CHF sinus cohort 
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5.4.2.2 CHF-AF group 
In the subgroup of CHF with concurrent atrial fibrillation (n=26), rate-adaptive 
pacing led to a higher mean (SD) heart rate at AT (99 (19) v 82 (21) bpm, 
p<0.05) and maximal exercise (121 (20) v 98 (27) bpm, p<0.05). The 
intrinsic heart rate test (RR off) in this cohort exhibited a blunted heart rate 
response overall. There was an initial brisk HRR, followed by a plateauing at 
sub-maximal exercise levels and a drop in the heart rate at peak. Rate 
adaptive pacing in the context of CHF with atrial fibrillation resulted in an 
increase in the heart rate achieved with each stage of exercise, and 
correction of the expected heart rate response (figure 5.4A). 
 
This was associated with higher mean pVO2 (15.3 (3.8) v 14.0 (3.8) 
ml/kg/min, p<0.05) but no change in the AT (11.3 (2.5) v 10.1 (3.5) 
ml/kg/min, p=0.177), exercise time (417 (237) v 373 (210) s, p=0.197), 
VE/VCO2 slopes (AT and peak) or perceived exertion level scores: shortness 
of breath scores (3.4 v 3.1, p=0.919) or leg fatigue (3.7 v 3.3, p=0.306) 
(figure 5.3, 5.4B-D, table 5.4 and 5.5). 
 
A comparison of those on beta-blockers (n=14) with those on both beta-
blockers and digoxin (n=12) revealed similar HRR (55 (18) v 49 (21) bpm, 
p=0.211) and AT (11.9 (3) v 10.6 (4), p=0.244), but lower pVO2 (16.7 (4) v 
14.4 (5), ml/kg/min, p<0.05) and exercise time (516 (255) v 401 (240) s, 
p<0.05) in the latter sub-group. 
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p<0.05 
p<0.05 
Figure 5.3 RR on and RR off in AF CHF cohort 
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Group (CHF-AF, n=26) Mean N 
Std. 
Deviation 
Std. Error 
Mean 
 Rest HR, bpm RR on 71.120 25 10.0471 2.0094 
RR off 68.800 25 11.8462 2.3692 
Peak HR, bpm RR on 121.000 25 20.3695 4.0739 
RR off 98.200 25 27.0201 5.4040 
Rest systolic blood 
pressure, mmHg 
RR on 120.240 25 16.1691 3.2338 
RR off 118.320 25 20.5400 4.1080 
Rest diastolic blood 
pressure, mmHg 
RR on 65.680 25 9.3217 1.8643 
RR off 64.560 25 11.8957 2.3791 
Peak systolic blood 
pressure, mmHg 
RR on 139.120 25 23.8613 4.7723 
RR off 133.120 25 21.6262 4.3252 
Peak diastolic blood 
pressure, mmHg 
RR on 65.600 25 10.3441 2.0688 
RR off 62.880 25 11.5337 2.3067 
Exercise time, 
seconds 
RR on 417.160 25 229.7406 45.9481 
RR off 373.480 25 205.3568 41.0714 
pVO2, ml/kg/min RR on 15.260 25 3.8550 .7710 
RR off 14.032 25 3.9088 .7818 
HR at AT, bpm RR on 98.68 22 15.628 3.332 
RR off 81.64 22 18.288 3.899 
AT, ml/kg/min RR on 11.24 22 2.654 .566 
RR off 10.14 22 3.081 .657 
VE/VCO2 slope (peak) RR on 37.4080 25 9.50166 1.90033 
RR off 39.4440 25 10.33078 2.06616 
VE/VCO2 slope (peak) RR on 31.85 22 8.824 1.881 
RR off 33.71 22 9.728 2.074 
Peak RER RR on 1.1475 24 .15845 .03234 
RR off 1.1396 24 .14505 .02961 
OUE slope RR on 1501.00 24 375.6624 76.6818 
RR off 1415.79 24 463.0956 94.5290 
MRT RR on 183.83 3 73.206 42.265 
RR off 232.83 3 130.359 75.263 
MRT recovery RR on 64.30 1a . . 
RR off 64.30 1a . . 
O2 pulse (peak) RR on 10.40 5 6.269 2.804 
RR off 10.40 5 5.983 2.676 
KEY:	CHF:	chronic	heart	failure,	HR:	heart	rate,	pVO2:	peak	oxygen	consumption,	AT:	
anaerobic	threshold,	VE/VCO2	slope:	slope	relating	ventilation	rate	to	carbon	dioxide	
output,	RER:	respiratory	efficiency	ratio,	OUE:	oxygen	uptake	efficiency,	MRT:	mean	VO2	
response	time. 
Table 5.4 Paired sample statistics (CHF-AF) 
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Group: CHF-AF 
 (n=26) 
Paired Differences 
t df 
P 
value Mean SD SE 
95% Confidence Interval 
Lower Upper 
 Resting HR, bpm 4.3200 6.8843 1.3769 1.4783 7.1617 3.138 24 .004 
 Peak HR, bpm 21.800 25.9037 5.1807 11.1075 32.4925 4.208 24 .000 
 Rest SBP, mmHg 1.9200 13.6806 2.7361 -3.7271 7.5671 .702 24 .490 
 Rest DBP, mmHg 1.1200 10.2807 2.0561 -3.1237 5.3637 .545 24 .591 
 Peak SBP, mmHg 6.0000 22.8035 4.5607 -3.4128 15.4128 1.316 24 .201 
 Peak DBP, mmHg 2.7200 11.6316 2.3263 -2.0813 7.5213 1.169 24 .254 
 Exercise time, s 16.680 98.1269 19.625 -23.8248 57.1848 .850 24 .404 
 pVO2, ml/kg/min 1.1280 2.7865 .5573 -.0222 2.2782 2.024 24 .054 
 HR at AT, bpm 12.045 25.688 5.477 .656 23.435 2.199 21 .039 
 AT, ml/kg/min 1.505 3.355 .715 .018 2.992 2.104 21 .048 
 VE/VCO2 slope (peak) -2.036 6.87222 1.3744 -4.87271 .80071 -1.481 24 .152 
 VE/VCO2 slope (AT) -1.858 4.805 1.024 -3.988 .273 -1.813 21 .084 
 Peak RER .01792 .15100 .03082 -.04584 .08168 .581 23 .567 
 OUE slope 85.208 284.67 58.108 -34.9991 205.4158 1.466 23 .156 
 MRT -49.00 69.864 40.336 -222.552 124.552 -1.215 2 .348 
 MRT recovery .000 2.550 1.140 -3.166 3.166 .000 4 1.000 
 O2 pulse (peak) 4.3200 6.8843 1.3769 1.4783 7.1617 3.138 24 .004 
 KEY:	CHF:	chronic	heart	failure,	HR:	heart	rate,	SBP:	systolic	blood	pressure,	DBP:	diastolic	
blood	pressure,	pVO2:	peak	oxygen	consumption,	AT:	anaerobic	threshold,	VE/VCO2	slope:	
slope	relating	ventilation	rate	to	carbon	dioxide	output,	RER:	respiratory	exchange	ratio,	
OUE:	oxygen	uptake	efficiency,	MRT:	mean	VO2	response	time.	
Table 5.5 Paired sample T tests (CHF-AF) 
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Figure 5.4A Heart rate profile in CHF AF cohort 
 
 
Figure 5.4B Oxygen consumption profile in CHF AF cohort 
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Figure 5.4C Symptom score profile (shortness of breath) for CHF AF cohort 
 
 
Figure 5.4D Symptom score profile (leg fatigue) for CHF AF cohort   
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5.4.2.3 Control sinus group 
In the control subjects with sinus rhythm (n=28), there was no evidence of 
chronotropic incompetence with RR off. This group had a normal intrinsic 
heart rate rise profile, even without rate adaptive pacing (RR off). The peak 
exertional heart rate achieved in both tests exceeded the 80%PPHR 
threshold that is traditionally used to define chronotropic incompetence, 
especially in the absence of heart failure.  
 
Rate adaptive pacing did result in a further increase in the peak heart rate 
alone (136 (30) v 126 (32) bpm, p<0.05), with no associated changes in any 
exercise variables, (pVO2 24.2 (9.3) v 24.3 (9.7) ml/kg/min, p=0.783, or 
exercise time (620 (217) v 584 (258) s, p=0.189) (tables 5.6 and 5.7).  
 
 
There was also no associated change in the stage-by-stage oxygen 
consumption achieved. However, the use of rate-adaptive pacing did result 
in a worsening of both shortness of breath and leg fatigue scores in the latter 
stages of exercise (Stages 5 to 8: ΔBorg (SOB), 2 (2) v 1 (2), p=0.05, ΔBorg 
(Leg Fatigue) 2 (2) v 1 (2), p<0.05) (figures 5.5B-D).  
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Group (Control sinus, n=28) Mean N 
Std. 
Deviation 
Std. Error 
Mean 
 Resting HR, bpm RR on 62.393 28 9.7841 1.8490 
RR off 62.964 28 10.9019 2.0603 
Peak HR, bpm RR on 136.786 28 29.5263 5.5800 
RR off 125.857 28 32.0910 6.0646 
Resting systolic BP, 
mmHg 
RR on 132.462 26 17.9270 3.5158 
RR off 135.846 26 18.3732 3.6033 
Resting diastolic BP, 
mmHg 
RR on 71.077 26 10.0754 1.9760 
RR off 72.615 26 10.8188 2.1217 
Peak systolic blood 
pressure, mmHg 
RR on 167.308 26 27.9997 5.4912 
RR off 169.923 26 27.3202 5.3579 
Peak diastolic blood 
pressure, mmHg 
RR on 70.462 26 16.5632 3.2483 
RR off 69.077 26 11.9897 2.3514 
Exercise time, 
seconds 
RR on 620.357 28 216.7993 40.9712 
RR off 583.679 28 257.6517 48.6916 
pVO2, ml/kg/min RR on 24.218 28 9.3391 1.7649 
RR off 24.346 28 9.6745 1.8283 
HR at AT, bpm RR on 102.48 25 20.514 4.103 
RR off 98.08 25 19.313 3.863 
AT, ml/kg/min RR on 16.36 25 5.128 1.026 
RR off 17.52 25 6.056 1.211 
VE/VCO2 slope (peak) RR on 32.4714 28 7.41284 1.40090 
RR off 33.0171 28 8.42776 1.59270 
VE/VCO2 slope (peak) RR on 27.11 25 7.055 1.411 
RR off 27.22 25 6.347 1.269 
Peak RER RR on 1.1293 28 .13018 .02460 
RR off 1.1364 28 .16473 .03113 
OUE slope RR on 2164.53 28 840.3618 158.8135 
RR off 2189.64 28 757.2785 143.1122 
MRT RR on 183.35 18 104.638 24.663 
RR off 159.23 18 100.300 23.641 
MRT recovery RR on 81.49 13 28.582 7.927 
RR off 80.95 13 31.110 8.628 
O2 pulse (peak) RR on 13.50 18 3.073 .724 
RR off 13.72 18 3.953 .932 
KEY:	 HR:	 heart	 rate,	 BP:	 blood	 pressure,	 pVO2:	 peak	 oxygen	 consumption,	 AT:	 anaerobic	
threshold,	 VE/VCO2	 slope:	 slope	 relating	 ventilation	 rate	 to	 carbon	 dioxide	 output,	 RER:	
respiratory	efficiency	ratio,	OUE:	oxygen	uptake	efficiency,	MRT:	mean	VO2	response	time. 
Table 5.6 Paired samples statistics (Controls sinus) 
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Group: Control sinus 
 (n=28) 
Paired Differences 
t df 
P 
value Mean SD SE 
95% Confidence 
Interval 
Lower Upper 
 Resting HR, bpm -.571 5.4530 1.030 -2.6859 1.5430 -.55 27 .584 
 Peak HR, bpm 10.92 20.421 3.859 3.0100 18.8471 2.83 27 .009 
 Rest SBP, mmHg -3.38 13.899 2.726 -8.9989 2.2297 -1.24 25 .226 
 Rest DBP, mmHg -1.53 10.012 1.963 -5.5828 2.5058 -.783 25 .441 
 Peak SBP, mmHg -2.61 16.625 3.260 -9.3306 4.0998 -.802 25 .430 
 Peak DBP, mmHg 1.384 16.769 3.288 -5.3886 8.1578 .421 25 .677 
 Exercise time, s 36.67 144.14 27.23 -19.2131 92.5703 1.347 27 .189 
 pVO2, ml/kg/min -.128 2.0109 .3800 -.9083 .6512 -.338 27 .738 
 HR at AT, bpm 4.400 15.281 3.056 -1.908 10.708 1.440 24 .163 
 AT, ml/kg/min -1.15 3.710 .742 -2.687 .375 -1.55 24 .132 
 VE/VCO2 slope (peak) -.545 4.8855 .9232 -2.44015 1.34872 -.591 27 .559 
 VE/VCO2 slope (AT) -.108 5.295 1.059 -2.293 2.078 -.102 24 .920 
 Peak RER -.007 .11718 .0221 -.05258 .03830 -.323 27 .750 
 OUE slope -25.1 369.56 69.84 -168.409 118.1949 -.359 27 .722 
 MRT 24.12 101.21 23.85 -26.212 74.456 1.011 17 .326 
 MRT recovery .545 30.817 8.547 -18.077 19.168 .064 12 .950 
 O2 pulse (peak) -.222 3.318 .782 -1.872 1.428 -.284 17 .780 
 KEY: HR: heart rate, SBP: systolic blood pressure, DBP: diastolic blood pressure, 
pVO2: peak oxygen consumption, AT: anaerobic threshold, VE/VCO2 slope: slope 
relating ventilation rate to carbon dioxide output, RER: respiratory exchange ratio, 
OUE: oxygen uptake efficiency, MRT: mean VO2 response time. 
Table 5.7 Paired samples T test (Controls sinus) 
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Figure 5.5A Heart rate profile in sinus controls 
 
Figure 5.5B Oxygen consumption profile in sinus controls 
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Figure 5.5C Symptom score profile (shortness of breath) in sinus controls 
 
Figure 5.5D Symptom score profile (leg fatigue) in sinus controls 
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5.4.2.4 Control AF group 
In the controls with AF (n=11), there was a blunted HRR with RR off (peak 
HR: 104 (42) bpm) compared to 80% PPHR (114 bpm). The higher HRR 
with rate adaptive pacing (RR on) led to no increase in peak VO2 and no 
change in exercise time (tables 5.8 and 5.9). 
 
Although rate adaptive pacing did increase the heart rate rise during the 
earlier stages of exercise (HRR (Stage 0 to Stage 4): 76 v 65 bpm, p<0.05), 
this equalised during the latter stages (HRR(Stage 5 to Stage 8): 21 v 30 
bpm, p=0.960) in those that reached stage 8, and overall there was no 
difference in profiles when comparing RR on and RR off (p=0.075), even 
though the RR on tests achieved a higher mean peak heart rate overall 
(figure 5.6A).  
 
Oxygen consumption followed an identical pattern, with an increase seen in 
the earlier stages (ΔVO2(Stages 0-4), 19.1(5) v 22.8(5) ml/kg/min, p=0.052), 
and no change from mid exercise to peak (ΔVO2(Stages5-8), 8.1 v 10.5 
ml/kg/min, p=0.770). There were no obvious differences in the self-reported 
symptom profiles with regards to either shortness of breath or leg fatigue 
(figures 5.6B-D). 
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Group (Controls AF, n=11) Mean N 
Std. 
Deviation 
Std. Error 
Mean 
 Resting HR, bpm RR on 64.636 11 8.9249 2.6910 
RR off 60.818 11 4.6004 1.3871 
Peak HR, bpm RR on 133.636 11 27.8039 8.3832 
RR off 103.818 11 42.4919 12.8118 
Resting systolic blood 
pressure, mmHg 
RR on 126.364 11 14.3337 4.3218 
RR off 127.273 11 12.7208 3.8355 
Resting diastolic 
blood pressure, 
mmHg 
RR on 68.182 11 9.8165 2.9598 
RR off 69.091 11 7.0065 2.1125 
Peak systolic blood 
pressure, mmHg 
RR on 162.182 11 23.7563 7.1628 
RR off 148.545 11 20.8632 6.2905 
Peak diastolic blood 
pressure, mmHg 
RR on 70.273 11 7.6693 2.3124 
RR off 64.909 11 10.6344 3.2064 
Exercise time, 
seconds 
RR on 482.545 11 332.6723 100.3045 
RR off 450.455 11 269.8834 81.3729 
pVO2, ml/kg/min RR on 20.173 11 8.8446 2.6667 
RR off 17.500 11 9.0916 2.7412 
HR at AT, bpm RR on 109.50 8 23.078 8.159 
RR off 80.50 8 22.947 8.113 
AT, ml/kg/min RR on 14.29 8 4.934 1.744 
RR off 12.30 8 6.430 2.273 
VE/VCO2 slope (peak) RR on 34.8545 11 8.45321 2.54874 
RR off 38.3818 11 13.56922 4.09127 
VE/VCO2 slope (peak) RR on 29.75 8 11.853 4.191 
RR off 30.75 8 6.798 2.403 
Peak RER RR on 1.0991 11 .19076 .05752 
RR off 1.2191 11 .16688 .05032 
OUE slope RR on 1624.27 11 512.7249 154.5924 
RR off 1426.36 11 678.1133 204.4589 
MRT RR on 117.55 2 26.234 18.550 
RR off 115.00 2 29.840 21.100 
O2 pulse (peak) RR on 12.00b 2 .000 .000 
RR off 17.00b 2 .000 .000 
KEY:	HR:	heart	rate,	pVO2:	peak	oxygen	consumption,	AT:	anaerobic	threshold,	VE/VCO2	
slope:	 slope	 relating	 ventilation	 rate	 to	 carbon	 dioxide	 output,	 RER:	 respiratory	
efficiency	ratio,	OUE:	oxygen	uptake	efficiency,	MRT:	mean	VO2	response	time. 
Table 5.8 Paired samples statistics (Controls AF) 
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Group: Controls  AF 
 (n=26) 
Paired Differences 
t df P value Mean SD SE 
95% 
Confidence 
Interval 
Lower Upper 
  Resting HR, bpm 3.8182 9.1304 2.7529 -2.3157 9.9520 1.387 10 .196 
 Peak HR, bpm 29.818 35.2925 10.641 6.1083 53.528 2.802 10 .019 
 Rest SBP, mmHg -.9091 20.7145 6.2457 -14.825 13.007 -.146 10 .887 
 Rest DBP, mmHg -.9091 8.3121 2.5062 -6.4932 4.6750 -.363 10 .724 
 Peak SBP, mmHg 13.6364 26.5604 8.0083 -4.2072 31.479 1.703 10 .119 
 Peak DBP, mmHg 5.3636 5.9038 1.7801 1.3974 9.3298 3.013 10 .013 
 Exercise time, s 32.0909 154.436 46.564 -71.660 135.84 .689 10 .506 
 pVO2, ml/kg/min 2.6727 4.3267 1.3045 -.2340 5.5794 2.049 10 .068 
 HR at AT, bpm 29.000 38.038 13.448 -2.800 60.800 2.156 7 .068 
 AT, ml/kg/min 1.987 5.118 1.809 -2.291 6.266 1.098 7 .308 
 VE/VCO2 slope (peak) -3.52727 15.6213 4.7100 -14.021 6.9672 -.749 10 .471 
 VE/VCO2 slope (AT) -1.000 11.161 3.946 -10.331 8.331 -.253 7 .807 
 Peak RER -.12000 .20586 .06207 -.25830 .01830 -1.933 10 .082 
 OUE slope 197.909 418.232 126.10 -83.063 478.88 1.569 10 .148 
 MRT 2.550 3.606 2.550 -29.851 34.951 1.000 1 .500 
 O2 pulse (peak) 1.000 4.243 3.000 -37.119 39.119 .333 1 .795 
  KEY: HR: heart rate, BP: blood pressure, pVO2: peak oxygen consumption, AT: 
anaerobic threshold, VE/VCO2 slope: slope relating ventilation rate to carbon dioxide 
output, RER: respiratory exchange ratio, OUE: oxygen uptake efficiency, MRT: 
mean VO2 response time. 
Table 5.9 Paired samples T test (Controls AF) 
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Figure 5.6A Heart rate profile in AF controls 
 
Figure 5.6B Oxygen consumption profile in AF controls 
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Figure 5.6C Symptom score profile (shortness of breath) in AF controls 
 
 
Figure 5.6D Symptom score profile (leg fatigue) in AF controls 
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5.5 Discussion 
 
If impaired HRR is the limiting factor for exercise capacity, then any increase 
in the HR response should increase cardiac output, especially in those with 
CI, and hence improve blood supply to skeletal muscles, allowing longer 
exercise time, higher peak oxygen consumption and less fatigue. This is an 
important area for research and has huge clinical implications because 
exercise intolerance due to breathlessness and fatigue is a cardinal feature 
of CHF and remains a problem for many patients despite optimal medical 
and device therapy.  
 
This study shows that in CHF, no improvement in functional capacity is seen 
by increasing the peak HR. This is a clinically important finding that has 
never been demonstrated in a randomised controlled trial before.  
  
 
5.5.1 Correcting choronotropic incompetence: sinus rhythm 
The results from this study conclusively prove that rate adaptive pacing can 
successfully improve the heart rate rise and thus restore ‘chronotropic 
competence’. However, in the CHF sinus cohort, the results of the CPX tests 
showed that this increase in the heart rate response throughout the period of 
activity did not result in any improvement in exercise time, peak oxygen 
consumption, subjective symptom scores, ventilation measurements or 
measures of submaximal activity (AT).  
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The peak RER achieved by both arms of this crossover study was lower 
than expected, with a mean value less than 1.1 (figure 5.7). Greater 
encouragement from the supervising team may induced patients to try 
harder and reach a higher RER, however this would have introduced an 
additional potential bias with regards to the level of motivation given, in what 
context and by whom.  
 
Figure 5.7 RER in the CHF-SR cohort 
 
 
The purpose of this investigation was to look at the role of the heart rate 
throughout exercise in a reproducible manner, rather than just the 
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and reported similar symptom scores in both arms. This ensures the validity 
of my results from the two study arms as being both comparable to one 
another and also relevant to the general HF population as a whole, given 
that these patients rarely achieve or aim to reach their absolute peak 
exercise capacity during usual activities of daily living. The primary concern 
of this study was whether increasing the rate and magnitude of heart rate 
rise altered any exercise capacity measures, at either sub-maximal or peak 
exertion levels. There was no change in either the rate or magnitude of 
increase in oxygen consumption at each stage of the exercise protocol, nor 
any change in reported symptoms.  
 
This was a large cohort with varied co-morbidities and medications, and thus 
it was truly representative of the actual CHF population as seen in the 
clinical setting. These results are firm evidence that increasing the heart rate 
throughout exercise in CHF (with sinus rhythm) does not have any effect on 
either the exercise capacity or patient symptoms.  
 
5.5.2 Correcting chronotropic incompetence: atrial fibrillation 
Atrial fibrillation frequently co-exists with CHF, and its presence results in 
further alteration of the cardiac haemodynamics at rest and during any 
activity. The irregularly irregular nature of AF at rest, also extends to the way 
in which cardio-acceleration occurs in these patients during exercise or 
activity. Thus it is important to study this group separately in order to 
determine any patterns within the chaotic heart rate response and also to be 
able to derive useful and practical clinical conclusions.  
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Intrinsic heart rate response during activity (RR off) followed a different 
pattern to the sinus CHF group discussed above. Whereas the response in 
sinus CHF remained linear despite being blunted, in CHF-AF there was a 
blunted linear rise in heart rate initially, followed by a plateauing of the heart 
rate response during sub-maximal exercise. Prior to symptom limited 
termination of exercise a drop in the heart rate response was recorded. This 
corresponded with a plateauing in the level of oxygen consumption, both 
occurring within the final stage of the exercise protocol. 
 
The use of rate adaptive pacing (RR on) resulted in a correction of the heart 
rate response, which then followed a linear increase to its maximum level 
achieved at peak exercise. The change in heart rate response (due to ‘RR 
on’) resulted in an increase in the peak oxygen consumption, with no change 
in exercise time, symptom perception or ventilatory efficiency measures 
(VE/VCO2 slope) at AT or peak. The peak RER achieved in this subgroup 
was also lower than expected given that the protocol aim was to reach peak 
exercise (Figure 5.8). However, this does not alter the validity of the results 
obtained, as my interest lies in the journey the heart rate takes throughout 
increasing levels of activity rather than simply the destination or peak 
exercise parameters. Altering the rate and magnitude of heart rate rise did 
not improve functional capacity. 
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Figure 5.8 RER profile in the CHF-AF cohort 
 
Rate adaptive pacing in the presence of AF, led to an increase in oxygen 
consumption with no change in overall exercise time, implying ‘wasted’ 
metabolic effort. A lower peak heart rate may actually improve the efficiency 
of the entire system, with similar exercise time but with lower skeletal muscle 
oxygen consumption. 
 
 
5.5.3 Correcting chronotropic incompetence in control subjects 
The sinus controls did not have chronotropic incompetence and thus did not 
receive any additional benefit from the increase in heart rate in terms of 
exercise capacity, symptoms or oxygen consumption. 
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Unexpectedly, the control subjects with AF did exhibit a blunted heart rate 
response to activity. The presence of intrinsic impairment in HRR during the 
incremental CPX test (RR off) suggests that the CI may be more prevalent in 
the AF population than previously thought, even in the absence of CHF.  
 
Previous studies have shown that controls with chronotropic incompetence 
might benefit from rate adaptive pacing, although the majority of the 
evidence is derived from studies that excluded AF.  
 
Rate adaptive pacing (RR on) resulted in an increase in the peak heart rate, 
which did not lead to any change in peak oxygen consumption, anaerobic 
threshold, VE/VCO2 slopes, symptom scores or exercise time.  
 
 
5.5.4 Clinical relevance 
Heart rate rise and exercise capacity are linked closely such that the exact 
nature of the relationship is difficult to ascertain. On the one hand, a 
limitation to heart rate rise in controls results in reduced exercise time and 
increased fatigue, which improves with pacemaker treatment to increase 
activity related cardio-acceleration. On the other hand, at moderate levels of 
activity or early termination of exercise due to other causes such as 
respiratory or skeletal muscle factors, the associated rise in heart rate is 
reduced. This is particularly the case in patients with HF who often have co-
morbidities, such that the limitation to heart rate rise might also be due to 
peripheral limitation in the skeletal muscles for example. 
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In this crossover RCT, pacing algorithms in conjunction with built-in 
movement sensors were utilised to increase heart rate rise. Our data confirm 
that pacemakers are capable of correcting CI and increasing heart rates 
throughout exercise. However, the evidence on how to program 
pacemakers, in terms of the heart rate range, response to exercise and 
whether or not to activate rate adaptive (RR) modes, is both conflicting and 
also based on studies in non-CHF sinus cohorts for the most part. It is 
generally assumed that the origins of the exercise intolerance in HF patients 
might be similar to those in patients without HF.  
 
 
5.5.5 Minimising bias 
The purpose of this double blind randomised controlled crossover trial was 
to assess the impact of acutely correcting CI on exercise capacity in four 
different patient cohorts. The crossover study design allowed each subject to 
act as their own control, and thus minimized the effects of differences in 
characteristics or co-morbidities to act as confounders. The double-blind 
arrangement removed opportunity for bias with regards to exercise duration 
or motivation.      
 
The relationship between heart rate rise and exercise capacity is both 
controversial and heavily debated in the clinical setting. Thus in order for this 
RCT to have far-reaching and general clinical relevance, it was important to 
keep the inclusion criteria broad and exclusion criteria to a minimum. The 
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cohort demographics reveal that this strategy was successful in recruiting 
subjects with a spread of co-morbidities, past medical history and 
medications into the study. The crossover design, and unselected patient 
selection, meant that this would still allow for valid comparisons to be made, 
and the main advantage to this was that any findings would be immediately 
and directly relevant to a contemporary heart failure population.  
 
The only differentiation that was made was based on the underlying cardiac 
rhythm. The reason for this was that heart rate is known to vary and respond 
differently in AF and sinus rhythm, and clinically the treatment approach 
differs dependent on whether or not the patient is in AF. Different 
medications, therapies and procedures are utilised, and thus it was felt that 
the exertional response to altering the heart rate rise would need to be 
assessed separately. 
 
5.5.6 Current clinical approach 
To complicate matters further, pharmacological agents that lower the resting 
HR and induce or worsen CI are actually proven to improve outcomes for 
patients with CHF due to LVSD. Trials involving either beta-blockers or sinus 
node If channel antagonists all show that the magnitude of resting heart rate 
reduction corresponds to the degree of increased survival and clinical 
improvements.  
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Due to the current lack of evidence, some CHF patients with pacemakers 
may be subjected to higher mean heart rates as a result of attempts to 
increase their exercise capacity by increasing the peak paced HR achieved, 
whereas patients without pacemakers are treated with maximal heart rate 
lowering medications in order to ensure resting heart rate is at the lowest 
tolerated level, in line with grade 1 evidence and international guidance, 
despite the fact that these agents also reduce the peak exertional HR.  
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5.6 Conclusion 
 
Our data provide clear evidence that ‘treating’ chronotropic incompetence in 
the CHF population, by increasing the exercise related heart rate response 
and peak heart rate achieved, does not improve exercise capacity or 
symptoms. 
 
However, this study does not clarify the entire role of heart rate on exercise 
capacity in heart failure. A question still remains as to whether heart rate 
limitation per se leads to impaired exercise capacity in patients with HF. 
Thus, further work is necessary in order to investigate whether reducing the 
resting and peak heart rate pharmacologically worsens exercise capacity.  
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Chapter 6: The influence of reducing the heart rate on 
exercise capacity in chronic heart failure (Opt-RATE 2 Study) 
 
6.1 Abstract 
 
Reduction of the heart rate (HR) at rest is associated with improvements in 
survival for both patients with heart failure and the general population as a 
whole,(333) however it is currently unknown whether acute pharmacological 
HR reduction in heart failure results in a worsening of functional capacity or 
patient symptoms. The aim of this double blind randomised placebo 
controlled trial was to ascertain whether an acute reduction in HR has any 
effect on exercise capacity in stable CHF.  
 
A total of 40 HFrEF patients with pacemakers, 26 in sinus rhythm and 14 
with concurrent atrial fibrillation (AF), were recruited into this interventional 
study. Each subject performed two exercise tests one week apart, starting 
either at their paced or intrinsic resting heart rate, or an iatrogenically 
lowered starting heart rate. This was done on the day of the visit, and the 
heart rate profiles were returned to normal following each test. No other 
interventions were performed and each patient acted as their own control. 
 
Lowering the resting heart rate in either the sinus (65 (13) v 57 (9) bpm) or 
the AF (65 (14) v 49 (18), bpm) cohort, did not result in any change in the 
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peak oxygen consumption (pVO2 - Sinus: 17.4 (5.7) v 17.2 (5.7) ml/kg/min, 
p=0.584; AF: 14.8 (4) v 14.4 (4) ml/kg/min, p=0.203) or exercise time.    
 
Thus, acutely reducing the resting heart rate in the context of either sinus 
rhythm or atrial fibrillation is well tolerated, and does not lead to any 
reduction in functional capacity.  This is a novel finding which has far 
reaching clinical implications for pharmacological and device treatment 
strategies in the context of significant systolic heart failure.    
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6.2 Introduction 
 
Exercise intolerance due to breathlessness and fatigue is a key feature of 
the heart failure syndrome. This often persists despite optimal medical 
therapy, and objective measures of peak exercise capacity such as exercise 
time or peak oxygen consumption are powerful and reproducible predictors 
for prognosis. Controversy exists around the role and impact of heart rate 
rise (HRR) and peak heart rate (PHR) on exertional capability.  
 
A limitation of either HRR or PHR is termed chronotropic incompetence (CI), 
which is considered by some to be both a key causal factor and a prognostic 
marker. However, in the modern era of medical therapy where 
pharmacological interventions with proven benefits to mortality and morbidity 
may impact the heart rate profile and cause iatrogenic CI, it remains unclear 
whether this definitely causes exercise limitation and also whether treatment 
should be directed to ‘correct’ the heart rate response.  
 
Resting heart rate is a strong predictor for outcomes and slower heart rates 
have been shown to be strongly associated with increased survival, in both 
CHF and controls. In contrast the use of pacemaker therapy to increase the 
resting heart rate results in worsening of outcomes and cardiac 
function.(334)   
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In health, the overall heart rate rise during exercise depends on the baseline 
resting heart rate, and the peak heart rate achieved at maximal exercise. 
The first interventional study of this investigation into the role of the heart 
rate on exercise capacity in heart failure (chapter 5: OPT-Rate 1) revealed 
that augmenting cardio-acceleration and thus increasing the peak heart rate 
did not result in any change in exercise capacity or symptoms.  
 
Whether the acute reduction in resting heart rate has any effect on exercise 
capacity in CHF has hitherto remained unexplored. This is an important area 
for investigation, as the main opposition for aggressive heart rate reduction 
in this context is the potential impact it could have on symptoms and 
functional capacity. Thus the aim of this double blind placebo controlled 
randomised crossover interventional trial was to focus solely on investigating 
the effect of acutely reducing the resting heart rate on overall exercise 
performance within a mixed heart failure cohort.   
- 175 - 
6.3 Methods 
 
This is a proof of concept study whereby the aim is to establish the feasibility 
of acute heart rate lowering in a population with pacemakers, and to explore 
the relationship between baseline heart rate reduction and functional 
capacity. A paced population was chosen for this study in order to ensure 
safe baseline heart rate reduction, without the risk of excessive or 
symptomatic bradycardia. This study was approved by the National 
Research Ethics Service (REC reference 09/H1305/60, Appendix B). 
 
 
6.3.1 Study design 
The study was designed to investigate the effect of reducing the resting 
heart rate on overall exercise performance. The crossover interventional 
design of this investigation negated the need for a control cohort, as each 
subject was randomised to undergo two symptom-limited maximal treadmill-
based cardio-pulmonary exercise (CPX) tests, and thus acted as their own 
controls. The only independent variable that was altered between tests was 
the resting heart rate. A pre-test consent appointment and familiarisation test 
were attended by all participants (described in chapter 3).  
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6.3.1.1 Study population 
 
A total of 40 subjects were enrolled into this double blind placebo controlled 
randomised trial.  All subjects were approached at routine outpatient 
pacemaker follow-up appointments, and all had a diagnosis of moderate-
severe systolic heart failure (ejection fraction less than 45%), a pacing 
device in situ for a clinical indication, and stable pacemaker device and lead 
variables for at least six months. The cohort was divided into those with 
permanent atrial fibrillation (n=14) and those in sinus rhythm (n=26).  
 
6.3.2 Inclusion and exclusion criteria 
The inclusion criteria for this study were confirmed CHF due to left 
ventricular systolic dysfunction (LVSD, moderate-severe; left ventricular 
ejection fraction <45%, and symptoms of breathlessness or fatigue on 
exertion), on optimal medical therapy and stable symptoms. They must have 
had their pacemaker for at least 6 months with stable lead variables and no 
change in medications or other invasive cardiac procedures for at least three 
months. All subjects were capable of performing a peak exercise test on a 
treadmill and giving informed written consent, which was obtained in all 
subjects.  
 
 Subjects with co-morbidities that would limit exercise capacity such as 
uncontrolled angina, peripheral vascular disease, severe valvular 
dysfunction, severe obstructive or restrictive respiratory conditions, oxygen 
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dependence and any musculoskeletal abnormalities or disorders that could 
restrict walking on a treadmill were excluded.  
 
Furthermore, any subjects enrolled into the sinus CHF cohort could not 
currently be taking the sinus node blocking agent, ivabradine. Other 
exclusion criteria included any contraindications to ivabradine use such as 
severe hepatic impairment, significant renal impairment (creatinine 
clearance <15ml.min-1), and long QT syndrome.  
 
6.3.3 Exercise testing 
Each subject was invited back to the exercise laboratory at least one week 
following the baseline visit and familiarisation test, for two further exercise 
tests at least one week apart. At the start of each visit, the subject was 
double blind randomised to either their ‘normal’ resting heart rate or a 
lowered resting heart rate, as detailed below. Following this, a maximal 
symptom-limited treadmill-based exercise test was performed.   
 
A screen was used to separate the heart rate and electrocardiographic 
monitor, which was only observed by the unblinded technician, from the 
metabolic cart, which was monitored by the blinded investigator. Resting, 
peak and recovery blood pressures were measured using a standard 
manual cuff sphygmomanometer. 
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6.3.4 Randomisation and heart rate lowering procedures 
Both the supervising physician and all subjects were blinded to the allocation 
order, pacemaker settings and heart rate profiles during the two tests.  
 
6.3.4.1 CHF sinus cohort 
In this cohort, heart rate lowering was achieved via a sinus node blocking 
agent, ivabradine. This is an If channel blocker that specifically targets the 
sinus node leading to a slower heart rate, with no known peripheral 
effects.(335)(336) The agent is approved and licensed for use in patients 
with heart failure at the doses used in this study. 
 
In order to ensure double blinding, subjects were randomised by the 
research pharmacist to receive either a single 7.5mg dose of ivabradine or 
matching placebo.  
 
Capsules containing ivabradine or placebo were formulated and 
encapsulated to be exactly identical in shape, size, colour, weight, taste and 
consistency. The capsule was taken in the presence of the primary 
investigator and the research technician. The time to peak plasma 
ivabradine concentration after a single oral dose is between 60 -120 
minutes.(337) Thus, the capsule was taken two hours prior to the exercise 
test. 
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Immediately prior to the start of exercise, the pacing device was 
programmed to a minimum base rate of 40 beats per minute. All other 
pacemaker settings were standardised during the two tests. At the end of 
each test the pacing device was returned to its original settings. 
 
6.3.4.2 CHF-AF cohort 
In the AF cohort, lowering of the resting heart rate was achieved by reducing 
the programmed pacemaker base rate to 30 beats per minute thus allowing 
the lower intrinsic heart rate to come through. No other pacemaker settings 
were altered and the pacing device was returned to its original settings at the 
end of each test. 
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6.3.5 Cohort size calculation 
Heart rate related changes on exercise capacity have not been fully 
investigated in heart failure patients, and remain poorly understood. 
However, the results from the previous RCT were useful for establishing the 
minimum sample size required in this study. The primary outcome was peak 
oxygen consumption, which is known to be both reliable and reproducible, 
with a coefficient of variation percentage of 9.73 in this laboratory. As before, 
a mean of 15 (2) ml/kg/min was expected in CHF subjects in sinus rhythm, 
and a mean of 13 (2) ml/kg/min for CHF with atrial fibrillation (mean 
difference 15% lower), with higher peak heart rates achieved in the AF 
cohort (mean difference 23% higher).  
 
By factoring in the results obtained from the previous study, the predicted 
group size required in order to demonstrate a clinically important change of 
2.0 ml/kg/min with 80% power, and a two sided alpha of 0.05 was revised. 
Thus, a minimum of 12 subjects was needed in the atrial fibrillation CHF 
group, and a minimum of 20 in the sinus CHF group. To allow for drop-outs 
and to confidently suggest equivalence, the recruitment aims were 15 atrial 
fibrillation subjects and 25 sinus subjects.  
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6.4 Results 
 
6.4.1 Baseline characteristics 
A total of 40 subjects with CHF and pacemakers were recruited to take part 
in this randomised controlled trial of intrinsic/usual resting heart rate 
compared to a lowered resting heart rate.  
 
6.4.2 Comparing demographics between groups 
The cohort was divided into two groups: sinus rhythm (n=26) and atrial 
fibrillation (n=14). Baseline characteristics for each group separately are 
shown in table 6.1 (parametric data as mean (SD); non-parametric as 
median±IQR). 
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 Sinus 
N=26 
AF 
N=14 
Height, cm 171 (6) 171 (8) 
Weight, kg 86 (17) 86 (21) 
Age, years 72 (10) 76 (10) 
NYHA class 2 2 
Ejection fraction, % 36 (9) 37 (7) 
Heart rate drop, bpm 8 (10) 16 (14) 
Peak predicted HR, bpm 148 (10) 145 (10) 
LVID (diastole), mm 56 (8) 51 (9) 
LVID(systole), mm 49 (9) 40 (9) 
EA ratio 0.8 (0.2) - 
E wave DT, ms 265 (44) - 
Furosemide dose, mg 53/31/12/4 [14/8/3/1] 29/43/14/14 [4/6/2/2] 
Diabetes mellitus 27% (7) 50% (n=7) 
Ischaemic heart disease 42% (11) 43% (6) 
Hypertension 23% (6) 43% (6) 
PMH: CABG 19% (5) 21% (3) 
PMH: PCI 19% (5) 21% (3) 
PMH: Valve surgery 4% (1) 29% (4) 
ACEi/ARB, ramipril equivalent, mg 10±5 10±5 
Beta-blocker, bisoprolol equivalent, mg 5±4.25 7.5±7 
Aldosterone antagonist 42% (11) 43% (6) 
Statin 77% (20) 64% (9) 
Calcium channel blocker 0% (0) 7% (1) 
Digoxin 11% (3) 29% (4) 
Amiodarone 4% (1) 0% (0) 
Anticoagulation 19% (5) 86% (12) 
Antiplatelets 46% (12) 29% (4) 
Normally distributed variables shown as mean (SD). 
 
KEY: AF: atrial fibrillation, NYHA: New York Heart Association, HR: heart rate, LVID: 
left ventricular internal diameter, DT: deceleration time, PMH: past medical history, 
CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention, 
ACEi: angiotensin converting enzyme inhibitor, ARB: angiotension II receptor 
blocker. 
Table 6.1 Baseline group demographics 
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6.4.3 Comparing intrinsic heart rate rise (placebo/base rate 60) to 
lowered resting heart rate (ivabradine/base rate 30) 
 
6.4.3.1 CHF-SR group   
Ivabradine resulted in HR reduction at rest (RHR: 65 (13) v 57 (9) bpm, 
p<0.05), at submaximal exercise (HR at anaerobic threshold: 97 (19) v 92 
(11) bpm, p<0.05) and at peak (PHR: 113 (23) v 106 (22) bpm, p<0.05), with 
no effect on the overall heart rate rise (HRR: 48 (22) v 49 (24) bpm, 
p=0.569). There was no change in exercise time (534 (242) v 554 (251) s, 
p=0.267) or oxygen consumption at the anaerobic threshold (AT: 14.4 (4.5) v 
14.6 (3.2) ml/kg/min, p=0.708) and at peak (pVO2: 17.4 (5.7) v 17.2 (5.7) 
ml/kg/min, p=0.584)(figure 6.1). The symptom score profiles and all other 
measured CPX parameters were similar in both tests.  
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Figure 6.1 Heart rate and oxygen consumption measurements in sinus CHF 
cohort 
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6.4.3.1 CHF-AF group 
 
In the CHF-AF group (n=14), starting at a lower resting heart rate by 
reducing the pacemaker base rate (BR 60 v BR 30) resulted in significant 
differences in the resting heart rate (65 (14) v 49 (18) bpm, p<0.05) and 
heart rate rise (47 (23) v 59 (20), p<0.05). There was no change in the 
chronotropic index (0.61 (0.3) v 0.66 (0.3), p=0.600).  
 
The lower resting heart rate group (BR 30) achieved a better exercise time 
(BR 60 v BR 30, 434 (225) v 482 (235) s, p<0.05) with no change in peak 
oxygen consumption (pVO2, 14.4 (4) v14.8 (4) ml/kg/min, p=0.203).  
 
There was no difference in heart rate at submaximal exercise (HR at AT, BR 
60 v BR 30, 107 (24) v 98 (22) bpm, p=0.137), however the anaerobic 
threshold was lower (AT, 12.8 (3) v 11.5 (3) ml/kg/min, p<0.05). A higher 
peak RER was achieved at the lower base rate setting (BR 60 v BR 30, 1.08 
(0.1) v 1.14 (0.1), p<0.05)(figure 6.2). All other measured CPX variables 
were similar within both two settings. 
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Figure 6.2 Heart rate and oxygen consumption measurements in AF CHF cohort 
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Starting at a lower resting rate (base rate 30) with the CHF-AF cohort 
resulted in lower heart rates being achieved throughout the exercise test, 
compared to the higher base rate (p<0.05). The same peak oxygen 
consumption was achieved in both tests, however starting at a lower resting 
rate allowed subjects to tolerate higher levels of ‘shortness of breath’ and 
‘leg fatigue’ (figures 6.3A-D).  
 
 
 
  
Figure 6.3B AF oxygen consumption profile 
Figure 6.3A AF heart rate profile 
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Figure 6.3C AF symptom score profile (shortness of breath) 
Figure 6.3D AF symptom score profile (leg fatigue) 
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6.5 Discussion 
 
This study showed that lowering the resting and peak heart rates did not 
result in any worsening of peak oxygen consumption, reported symptoms or 
exercise time.  
 
Acute administration of ivabradine in the CHF cohort in sinus rhythm, 
resulted in a reduction in both the resting and peak heart rates, such that the 
heart rate rise (HRR) remained unchanged. This blunting of the heart rate 
profile, and iatrogenic worsening of CI did not impact oxygen consumption or 
exercise time.   
 
These data conclusively prove that while CI is a marker of poor prognosis in 
CHF, it does not cause exercise tolerance. Correcting CI (Chapter 5, OPT-
Rate 1) or worsening CI in this context makes no difference to either the 
peak oxygen consumption achieved or the total exercise time. Ivabradine 
use was safe in the acute setting in a paced CHF cohort, regardless of the 
pre-dose resting HR, and did not alter functional capacity or symptoms. 
 
In addition, acute reduction in the pacemaker baseline heart rate in the CHF-
AF cohort did not result in any worsening of symptoms or exercise capacity. 
Surprisingly, this resulted in a higher HRR, and allowed subjects to tolerate 
higher levels of shortness of breath and fatigue, so achieving both a higher 
peak RER and a better exercise time with the lower base rate, yet still 
reaching the same peak oxygen consumption level.  
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Thus lowering the resting heart rate in a cohort of AF patients with LVSD, 
resulted in an increase in exercise efficiency, allowing the participants to 
achieve significantly longer exercise times with the same level of skeletal 
muscle oxygen consumption at peak exercise.   
 
Lowering the resting heart rate in AF did not result in fatigue, and actually 
allowed subjects to tolerate exercise for longer, at higher reported symptom 
score levels. These results demonstrate that heart rate reduction in a CHF 
cohort with atrial fibrillation does not affect peak oxygen consumption or 
symptoms, and CI may actually represent an adaptation that increases both 
exercise capacity and tolerance.  
 
 
6.5.1 Clinical implications 
Resting heart rate is a prognostic factor in heart failure due to LVSD. It is 
also a recognised risk factor for cardiovascular events in heart failure 
secondary to systolic dysfunction. This situation exists because the resting 
heart rate is a marker of underlying neuro-hormonal activity, excessive 
activation of which is associated with adverse outcomes.(264) Thus reducing 
the resting HR is seen as the aim of pharmacological therapy and a marker 
of treatment success.  
 
The extent of resting heart rate reduction has been shown to be 
prognostically significant in trials involving beta-blockers and sinus node 
blocking agents. Conversely, every beat per minute increase in the baseline 
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heart rate in heart failure is associated with an increase in cardiovascular 
death and heart failure hospital admissions.  This relationship was first 
postulated on the basis of meta-regression analyses on heart rate in 
comparison to other outcome variables, which revealed a strong correlation 
between heart rate reduction and improvements in both mortality and left 
ventricular ejection fraction.(269)  
 
These findings were confirmed more recently in SHIFT (Systolic Heart failure 
treatment with the If inhibitor ivabradine Trial), a randomised placebo 
controlled study whereby heart rate reduction with long-term use of a pure 
heart-rate lowering agent ivabradine, which is an inhibitor of the If current in 
the sinoatrial node with no peripheral activity or blood pressure effects, 
resulted in a significant reduction in heart failure related deaths and 
hospitalisations.(258) 
 
The long-term prognostic effects of reducing the baseline heart rate in 
chronic heart failure have been well established. However, heart rate, in 
conjunction with stroke volume, determines cardiac output and hence 
oxygen availability for both myocardial and skeletal metabolism. So any 
agents that lower the resting heart rate will also affect the heart rate profile 
during exercise, and may impact on overall performance.  
 
CI has long been established as a marker of poor prognosis and reduced 
functional capacity in heart failure. However, whether CI is a causal factor for 
exercise intolerance and poor prognosis has been a long-standing topic of 
debate and conflicting opinions, with no evidence to back either claim. 
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Regardless of biological plausibility, in order to establish a prognostic marker 
as a causal factor, it is necessary to demonstrate not only that an outcome is 
quantitatively related to the factor, but also that modification of the alleged 
risk factor will alter the outcome.  
 
The unique combination of a double blind randomised controlled crossover 
study design along with therapeutic modalities that alter heart rate, and 
hence CI, in isolation, such as the pacemaker and ivabradine, to reduce the 
heart rate, has made it possible to study the effects of worsening CI without 
changing any other cardiovascular parameters.  
 
Baseline characteristics of the population show that this RCT cohort is well 
representative of the ‘typical’ heart failure patient. All patients had a 
pacemaker device and the majority were taking ACEi/ARBs (92.5%), beta-
blockers (95%) and loop diuretics (55%). One third had concurrent diabetes 
and a high proportion also had either hypertension (30%) or ischaemic heart 
disease (45%), all in keeping with global heart failure and diabetes 
statistics.(338) No adverse events were reported during any test, thus 
confirming the safety of such an approach to induce bradycardia clinically, in 
a pacemaker population. 
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6.6 Conclusion 
 
Previous studies have suggested that a potential therapeutic target to 
improve symptoms in HF may be to increase the heart rate response during 
exercise.(339) In addition it is commonly assumed that the heart rate 
lowering achieved by contemporary therapies to improve outcomes in HF 
induces exercise intolerance.  
 
This interventional RCT has shown that acutely inducing iatrogenic 
bradycardia, and worsening CI by reducing both the resting heart rate and 
the heart rate response does not worsen exercise capacity, suggesting that 
exercise intolerance might more likely be due to peripheral factors relating to 
CHF, and that CI might not be a causal factor in the symptoms expressed by 
patients. 
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Chapter 7: Investigating the relationship between heart rate 
and cardiac contractility (Opt-RATE 3 Study)  
 
7.1 Abstract 
 
Increases in cardiac contractility during exercise are under two major 
influences: depolarisation-rate dependent (heart rate dependent; force 
frequency relationship (FFR)), and catecholamine-dependent. The FFR is 
thought to be impaired in chronic heart failure (CHF) such that contractility 
does not rise normally with increases in heart rate.(340) It is not known 
whether an optimal heart rate range exists in CHF, and whether this is 
related to cardiac function, levels of symptoms and exercise capacity, or 
indeed whether modifying heart rates in CHF patients can positively 
influence cardiac contractility. 
 
The aim of this double-blind case-control pilot study was to measure the 
FFR in at least 10 controls with normal cardiac function and 15 subjects with 
moderate to severe heart failure (left ventricular ejection fraction <45%), 
pacemaker devices, in sinus rhythm on optimally tolerated medical and 
pacemaker therapy. The subjects remained at rest throughout the testing 
period, with heart rate increases driven solely through atrial/bi-ventricular 
pacing, in 10 beats/minutes increments from the minimum underlying heart 
rate. The FFR was calculated non-invasively using blood pressure and 
echocardiographic measures. 
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The results showed clear differences in the relationship between heart rate 
and contractility in healthy patients and patients with CHF. Contractility 
increased in both groups as the heart rate was increased, albeit at different 
rates, however FFR was blunted in CHF and fell beyond heart rates of 100 
bpm.  
 
This provides a mechanistic basis to explain the results of the two previous 
RCTs (OPT-Rate 1 and 2), wherein altering the peak heart rate did not 
influence functional capacity. 
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7.2 Introduction 
 
Cardiac output is dependent on heart rate and stroke volume, which is the 
difference between end diastolic left ventricular volume and end systolic 
ventricular volume. These three factors are interdependent, and 
continuously increasing the heart rate will affect the stroke volume by 
reducing the filling time and hence the end diastolic volume. (341)  
  
 
Simply increasing the heart rate in response to increased metabolic 
demands during exercise is not sufficient to allow maintenance of cardiac 
output. The role of contractility in exercise is to ensure that cardiac output 
matches venous return. Increasing the cardiac output by increasing the heart 
rate and reducing the end systolic volume is energetically more favourable 
initially, rather than increasing the end diastolic volume, which requires 
greater energy in order to achieve the necessary pressure and wall 
tension.(342)  
 
The depolarisation-rate dependent (catecholamine-independent) mechanism 
whereby increases in heart rate lead to increases in the force of contraction 
is known as the Treppe phenomenon, or the force frequency relationship 
(FFR). This frequency-dependent up-regulation of contractility is rapid and 
intrinsic to the myocardial cell with no external involvement from neuronal or 
hormonal controls. The FFR is vital because when heart rate increases, 
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diastolic filling time is reduced. Hence contractility must increase to avoid a 
paradoxical fall in cardiac output.  
 
The FFR is thought to be impaired in CHF such that contractility in heart 
failure does not rise normally with increases in heart rate.(343)  This raises 
the possibility that there may be a lower optimal heart rate range for cardiac 
contraction in CHF patients than in control subjects. 
 
The aim of this study is to measure cardiac contractility non-invasively and 
thus examine the FFR throughout the full range of heart rates achievable via 
pacemaker programming, independent of activity, cardiac loading or 
catecholamine activity. 
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7.3 Methods 
 
7.3.1 Study population 
A total of 31 subjects were enrolled into this study. All participants were 
approached at routine outpatient pacemaker follow-up appointments and 
given information sheets. This study was approved by the National Research 
Ethics Service (REC reference 12/YH/0097, Appendix B). 
 
Controls (n=13) were selected on the basis of no diagnosis or symptoms of 
heart failure and normal heart function on echocardiogram.  
 
The HF subjects (n=18) had a known diagnosis of moderate-severe systolic 
heart failure (ejection fraction less than 45%), a pacing device in situ for a 
clinical indication, and were clinically stable on optimally tolerated medical 
and pacemaker therapy for at least six months. 
  
  
 
7.3.2 Inclusion and exclusion criteria 
The inclusion criteria for controls in this study were no known diagnosis of 
heart failure, no signs or symptoms consistent with HF and no abnormalities 
on echocardiogram. 
  
Inclusion in the HF cohort required confirmed CHF due to left ventricular 
systolic dysfunction on echocardiogram (LVSD, moderate-severe; left 
ventricular ejection fraction <45%, and symptoms of breathlessness or 
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fatigue on exertion), on optimal medical therapy and stable symptoms. They 
must have had their pacemaker for at least six months with stable lead 
variables and no change in medications or other invasive cardiac procedures 
for at least three months. All subjects were capable lying in a supine 
recumbent position for the duration of the test and of giving informed written 
consent, which was obtained in all subjects. 
  
Subjects unable to give informed consent or with co-morbidities that 
prevented lying flat comfortably for the duration of the test, such as severe 
obstructive or restrictive respiratory conditions, uncontrolled symptomatic 
heart failure, uncontrolled angina or musculoskeletal conditions, were 
excluded. 
  
7.3.3 Testing 
7.3.3.1 Pre-test data collection 
Each subject attended the research department for a single visit. Height and 
weight were measured to allow FFR measures to be adjusted for body-
surface-area (BSA (m2) = SQRT( [Height(cm) x Weight(kg) ]/ 3600)). 
 
Information was also collected regarding co-morbidities, past medical 
history, medication types and dosages, pacemaker settings, NYHA symptom 
class and activities of daily living. A symptom limited treadmill based 
maximal cardio-pulmonary exercise test was also performed at baseline. All 
data were stored in a secure anonymised electronic database. 
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 7.3.3.2 Test procedure 
The subjects remained at rest throughout the testing period, with heart rate 
increases driven solely through atrial/bi-ventricular pacing, in 10 beat/minute 
increments starting at either a paced base rate of 30 beats per minute or the 
underlying intrinsic heart rate (if above 30 bpm). The FFR was calculated 
non-invasively using the systolic blood pressure and the end systolic volume 
index, as described previously in chapter 3. 
  
Blood pressures were measured at each heart rate setting using a standard 
manual cuff sphygmomanometer and a standard stethoscope by the blinded 
clinician. The systolic pressure was recorded as the point where the first 
tapping sound occurred for 2 consecutive beats. Echocardiographic images 
were recorded by a blinded echosonographer. Heart rate was increased at 
10 beat increments by the unblinded technician, who also monitored the 
ECG throughout the test. The patient was not made aware of the heart rate, 
blood pressure or echocardiographic measures at any stage of the testing 
process. 
 
7.3.3.3 Data collection 
Heart rate settings were recorded and adjusted by the unblinded pacing 
technician. Prior to starting the test, the technician positioned the patient on 
the echocardiogram couch, attached ECG monitoring and determined the 
lowest tolerated heart rate by reducing the pacemaker base rate to 40 bpm. 
The two key measurements for determining contractility non-invasively are 
the end-systolic volume and systolic blood pressure, which is used as a 
surrogate for end-systolic LV pressure. The end systolic volume was 
determined using the Simpsons bi-plane method using two dimensional 
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echocardiographic images. This was collected by the blinded 
echosonographer, and analysed by two independent senior 
echosonographers off-line. Heart rate (HR, bpm) was increased at 10 bpm 
increments by the unblinded technician, who would alter the pacing rate, 
wait for exactly one minute and then instruct the echosonographer to begin 
image acquisition.  
 
Systolic blood pressure readings were taken manually by the blinded 
physician at the same time as the recording of end systolic images to ensure 
maximum accuracy of the resulting contractility measure. Blood pressure 
readings were taken twice during that time period, and an average was 
recorded on the data capture form. Serial measures were taken in this way 
until either the peak predicted heart rate was achieved, the patient 
complained of any discomfort or the unblinded technician detected any 
ischaemic ECG changes. All pacemaker settings were returned to baseline 
following the test. Five minutes after the end of the test, a final set of images 
and a blood pressure were recorded. 
 
 
7.3.4 Cohort size calculation 
Heart rate related changes in contractility have not been previously 
investigated in paced controls or heart failure patients, using a non-invasive 
incremental study protocol. This part of the study is therefore necessarily 
exploratory. However previous studies have demonstrated that non-invasive 
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contractility measures using the end-systolic volume (adjusted to BSA) and 
the systolic blood pressure are reliable and reproducible. Moreover, all major 
previous studies looking at contractility and Treppe have been able to 
demonstrate significance using HF cohorts of 11 ± 4 and control cohorts of 8 
± 3.(313)  
 
Therefore, in order to demonstrate a clinically important change in 
contractility, a minimum of 8 subjects were needed in the control group, and 
a minimum of 11 in the CHF group. To allow for drop-outs and to confidently 
suggest equivalence, the recruitment aims were a minimum of 10 controls 
and 15 CHF subjects.  
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7.4 Results 
 
7.4.1 Baseline characteristics for entire cohort  
A total of 31 participants were recruited in to this study (CHF n=19, Controls 
n=12). Weight, body surface area, ejection fraction, pVO2, furosemide dose, 
NYHA status and age followed a non-parametric distribution (Shapiro-Wilk 
normality test; p<0.05) and are hence reported as median ± interquartile 
range (table 7.1). 
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 Full cohort (n=31) 
Height, cm 173 (8) 
Weight, kg 78 ± 18 
Age, years 77 (15) 
Body Surface Area, m2 1.95 ± 0.2 
NYHA class 1 90% (28) 
NYHA class 2 10% (3) 
Ejection fraction, % 45 (19) 
Exercise Time, second 526 (266) 
pVO2, ml/kg/min 18.2 ± 10 
Baseline HR, bpm 50 (13) 
Syst BP (SP) 125 (19) 
Diast BP (DP) 70 (11) 
Furosemide 32% (10) 
Diabetes mellitus 20% (6) 
Ischaemic heart disease 29% (9) 
Hypertension 10% (3) 
PMH: CABG 13% (4) 
PMH: PCI 3% (1) 
PMH: Valve surgery 7% (2) 
ACEi/ARB 68% (21) 
Beta-blocker 68% (21) 
Spironolactone 23% (7) 
Statin 52% (16) 
Calcium channel blocker 3% (1) 
Digoxin 10% (3) 
Amiodarone 10% (3) 
Anticoagulation 45% (14) 
Antiplatelet 29% (9) 
Non-parametric variables reported as median ± interquartile range. Normally 
distributed variables as mean (SD). 
 
KEY: NYHA: New York Heart Association, HR: heart rate, BP: blood pressure, 
pVO2: peak oxygen consumption,, CABG: coronary artery bypass grafting, PCI: 
percutaneous coronary intervention, ACEi: angiotensin converting enzyme 
inhibitor, ARB: angiotension II receptor blocker. 
               Table 7.1 Baseline characteristics 
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7.4.2 Comparing demographics between groups 
Baseline characteristics for each group separately are shown in table 7.1 
(parametric data as mean (SD); non-parametric as median±IQR). 
 CHF (n=19) Controls (n=12) P value 
Height, cm 172 (7) 175 (8) 0.450 
Weight, kg 83 ± 16 76 ± 10 0.068 
Age, years 77 (9) 70 (16) 0.183 
Body Surface Area, m2 2.0 ± 0.2 1.9 ± 0.2 0.134 
NYHA class 1 84% (16) 100% (12) 0.148 
NYHA class 2 16% (3) 0  
Ejection fraction, % 34 (7) 55 (5) <0.05 
Exercise Time, second 441 (233) 639 (275) 0.050 
pVO2, ml/kg/min 15.8 (4) 26.7 (11) <0.05 
Baseline heart rate, bpm 49 (13) 53 (13) 0.434 
Systolic BP, mmHg 121 (23) 129 (13) 0.171 
Diastolic BP, mmHg 68 (12) 71 (10) 0.317 
Furosemide dose, mg 20 ± 70 0 <0.05 
Diabetes mellitus 21% (4) 17% (2) 0.763 
Ischaemic heart disease 42% (8) 8% (1) <0.05 
Hypertension 6% (1) 17% (2) 0.296 
PMH: CABG 16% (3) 8% (1) 0.546 
PMH: PCI 5% (1) 0% (0) 0.419 
PMH: Valve surgery 11% (2) 0% (0) 0.245 
ACEi 53% (10) 25% (3) 0.129 
ARB 42% (8) 8% (1) <0.05 
Beta-blocker 95% (18) 25% (3) <0.05 
Spironolactone 37% (7) 0% (0) <0.05 
Statin 74% (14) 17% (2) <0.05 
Calcium channel blocker 5% (1) 0% (0) 0.419 
Digoxin 16% (3) 0% (0) 0.148 
Amiodarone 16% (3) 0% (0) 0.148 
Anticoagulation 63% (12) 17% (2) <0.05 
Antiplatelet 32% (6) 25% (3) 0.694 
KEY: NYHA: New York Heart Association, HR: heart rate, BP: blood pressure, 
pVO2: peak oxygen consumption,, CABG: coronary artery bypass grafting, PCI: 
percutaneous coronary intervention, ACEi: angiotensin converting enzyme inhibitor, 
ARB: angiotension II receptor. blocker. 
Table 7.2 Group demographics 
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7.4.3 Comparing echocardiographic measures 
A comparison was made of the ejection fraction (calculated using the 
Simpson’s bi-plane method), left ventricular internal diameter in systole, left 
ventricular internal diameter in diastole, the estimated cardiac output and the 
aortic pre-ejection time. The data was analysed by two independent 
echosonographers, and the mean of the values obtained was used in all 
subsequent analyses after performing a Bland-Altman test to assess the 
level of agreement, using measurements and calculations on the resting pre-
test echocardiogram (correlation R=0.712, p<0.05). 
 
Both the control and the CHF cohort exhibited a similar relationship in these 
measures with increasing heart rates, albeit worse in the CHF group (Figure 
7.1A-E). 
 
  
Figure 7.1A Ejection fraction 
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Figure 7.1B Left ventricular internal diameter (systole) 
Figure 7.1C Left ventricular internal diameter (diastole) 
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Figure 7.1D Cardiac output 
Figure 7.1E Aortic pre-ejection time 
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7.4.4 Contractility 
The end-systolic volume index and systolic blood pressure reading was used 
to non-invasively estimate the cardiac contractility at each heart rate for the 
participants. The resultant data is shown in Figure 7.2.  
 
 
Figure 7.2 Contractility measures 
 
A clear difference was seen in the relationship between heart rate and 
contractility in healthy controls and patients with CHF (figure 7.3). Examining 
the relationship in linear regression models (dashed lines) showed that there 
was evidence of a quadratic relationship in each group of patients: 
• Controls: 0.04638×HR−0.0002112×HR2+0.9288 
• CHF: 0.1682009×HR−0.0006316×HR2−2.4876 
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Figure 7.3 Contractility linear regression model 
 
In each model the linear term was significant (p<0.05) and the quadratic 
term at least borderline significant (p=0.001 for controls and p=0.06 for 
CHF).  
 
Separate models were required for each group, as compared to considering 
the data overall. This was confirmed by a likelihood ratio test for a saturated 
model compared to a simple additive model for HR, HR2 and patient group 
(χ23=38.96, p<0.05).  
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7.5 Discussion 
 
The results obtained in this study explain one of the potential mechanisms 
underlying the relationship between heart rate and exercise capacity in CHF. 
While heart rate plays an important role in increasing cardiac output during 
activity in health, this relationship between heart rate and heart function is 
different in CHF, as a result of a blunted FFR response. 
 
Heart rate is a fundamental modulator of cardiac output, and increases 
therein are physiologically essential in order to meet the increased metabolic 
demands of activity and exercise. Cardiac output is dependent on both heart 
rate and stroke volume. These two factors are interdependent as a result of 
the Treppe phenomenon. 
 
Increases in heart rate are normally linked to increases in cardiac 
contractility, via a positive FFR. One of the restrictions to achieving 
increased cardiac output during exercise in patients with heart failure might 
be the limited rise in cardiac contractility with increases in heart rate, as 
shown by this study. 
 
It is clear from this study that contractility increases as heart rate increases 
in both groups, but the rate of the change is very different in patients with 
CHF as compared to controls. In the control group, contractility continues to 
increase until very high heart rates are achieved, up to 140 beats per 
minute. However, the contractility response is slow in CHF, and a decrease 
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in the contractility slope occurs at heart rates over 100 bpm. Thus higher 
heart rates are not energetically favourable in CHF, and increasing the peak 
heart rate above 100 bpm does not result in any increase in cardiac 
contractility.  
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7.5.1 Clinical relevance  
Not only does this explain why worsening CHF is associated with increasing 
CI, but also why correcting CI by augmenting cardio-acceleration does not 
increase exercise capacity.  This has definite and far-reaching clinical 
implications with regards to treatment goals in CHF with pharmacological 
and pacemaker device therapy.  
 
In addressing the heart rate clinically, heart failure physicians are faced with 
a conflicting dilemma. Evidence from numerous large studies, as well as 
international guidelines all encourage the use of medications to lower the 
resting heart rate, as this intervention is known to improve patient survival. 
However, all CHF patients are functionally limited to varying extents, and the 
origin of this limitation has hitherto been unclear.  
 
Chronotropic incompetence has been proposed by many as being the major 
cause, and therein lies the conflict. Lowering the resting heart rate to 
improve mortality will necessarily worsen heart rate rise (HRR) and will lower 
the peak heart rate achieved. In contrast using a pacemaker to treat CI or 
reducing HR lowering medications will improve HRR, but has a negative 
effect on overall survival and mortality. 
 
These results show that there is no favorable HR related change in cardiac 
contractility at heart rates above 100 bpm in the context of CHF. Thus, there 
is no symptomatic or functional benefit to be gained from treating CI with 
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higher pacemaker resting heart rate settings, rate adaptive pacing or 
suboptimal utilisation of prognostically beneficial pharmacological agents 
such as beta-blockers or sinus node If current blockers, that induce an 
iatrogenic bradycardia and may limit HRR.  
 
The presence of CI is neither the causal factor for exercise intolerance, nor a 
target for treatment. Rather it may be an intrinsic cardio-protective measure 
that ensures the heart rate range does not increase to such a degree that 
contractility, as hence cardiac function, declines during physical activity. 
Myocardial perfusion also predominantly occurs in diastole, and the lower 
HRR in CI may be a physiological response to improve myocardial 
oxygenation by ensuring longer diastolic time.(344)  
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7.6 Conclusion 
 
Our data show that in controls, higher heart rates lead to greater contractility, 
and thus greater potential for cardiac output to increase in response to 
increasing activity. In CHF, the FFR is blunted so that contractility does not 
increase to the same degree or in the same manner, as in the control group. 
 
As the force-frequency relationship is different in controls and CHF patients 
with increasing heart rates, independent of cardiac loading or physical 
activity levels. These two groups cannot be subjected to the same treatment 
rationale when it comes to resting heart rate, peak heart rate and exertion 
related heart rate rise.    
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Chapter 8: The role of the heart rate on exercise capacity in 
chronic heart failure: association or contribution? 
 
8.1 Introduction 
 
The constant beating of our heart; it is the very first and also the very last 
thing any of us will ever experience. The very presence of a heartbeat 
signifies the presence of life, and its absence marks its end. Heart rate is the 
metronome of our existence and it regulates the level of overall energy 
consumption. This vital and familiar life companion is unappreciated, 
misunderstood and often overlooked. Yet even when the heart starts to fail, 
the heart rate will adapt to compensate and thus keep us alive. This 
investigation is an attempt at reconciliation, and its purpose is to show 
appreciation to the heart rate by exploring, expounding and clarifying its role 
during activity in the context of heart failure.  
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8.2 Overview 
 
Exercise capacity refers to the maximum degree of physical exertion 
attainable. This can be affected by functional abnormalities in the 
cardiovascular, respiratory and skeletal muscle systems. Exercise 
intolerance is pathognomonic of chronic heart failure (CHF). This is 
considered to be the result of reduced cardiac output at rest because of 
myocardial contractile impairment and impaired increase in cardiac output 
with exercise, resulting in lower oxygen consumption, exercise intolerance 
and fatigue. Cardiac output is dependent on alterations in heart rate (HR) 
and stroke volume, both of which are impaired in the context of CHF. The 
focus of this investigation was to assess the role of HR on exercise capacity 
in heart failure.  
 
An overall estimate of exercise capacity can be expressed by measuring the 
maximal symptom-limited oxygen uptake (peak VO2) in an incremental 
exercise regime with breath-by-breath analysis of oxygen uptake and carbon 
dioxide release. Peak VO2 is known to be lower in patients with heart failure 
compared to healthy controls, in reflection of the lower exercise tolerance. 
Patients with CHF also commonly have a blunted heart rate rise, known as 
chronotropic incompetence (CI). This refers to an inability of the HR to 
increase in proportion to the level of physical exertion or metabolic demand. 
There is conflicting evidence as to whether CI contributes to, or is the result 
of, the reduced exercise capacity that is characteristic of worsening heart 
failure. 
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The degree of CI relates to both the severity of LVSD and the level of 
exercise limitation, although it is unclear as to whether this is merely an 
association or a causative link.(235) Multiple studies have explored the 
relationship between CI and exercise capacity with conflicting results that 
demonstrate a strong association but no definite causation. 
(229)(230)(236)(231)(237) A negative force-frequency association may 
also exist within failing myocardium cells.(35)(265) 
 
As heart rate lowering agents can affect both the resting and the peak 
HR, there is controversy as to whether these could worsen symptoms by 
increasing the level of CI, despite the likelihood of long-term mortality 
benefits. Conversely, perhaps the reduced heart rates seen in CHF 
throughout exercise is form of chronotropic adaptation (CA), which 
favours energy kinetics by reducing the resting myocardial oxygen 
demand, resulting in less cardiac ischaemia and a better contractile 
response at lower heart rates. 
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8.3 Resting heart rate 
 
 
Resting heart rate (RHR) has been established as both a marker of 
prognosis, and a viable treatment objective in multiple large epidemiological 
studies.(63)(258) RHR becomes increasingly elevated in heart failure as the 
disease progresses. Pharmacological targeting to lower RHR results in 
improvements in both mortality and morbidity.(269)(345) However, despite 
the burden of evidence showing all-cause mortality benefits with reducing 
the RHR, there is a failure to achieve recommended doses in a large 
proportion of patients,(346) and mortality remains high with a 5-year survival 
rate of around 40%.(338)   
 
Some of these cases may be due to contraindications or poor tolerance, 
however there is also a great degree of reluctance in using high dose beta-
blockers or aggressive RHR lowering through combination with other 
pharmacological agents such as sinus node blockers, due to a fear of 
inducing exercise intolerance, severe symptomatic bradycardia and 
increasing symptoms of breathlessness and fatigue.  
 
In those patients with pacemakers or bi-ventricular devices in-situ, higher 
doses of rate-limiting agents can be safely used without risk of inducing 
severe RHR lowering. One of the indications for pacemaker implantation is 
prevention of excessive bradycardia, hence devices are often set to maintain 
a higher HR than what the current evidence shows to be optimal for CHF. 
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Thus devices are seldom programmed in a way to allow pharmacologically 
induced, prognostically beneficial bradycardia.  
 
A recent pilot study of patients with systolic dysfunction and pacemakers 
showed an improvement in cardiac function with the lower base rate of 55 
beats/min compared to 75 beats/min.(347) However, the situation becomes 
more complicated when considering the cardiac response to exertion within 
LVSD, and whether altering the HR profile affects fatigability and exercise 
capacity.  
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8.4 Peak heat rate 
 
A key feature of HR in moderate-severe LVSD is the inability to achieve the 
maximum predicted peak HR (PHR), known as chronotropic incompetence 
(CI). The increased peripheral demand during exercise results in an increase 
in the heart rate via the autonomic nervous system. In the non-diseased 
heart, myocardial contractility will increase in response to the increased rate. 
This is known as the force-frequency relationship, or the Bowditch 
effect.(194) CI refers to an inability of the heart rate to increase in proportion 
to the level of physical exertion or metabolic demand. Rate-adaptive cardiac 
pacing was developed as an attempt to optimise exercise tolerance in 
patients with CI.(348)(349) 
 
Pacemakers can be programmed to deliver either fixed rate pacing or utilise 
a rate-adaptive pacing algorithm, where the heart rate is altered in proportion 
to the level of activity as detected by internal device sensors. Rate-adaptive 
pacing in people without CHF is associated with an increase in cardiac 
output during exercise (252) and better quality of life (253)(254)(255) but 
inconsistent (256)(257) improvements in exercise capacity, when compared 
to fixed rate pacing. Using pacemakers to increase PHR in CHF has been 
shown to worsen prognosis and cardiac function.(259)(260)  
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8.5 Clinical implications 
 
There is no conclusive evidence of benefit on exercise time or quality of life 
in CHF from increasing the mean and peak HR with rate-adaptive 
pacing.(263) Despite this, rate-adaptive pacing with high base rates remains 
the standard of care for all patients with pacemakers including those with 
CHF, creating a paradox that medical therapy to reduce mean heart rate is 
proven and applied, yet those with a pacemaker may be inadvertently 
subjected to higher mean heart rates, thus missing a therapeutic opportunity.  
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8.6 Investigation Rationale 
 
The close relationship between the heart rate and exercise capacity, and 
limited techniques to detach one from the other means that published data 
are inconclusive. Although an association between exercise capacity and CI 
is both plausible and coherent through analogous comparisons with controls, 
in order to prove causality, it is necessary to also determine strength of 
association, biological gradient, temporality, consistency and specificity 
through carefully designed and controlled experimental studies. The 
Bradford-Hill criteria for causality act as guidelines to help determine 
whether an observed relationship is merely associatory, or actually 
contributory (Table 8.1).(350) 
 
Bradford-Hill	criteria		 Explored/Tested	in:	
Plausibility	 Background	
Coherence	 Background	
Analogy	 Observational	study	
Strength	of	association	 Observational	study	
Biological	gradient	 Observational	study	
Experiment	 Interventional	RCT	1	and	2	
Temporality	 Interventional	RCT	1	and	2	
Consistency	 Interventional	RCT	1	and	2	
Specificity	 Case-control	contractility	study	
Table 8.1 Bradford-HiIl Criteria 
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In heart failure, the force-frequency relationship is greatly reduced. 
Furthermore, the higher HR in CHF is associated with reduced cardiac 
efficiency and increased myocardial oxygen demands. An impaired Bowditch 
effect during exertion may not only result in declining functional capacity, but 
also an overall reduction in cardiac function.(194) HR reduction would 
prolong diastole and thus increase efficiency by improving FFR and reducing 
energy consumption.(264)  
 
There is a pathophysiological argument to be made in support of the 
haemodynamically optimal heart rate range in heart failure being different to 
that expected from controls, with a lower optimal peak heart rate beyond 
which there is no improvement in exercise capacity.(351) 
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8.7 Observational study 
 
Thus, this investigation started with a retrospective cohort analysis in order 
to explore some of these factors. In particular, the observational data were 
analysed for the existence and strength of any association between the 
presence of CI and limited exercise capacity, and the possibility of a 
biological gradient between the degree of CI and severity of exercise 
intolerance.  
 
This involved analysis of clinical, echocardiographic and cardio-pulmonary 
exercise test (CPX) data from 195 consecutive patients. There was a strong 
correlation between HRR and peak oxygen consumption in the control group 
(n=48). This association was much weaker in the CHF cohort (n=147), within 
which both the presence and degree of CI was associated with worsening 
exercise capacity. Therefore both an association and a biological gradient 
(dose-response relationship) were present within the CHF cohort.  
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8.8 Interventional studies 
 
In order to determine causality, further experiments were required to also 
demonstrate temporality, consistency and specificity.  
 
8.8.1 Increasing the heart rate during exercise 
If the presence of CI caused a limitation in exercise capacity, then correcting 
CI by increasing the heart rate rise achieved during exercise should result in 
improved exercise capacity.  
 
In our study, increasing the peak HR achieved during a maximal exercise 
test on subjects with CHF did not result in any improvement in exercise 
capacity. The results of this RCT demonstrate that ‘correcting’ chronotropic 
incompetence in patients with CHF, or unnecessarily activating rate adaptive 
pacing in patients with a pacemaker and no LV dysfunction, does not result 
in any improvement in oxygen consumption, exercise capacity, exercise time 
or symptoms.  
 
The situation differed in the presence of AF. Here, rate adaptive pacing 
resulted in higher peak oxygen consumption, despite no change in exercise 
time or anaerobic threshold implying ‘wasted’ metabolic effort. Thus a lower 
peak heart rate may actually improve skeletal or cardiac muscle efficiency in 
CHF with AF, as the same output is delivered (exercise time) but with lower 
oxygen consumption. These findings offer a possibility of future work to 
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consider whether the CI in HF patients might be beneficially adaptive, rather 
than as commonly considered, maladaptive. 
 
Overall, our data suggest that a temporal relationship does not exist, 
whereby correcting the HRR results in any change in total exercise capacity.  
 
8.8.2 Decreasing the heart rate during exercise 
A further randomised controlled trial was carried out in order to demonstrate 
whether a dose-response relationship or any specificity existed such that 
worsening CI by reducing the resting heart rate could result in any reduction 
of exercise capacity. To ensure consistency, the same selection criteria were 
used to identify a different cohort of patients for this study.  
 
A total of 40 patients were recruited into this interventional double blind 
cross-over randomised controlled trial, of which 14 had concurrent atrial 
fibrillation and 26 were in sinus rhythm. Each participant performed two 
cardiopulmonary treadmill based exercise tests at either the normal resting 
HR (using usual pacemaker settings in the AF cohort, or placebo in the sinus 
cohort) or a reduced resting HR (pacemaker resting rate reduced to 30 in the 
AF cohort, or pharmacological heart rate lowering in the sinus group with a 
sinus node blocking agent, ivabradine). Reducing the resting heart rate did 
not result in any worsening of exercise capacity in either cohort. In fact, 
starting at a lower resting heart rate in the AF cohort resulted in an increase 
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in exercise efficiency, with a higher HRR and longer exercise time, despite 
achieving the same peak oxygen consumption.   
 
8.8.3 Mechanistic study 
Data from the previous studies prompted a further interventional case-
control study to explore the cardiac force-frequency relationship (FFR) in 
heart failure (Treppe phenomenon), in order to understand why both 
lowering the resting heart rate and increasing the peak heart rate had no 
effect on functional capacity.   
 
A double blind interventional case-control study was carried out on 31 
patients with pacemakers (CHF n=19, Controls n=12) in order to determine a 
mechanistic basis and suggest an optimal heart rate range for moderate-
severe CHF. 
 
Linear regression modelling of cardiac contractility measures (systolic blood 
pressure/end-systolic volume index) across a range of pacemaker-induced 
heart rates revealed a different relationship between heart rate and 
contractility in healthy patients and patients with CHF. In controls, higher 
heart rates led to greater contractility throughout the full range of 
measurements. In CHF, the FFR was blunted with only modest increases at 
a lower heart rate range (40 to 100 beats per minute), with flattening 
thereafter.  
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8.9 Discussion 
 
This investigation provides persuasive evidence that CI is simply a marker of 
exercise intolerance that fails to meet the minimum criteria to infer causality, 
namely lacking a temporal relationship, consistency or any dose-response 
effect. Furthermore, there is clinical benefit to be gained from lowering the 
resting heart rate both in terms of exercise capacity acutely, and prognostic 
benefits long term. 
 
The unique combination of a double blind randomised controlled cross-over 
study design along with therapeutic modalities that can alter the heart rate in 
isolation, and hence manipulate the chronotropic response, such as rate 
adaptive pacing to increase the heart rate and ivabradine, a pharmacological 
sinus node If current blocking agent that induces bradycardia with no 
peripheral effects, to reduce the heart rate, has made it possible to study the 
effects of modifying CI without changing any other cardiovascular 
parameters. Non-invasive measurement of the force-frequency relationship 
independently of cardiac loading or catecholamine activity throughout the full 
range of heart rates achievable in a CHF cohort has provided a mechanistic 
basis to explain the RCT results. 
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8.10 Clinical implications 
 
In addressing the heart rate clinically, heart failure physicians are faced with 
a conflicting dilemma. Evidence from numerous large studies, as well as 
international guidelines all encourage the use of medication to lower the 
resting heart rate, as this intervention is known to improve patient survival. 
However, all CHF patients are functionally limited to varying extents, and the 
origin of this limitation is unclear.  
 
Chronotropic incompetence has been proposed by many as being the major 
cause, and therein exists the conflict. Lowering the resting heart rate to 
improve mortality will necessarily worsen heart rate rise and will lower the 
peak heart rate achieved. In contrast using a pacemaker to treat CI or 
reducing the dosage of HR lowering medications will improve heart rate rise, 
but will have a negative effect on overall survival and mortality. 
 
The novel findings reported here have clinical implications for both 
pharmacological and device treatment strategies in the context of significant 
systolic heart failure.  Even though the presence of CI in CHF relates to 
reduced functional capacity, correcting this may be unnecessary as it will not 
improve oxygen consumption, symptoms or exercise time in CHF. This leads 
to the conclusion that CI does not play a causal role within the exercise 
intolerance seen in CHF.  
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Heart rate rise is not a limiting factor for peak exercise capacity, and is thus 
precluded from being a potential therapeutic target. The reduced heart rate 
increase seen in CHF corresponds to the HR range where the contractility 
response is positive, which raises the possibility that the ‘chronotropic 
adaptation’ seen in worsening CHF is likely a cardio-protective measure, in 
order to maximise contractile response and exertional cardiac output.  
 
Exercise capacity is also not worsened by reducing the resting HR, in both 
sinus and AF heart failure patients. As such, pharmacological goals and 
pacemaker programming should be different in moderate-severe LVSD, 
compared to those with normal LV function. 
 
A tailored patient specific approach is necessary when utilising interventions 
that may alter the heart rate. Further research is required in order to explore 
whether using FFR estimation to determine a tailored optimal heart rate 
range to guide personalisation of treatment strategies for each CHF patient 
could improve exercise capacity in the short term, and mortality in the long 
term, by mimicking the natural chronotropic adaptation observed in CHF 
rather than attempting to exceed it.  
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8.11 Future Research 
 
If contractility does not respond normally to increases in heart rate in CHF 
patients and plateaus or indeed worsens with increasing heart rate, there 
may be a lower optimal heart rate range for cardiac contraction in CHF 
patients, with respect to improving functional capacity and symptoms. Thus 
the next step will be to use these findings as the basis for programming 
pacemakers based on the optimal heart rate range in relation to each 
individual’s FFR profile and contractility response within a large-scale 
randomised controlled trial. The non-invasive echocardiography techniques 
used in the current investigation would be utilised to calculate the optimal 
HR range to achieve peak contractility. The study participants would then be 
double-blind randomised to have two treadmill-based cardiopulmonary 
exercise tests one week apart, with either the usual pacing settings, or 
tailored pacemaker HR settings with a lower peak HR, in order to optimise 
the FFR response. The aim would be to determine whether such an 
approach could reduce symptoms and increase functional capacity in 
moderate-severe CHF. 
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8.12 Conclusion  
 
The clinical implications of this series of investigations are clear. Even 
though the presence of CI in CHF relates to reduced functional capacity, 
correcting this in the CHF population is futile and unnecessary as it will not 
improve oxygen consumption, symptoms or exercise time. Also, lowering the 
resting HR does not worsen exercise capacity. This leads to the conclusion 
that CI does not play a major role within the exercise intolerance seen in 
CHF, and may instead be a cardio-protective ‘chronotropic adaptation’ 
response. The rationale for this lies in the blunted FFR seen with moderate-
severe CHF, whereby no improvement in contractility is seen with heart 
rates over 110 beats per minute.  
 
This thesis has expounded the role of the heart rate on exercise capacity in 
heart failure, and provides evidence that chronotropic incompetence is 
neither a limiting nor a causal factor for exertional intolerance in CHF.  
 
Instead, the findings of these interventional studies demonstrate that the 
seemingly counter-intuitive approach of lowering the HR, which is known to 
improve mortality, does not negatively impact functional capacity.  The 
chronotropic adaptation seen with worsening heart failure should be 
supported, with the aim to maintain the exertional heart rate rise between an 
optimal range of 50 to 110 beats per minute. 
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List of Abbreviations 
 
ACC/AHA American College of Cardiology  
ACEi angiotensin converting enzyme inhibitor 
ADL activities of daily living  
AF atrial fibrillation 
AHA American Heart Association 
ARB angiotensin II receptor blocker 
AT lactate/anaerobic threshold  
ATP adenosine triphosphatase 
AV atrio-ventricular 
BMI body mass index 
BNP brain natriuretic peptide 
BSE British Society of Echocardiography 
Ca2+ calcium ions 
CABG coronary artery bypass grafting 
CAD coronary artery disease 
cAMP cyclic adenosine monophosphate 
CHF chronic heart failure 
CI chronotropic incompetence 
CO  cardiac output 
CPX cardiopulmonary exercise test 
ECC excitation-contraction coupling 
ECG electrocardiogram 
EDV end diastolic left ventricular volume 
EF ejection fraction 
ESC European Society of Cardiology 
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ESP end-systolic pressure 
ESPVR end-systolic pressure volume ratio 
ESV end systolic left ventricular volume 
FFR force-frequency relationship 
HFpEF heart failure with preserved ejection fraction 
HFrEF heart failure with reduced ejection fraction 
HR heart rate 
HRR heart rate rise 
ICa calcium influx current  
IHD ischaemic heart disease 
IQR interquartile range 
LTCC L-type calcium channels 
LVEF left ventricular ejection fraction  
LVESV end systolic left ventricular volume 
LVESVi end systolic left ventricular volume index 
LVIDd left ventricular internal diameter in diastole 
LVIDs left ventricular internal diameter in systole 
LVSD left ventricular systolic dysfunction 
MI myocardial infarction 
MRT mean response time 
MyBP-C myosin binding protein C 
NCX sodium–calcium exchange protein 
NT-proBNP N- terminal brain natriuretic peptide prohormone 
NYHA New York Heart Association 
OUES oxygen uptake efficiency slope 
PCI percutaneous coronary intervention 
PetCO2 partial pressure of end tidal CO2 
PHR peak heart rate 
PKA protein kinase A 
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PLB phospholamban 
PMH past medical history 
RCT randomised controlled trial 
RER respiratory exchange ratio (ratio of VCO2 to VO2) 
RHR resting heart rate 
RR respiratory rate 
RV right ventricle 
RyR2 ryanodine receptors 
SD standard deviation 
SE standard error 
SND sinus node disease 
SR sarcoplasmic reticulum 
Tm tropomysin 
TnC troponin C  
TnI troponin I 
TTE transthoracic echocardiogram 
VE ventilation 
VE/VCO2 slope slope relating ventilation rate to carbon dioxide output 
VO2 oxygen uptake/consumption 
Vt tidal volume 
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Appendix A Detailed statistical analyses data 
 
Appendix A.1 Stratified cohort data comparing 
worsening degrees of chronotropic incompetence (study 
1, chapter 4, section 4.3.3) 
 
 N Mean SD SE 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
Age, 
years 
1 16 68.063 13.0255 3.2564 61.122 75.003 
2 8 70.500 11.2504 3.9776 61.094 79.906 
3 18 72.611 15.9268 3.7540 64.691 80.531 
4 32 68.813 9.5087 1.6809 65.384 72.241 
5 40 70.650 11.4703 1.8136 66.982 74.318 
6 23 71.522 11.9197 2.4854 66.367 76.676 
7 10 67.700 12.4012 3.9216 58.829 76.571 
Total 147 70.136 11.8603 .9782 68.203 72.069 
PPHR, 
bpm 
1 16 151.94 13.025 3.256 145.00 158.88 
2 8 149.50 11.250 3.978 140.09 158.91 
3 18 147.39 15.927 3.754 139.47 155.31 
4 32 151.19 9.509 1.681 147.76 154.62 
5 40 149.35 11.470 1.814 145.68 153.02 
6 23 148.48 11.920 2.485 143.32 153.63 
7 10 152.30 12.401 3.922 143.43 161.17 
Total 147 149.86 11.860 .978 147.93 151.80 
HRR, 
bpm 
1 16 82.13 29.111 7.278 66.61 97.64 
2 8 73.00 11.588 4.097 63.31 82.69 
3 18 63.44 19.515 4.600 53.74 73.15 
4 32 53.44 12.941 2.288 48.77 58.10 
5 40 37.70 8.683 1.373 34.92 40.48 
6 23 23.22 7.299 1.522 20.06 26.37 
7 10 12.10 4.654 1.472 8.77 15.43 
Total 147 47.03 24.775 2.043 42.99 51.07 
Height, 
cm 
1 16 175.125 9.7271 2.4318 169.942 180.308 
2 7 170.500 10.6575 4.0282 160.643 180.357 
3 16 166.088 11.6694 2.9174 159.869 172.306 
4 32 163.516 31.2819 5.5299 152.237 174.794 
5 38 171.416 8.1858 1.3279 168.725 174.106 
- 238 - 
6 23 168.452 6.1106 1.2741 165.810 171.095 
7 10 170.200 8.8544 2.8000 163.866 176.534 
Total 142 168.842 16.9352 1.4212 166.033 171.652 
Weight, 
kg 
1 16 90.813 16.9763 4.2441 81.766 99.859 
2 7 85.400 20.5101 7.7521 66.431 104.369 
3 16 76.899 19.3668 4.8417 66.580 87.219 
4 32 81.089 24.3065 4.2968 72.325 89.852 
5 38 85.091 16.7138 2.7113 79.597 90.584 
6 23 82.630 17.3270 3.6129 75.138 90.123 
7 10 88.960 18.1838 5.7502 75.952 101.968 
Total 142 83.800 19.3636 1.6250 80.587 87.012 
Exercise 
time, s 
1 16 417.56 200.239 50.060 310.86 524.26 
2 8 562.88 169.978 60.096 420.77 704.98 
3 18 486.44 247.336 58.298 363.45 609.44 
4 32 476.88 218.714 38.663 398.02 555.73 
5 40 393.53 182.723 28.891 335.09 451.96 
6 23 311.52 198.020 41.290 225.89 397.15 
7 10 211.70 136.042 43.020 114.38 309.02 
Total 147 409.68 214.559 17.697 374.71 444.65 
AT, 
ml/kg/min 
1 10 13.80 4.827 1.527 10.35 17.25 
2 6 13.93 3.561 1.454 10.20 17.67 
3 14 13.32 3.577 .956 11.26 15.39 
4 21 12.67 2.843 .620 11.38 13.97 
5 23 11.87 2.753 .574 10.68 13.06 
6 7 12.49 4.640 1.754 8.19 16.78 
7 2 8.05 2.333 1.650 -12.92 29.02 
Total 83 12.66 3.472 .381 11.90 13.42 
RER 1 16 1.11 .122 .031 1.04 1.17 
2 8 1.13 .139 .049 1.02 1.25 
3 16 1.06 .123 .031 1.00 1.13 
4 31 1.12 .131 .023 1.07 1.16 
5 38 1.07 .119 .019 1.03 1.11 
6 23 .99 .118 .025 .94 1.04 
7 9 1.08 .205 .068 .92 1.23 
Total 141 1.07 .135 .011 1.05 1.10 
VE/VCO2 
slope (AT) 
1 12 28.46 6.014 1.736 24.64 32.28 
2 8 31.68 5.163 1.825 27.36 36.00 
3 15 30.59 5.188 1.340 27.72 33.47 
4 25 30.50 6.362 1.272 27.88 33.13 
5 28 30.92 7.938 1.500 27.85 34.00 
6 11 35.58 5.083 1.533 32.17 39.00 
7 3 31.15 10.031 5.791 6.23 56.07 
Total 102 31.05 6.611 .655 29.75 32.35 
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VE/VCO2 
slope 
(Peak) 
1 16 35.85 14.555 3.639 28.09 43.61 
2 8 33.48 5.681 2.009 28.73 38.23 
3 18 34.75 9.254 2.181 30.15 39.36 
4 31 34.55 11.214 2.014 30.44 38.67 
5 40 36.49 10.103 1.597 33.26 39.72 
6 22 40.08 9.567 2.040 35.84 44.33 
7 10 41.96 12.459 3.940 33.05 50.87 
Total 145 36.55 10.790 .896 34.78 38.32 
Resting 
HR, bpm 
1 16 103.25 18.760 4.690 93.25 113.25 
2 8 81.25 11.997 4.242 71.22 91.28 
3 18 74.94 16.917 3.987 66.53 83.36 
4 32 73.94 13.907 2.459 68.92 78.95 
5 40 72.45 15.332 2.424 67.55 77.35 
6 23 72.13 16.966 3.538 64.79 79.47 
7 10 69.70 10.884 3.442 61.91 77.49 
Total 147 76.67 17.971 1.482 73.74 79.60 
Peak HR, 
bpm 
1 16 185.38 23.309 5.827 172.95 197.80 
2 8 154.25 13.079 4.624 143.32 165.18 
3 18 138.39 15.790 3.722 130.54 146.24 
4 32 127.38 9.517 1.682 123.94 130.81 
5 40 110.15 12.209 1.930 106.25 114.05 
6 23 95.35 12.737 2.656 89.84 100.86 
7 10 81.80 11.094 3.508 73.86 89.74 
Total 147 123.70 31.287 2.580 118.60 128.80 
EF, % 1 16 33.94 11.204 2.801 27.97 39.91 
2 8 31.00 7.578 2.679 24.66 37.34 
3 18 34.56 9.044 2.132 30.06 39.05 
4 32 34.09 8.880 1.570 30.89 37.30 
5 40 33.50 10.201 1.613 30.24 36.76 
6 22 30.77 11.980 2.554 25.46 36.08 
7 10 34.80 6.746 2.133 29.97 39.63 
Total 146 33.35 9.778 .809 31.75 34.95 
LVIDd, 
mm 
1 15 56.07 9.625 2.485 50.74 61.40 
2 8 61.50 9.274 3.279 53.75 69.25 
3 15 55.20 8.760 2.262 50.35 60.05 
4 25 56.12 8.343 1.669 52.68 59.56 
5 36 57.64 9.523 1.587 54.42 60.86 
6 18 61.11 7.136 1.682 57.56 64.66 
7 9 55.67 5.545 1.848 51.40 59.93 
Total 126 57.46 8.709 .776 55.92 59.00 
LVIDs, 
mm 
1 7 47.00 12.014 4.541 35.89 58.11 
2 6 54.33 11.396 4.652 42.37 66.29 
3 5 41.40 7.197 3.219 32.46 50.34 
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4 16 44.31 6.770 1.692 40.71 47.92 
5 17 49.65 11.710 2.840 43.63 55.67 
6 12 50.58 9.317 2.690 44.66 56.50 
7 4 53.50 4.655 2.327 46.09 60.91 
Total 67 48.30 9.961 1.217 45.87 50.73 
pVO2, 
ml/kg/min 
1 16 17.7875 6.55885 1.63971 14.2925 21.2825 
2 8 18.5500 3.98676 1.40953 15.2170 21.8830 
3 18 16.6889 6.08149 1.43342 13.6646 19.7131 
4 32 17.4081 5.81436 1.02784 15.3118 19.5044 
5 40 15.2980 4.55806 .72069 13.8403 16.7557 
6 23 13.5652 4.53437 .94548 11.6044 15.5260 
7 10 9.6600 2.39824 .75839 7.9444 11.3756 
Total 147 15.7210 5.53281 .45634 14.8191 16.6228 
QRS 
duration, 
ms 
1 16 98.00 14.823 3.706 90.10 105.90 
2 8 123.75 29.769 10.525 98.86 148.64 
3 15 121.73 31.594 8.158 104.24 139.23 
4 28 119.61 29.700 5.613 108.09 131.12 
5 37 126.51 24.986 4.108 118.18 134.84 
6 21 129.19 21.507 4.693 119.40 138.98 
7 9 120.67 24.062 8.021 102.17 139.16 
Total 134 120.99 26.694 2.306 116.43 125.55 
Key: N: number of patients in each sub-cohort, SD: standard deviation, SE: standard error, PPHR: 
peak predicted heart rate, HRR: heart rate rise, AT: anaerobic threshold, RER respiratory exchange 
ratio, VE/VCO2 slope: slope relating ventilation rate to carbon dioxide output, HR: heart rate, 
EF: ejection fraction, LVIDd: left ventricular internal diameter in diastole, LVIDs: left 
ventricular internal diameter in systole, pVO2: peak oxygen consumption. 
Table A.1 Stratified cohort data comparing worsening degrees of chronotropic 
incompetence (study 1, chapter 4, section 4.3.3) 
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Appendix A.2 Paired sample statistics, CHF-AF (Study 2, 
chapter 5, section 6.3.3.1) 
Group	1	–	CHF-AF	(n=14)	 Mean	 N	 SD	 SE	
Resting	HR,	bpm	 BR	60	 64.786	 14	 14.1431	 3.7799	
BR	30	 49.214	 14	 18.2385	 4.8744	
Peak	HR,	bpm	 BR	60	 111.857	 14	 30.2626	 8.0880	
BR	30	 108.500	 14	 30.2903	 8.0954	
Heart	rate	rise,	bpm	
	
BR	60	 47.07	 14	 22.923	 6.126	
BR	30	 59.29	 14	 20.496	 5.478	
%Predicted	Peak	HR	
	
BR	60	 .778	 14	 .213	 .05744	
BR	30	 .753	 14	 .208	 .05567	
Rest	systolic	BP,	mmHg	 BR	60	 117.286	 14	 13.3037	 3.5556	
BR	30	 114.857	 14	 15.7229	 4.2021	
Rest	diastolic	BP,	mmHg	 BR	60	 64.000	 14	 6.6564	 1.7790	
BR	30	 59.143	 14	 8.1037	 2.1658	
PP	(rest),	mmHg	 BR	60	 53.29	 14	 14.024	 3.748	
BR	30	 55.71	 14	 11.658	 3.116	
Peak	systolic	BP,	mmHg	 BR	60	 131.571	 14	 21.5432	 5.7577	
BR	30	 135.857	 14	 19.2548	 5.1461	
PP	BP,	mmHg	 BR	60	 61.143	 14	 6.2124	 1.6603	
BR	30	 61.000	 14	 9.9460	 2.6582	
Pulse	pressure	(peak),	mmHg	 BR	60	 70.43	 14	 20.429	 5.460	
BR	30	 74.86	 14	 18.576	 4.965	
Exercise	time,	seconds	 BR	60	 434.357	 14	 224.6521	 60.0408	
BR	30	 482.714	 14	 235.0743	 62.8262	
pVO2,	ml/kg/min	 BR	60	 14.836	 14	 4.3143	 1.1530	
BR	30	 14.393	 14	 4.0189	 1.0741	
HR	at	AT,	bpm	 BR	60	 107.00	 13	 23.759	 6.590	
BR	30	 97.69	 13	 22.429	 6.221	
AT,	ml/kg/min	 BR	60	 12.8377	 13	 3.46787	 .96181	
BR	30	 11.5146	 13	 2.54400	 .70558	
VE/VCO2	slope	(peak)	 BR	60	 39.186	 14	 14.7624	 3.9454	
BR	30	 39.4071	 14	 14.52999	 3.88330	
VE/VCO2	slope	(AT)	 BR	60	 32.50	 13	 12.094	 3.354	
BR	30	 36.30	 13	 12.961	 3.595	
Peak	RER	 BR	60	 1.0764	 14	 .12701	 .03395	
BR	30	 1.1400	 14	 .12848	 .03434	
OUE	slope	 BR	60	 1498.214	 14	 521.3492	 139.3364	
BR	30	 1454.071	 14	 473.4275	 126.5288	
MRT	 BR	60	 177.58	 5	 104.181	 46.591	
BR	30	 202.20	 5	 113.632	 50.818	
MRT	recovery	 BR	60	 73.97	 3	 15.646	 9.033	
BR	30	 81.67	 3	 5.686	 3.283	
O2	pulse	(peak)	 BR	60	 12.500	 10	 5.1694	 1.6347	
BR	30	 12.900	 10	 4.6296	 1.4640	
O2	pulse	(AT)	 BR	60	 10.67	 9	 2.828	 .943	
BR	30	 10.33	 9	 2.449	 .816	
Key:	N:	number	of	entries,	SD:	standard	deviation,	SE:	standard	error,	HR:	heart	rate,	BP:	blood	pressure,	PP:	pulse	
pressure,	pVO2:	peak	oxygen	consumption,	AT:	anaerobic	threshold,	VE/VCO2:	slope	relating	ventilation	rate	to	
carbon	dioxide	output,	RER:	respiratory	efficiency	ratio,	OUES:	oxygen	uptake	efficiency,	MRT:	mean	VO2	response	
time.	
Table A.2 Paired sample statistics, CHF-AF, Study 2, chapter 5, section 6.3.3.1 
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Appendix A.3 Paired samples tests - CHF-AF (Study 2, 
chapter 5, section 6.3.3.1) 
 
Paired	Samples	Test	
Group	1	(AF	CHF)	 Paired	Differences	
t	 df	
Sig.	
(2-tail)	Mean	 SD	 SE	
95%	Confidence	
Interval	
Lower	 Upper	
Resting	HR,	bpm	 15.571	 14.4952	 3.8740	 7.2022	 23.9407	 4.019	 13	 .001	
Peak	HR,	bpm	 3.3571	 13.5056	 3.6095	 -4.4408	 11.1550	 .930	 13	 .369	
Heart	rate	rise,	bpm	 -12.21	 17.894	 4.782	 -22.546	 -1.883	 -2.554	 13	 .024	
%Predicted	Peak	HR	 .0247	 .0957	 .0255	 -.0305	 .0800	 .967	 13	 .351	
Resting	systolic	BP,	mmHg	 2.4286	 18.2492	 4.8773	 -8.1082	 12.9653	 .498	 13	 .627	
Resting	diastolic	BP,	mmHg	 4.8571	 9.9139	 2.6496	 -.8670	 10.5813	 1.833	 13	 .090	
PP	(rest),	mmHg	 -2.429	 16.402	 4.384	 -11.899	 7.042	 -.554	 13	 .589	
Peak	systolic	BP,	mmHg	 -4.285	 13.8532	 3.7024	 -12.2843	 3.7129	 -1.158	 13	 .268	
Peak	diastolic	BP,	mmHg	 .1429	 7.7842	 2.0804	 -4.3516	 4.6373	 .069	 13	 .946	
PP	(peak),	mmHg	 -4.429	 12.358	 3.303	 -11.564	 2.707	 -1.341	 13	 .203	
Exercise	time,	seconds	 -48.35	 80.8699	 21.6134	 -95.0500	 -1.6643	 -2.237	 13	 .043	
pVO2,	ml/kg/min	 .4429	 1.2364	 .3305	 -.2710	 1.1568	 1.340	 13	 .203	
HR	at	AT,	bpm	 9.308	 18.250	 5.062	 -1.721	 20.336	 1.839	 12	 .091	
AT,	ml/kg/min	 1.3230	 1.93372	 .53632	 .15454	 2.49161	 2.467	 12	 .030	
VE/VCO2	slope	(peak)	 -.2214	 6.01283	 1.60700	 -3.69313	 3.25028	 -.138	 13	 .893	
VE/VCO2	slope	(AT)	 -3.800	 10.391	 2.882	 -10.079	 2.479	 -1.319	 12	 .212	
Peak	RER	 -.0635	 .10263	 .02743	 -.12283	 -.00432	 -2.318	 13	 .037	
OUE	slope	 44.142	 161.3676	 43.1273	 -49.0280	 137.3138	 1.024	 13	 .325	
MRT	 -24.62	 190.019	 84.979	 -260.560	 211.320	 -.290	 4	 .786	
MRT	recovery	 -7.700	 21.184	 12.231	 -60.324	 44.924	 -.630	 2	 .593	
O2	pulse	(peak)	 -.4000	 1.5776	 .4989	 -1.5286	 .7286	 -.802	 9	 .443	
O2	pulse	(AT)	 .333	 1.803	 .601	 -1.052	 1.719	 .555	 8	 .594	
Key:	SD:	standard	deviation,	SE:	standard	error,	HR:	heart	rate,	BP:	blood	pressure,	PP:	pulse	pressure,	pVO2:	peak	
oxygen	consumption,	AT:	anaerobic	threshold,	VE/VCO2:	slope	relating	ventilation	rate	to	carbon	dioxide	output,	
RER:	respiratory	efficiency	ratio,	OUES:	oxygen	uptake	efficiency,	MRT:	mean	VO2	response	time.	
Table A.3 Paired samples tests - CHF-AF, Study 2, chapter 5 section 6.3.3.1 
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A Research Ethics Committee established by the Health Research Authority 
 
NRES Committee Yorkshire & The Humber - Humber Bridge 
HRA NRES Centre North West 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Telephone: 0161 625 7816  
Facsimile: 0161 625 7299 
07 June 2013 
 
Dr Klaus Witte 
Senior Lecturer in Cardiology 
University of Leeds 
LIGHT building, 
Clarendon Road 
Leeds 
LS2 9JT 
 
 
Dear Dr Witte 
 
Study Title: Iatrogenic chronotropic incompetence and exercise 
tolerance in heart failure 
REC reference: 13/YH/0144 
IRAS project ID: 129113 
 
The Research Ethics Committee reviewed the above application at the meeting held on 29 May 
2013.  
 
Documents reviewed 
 
The documents reviewed at the meeting were: 
  
Document    Version    Date    
Covering Letter    22 April 2013  
Evidence of insurance or indemnity    21 September 2012  
GP/Consultant Information Sheets  1.0  24 February 2013  
Investigator CV - Dr Klaus Witte  12 January 2012  
Investigator CV - Haqeel Jamil  25 September 2012  
Other: Certificate: Patient Consent for Clinical Trials    20 June 2012  
Other: Email from MHRA confirming non-CTIMP    04 April 2013  
Participant Consent Form  1.0  27 March 2013  
Participant Information Sheet: Simus rhythm  1.0  24 February 2013  
Participant Information Sheet: Atrial fibrillation  1.0  24 February 2013  
Protocol  1.4  23 March 2013  
REC application  3.5  22 April 2013  
 
Provisional opinion 
 
The Committee is unable to give an ethical opinion on the basis of the information and 
documentation received so far.  Before confirming its opinion, the Committee requests that you 
provide the further information set out below. 
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Authority  to  consider  your  response  and  to  confirm  the  Committee’s  final  opinion  has  been  
delegated to the Chair. 
 
Further information or clarification required 
 
1. The Committee questioned why the research team had not adapted an opt-in 
approach. 
 
2. The GP Letter states the visits will be one week apart although there is no mention of 
this in the participant information sheet.  Please provide clarification and 
documentation should be amended accordingly.  
 
3. The Committee questioned why the paragraph regarding compensation was 
highlighted in bold. 
 
4. The Committee would like to see the Participant Information Sheet revised as follows:  
a. Ensure they are rewritten using the standard template which can found on the 
National Research Ethics Service website at the following link: 
http://www.nres.nhs.uk/applications/guidance/consent-guidance-and-forms/ 
paying particular attention to the first part of the form, you should also ensure 
they are rewritten in less technical language.  
b. Under  the  heading  ‘Do  I  have  to  take  part’  should  say  ‘No,  it  is  up  to  you….’ 
c. Under  the  heading  ‘What  will  happen  to  me  if  I  take  part’  this  should  be  broken  
down in to two parts, detailing what will happen at visit 1 and visit 2. 
d. Explain in more detail what will happen during the exercise test, how long each 
stage will last.  
e. Should state whether the mouthpiece used to measure the levels of oxygen 
will be used throughout the exercise programme. 
f. Explain the method of recruitment; this should be made clear and in lay 
language. 
g. Under  the  heading  ‘Who  has  reviewed  the  study?’  Should  say  the  study  has  
been reviewed by NRES Committee Yorkshire and Humber – Humber Bridge 
REC. 
 
5. The Committee suggests the Participant Information Sheets are reviewed by a patient 
representative to ensure the understandability of language. 
 
If you would find it helpful to discuss any of the matters raised above or seek further 
clarification from a member of the Committee, you are welcome to contact Diane Catterall 
whose contact details are on this letter. 
 
When submitting your response to the Committee, please send revised documentation where 
appropriate underlining or otherwise highlighting the changes you have made and giving revised 
version numbers and dates.   
 
If the committee has asked for clarification or changes to any answers given in the application form, 
please do not submit a revised copy of the application form; these can be addressed in a covering 
letter to the REC. 
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from the date of 
initial receipt of the application, excluding the time taken by you to respond fully to the above 
points.  A response should be submitted by no later than 07 July 2013. 
 
Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed on the attached sheet. 
 
Dr Ian Woollands declared that he was the lead reviewer on a previous study submitted, but it was 
agreed that as he does not have any knowledge or interest in the study he should take part in the 
review and decision making process. 
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A Research Ethics Committee established by the Health Research Authority 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK.  
 
13/YH/0144   Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
Dr Lynn Cawkwell 
Chair 
 
Email: nrescommittee.yorkandhumber-humberbridge@nhs.net 
 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments. 
 
Copy to: Clare Skinner, University of Leeds 
Mrs Amanda Burd, Research & Development LTHT 
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A Research Ethics Committee established by the Health Research Authority 
NRES Committee Yorkshire & The Humber - Humber Bridge 
Attendance at Committee meeting on 29 May 2013 
 
  
Committee Members:  
 
Name   Profession   Present    Notes    
Reverend Annabel  Barber  Lay Member  Yes    
Dr Stephen Beer  Consultant Physician  Yes    
Mrs Kate Bollington  Customer Services 
Manager  
Yes    
Dr Lynn Cawkwell  Senior Lecturer in 
Cancer Genetics  
No    
Dr Fiona Cowdell  Senior Research Fellow  Yes    
Mr Michael Davidson  Retired Senior Personnel 
Manager  
Yes    
Dr Karen Dunderdale  Chief Nurse  No    
Mr Michael Hockey  Consultant in Accident & 
Emergency  
No    
Dr Sandeep Kapoor  Consultant Paediatrician  No    
Mrs Wendy Witter  Farm Administrator   Yes    
Dr Ian Woollands  Independent Medical 
Practitioner  
Yes    
  
Also in attendance:  
 
Name   Position (or reason for attending)   
Miss Diane Catterall  Coordinator  
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A Research Ethics Committee established by the Health Research Authority 
 
NRES Committee Yorkshire & The Humber - Humber Bridge 
HRA NRES Centre North West 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Telephone: 0161 625 7816  
Facsimile: 0161 625 7299 
12 June 2013 
 
Dr Klaus Witte 
Senior Lecturer in Cardiology 
University of Leeds 
LIGHT building, 
Clarendon Road 
Leeds 
LS2 9JT 
 
 
Dear Dr Witte 
 
Study title: Iatrogenic chronotropic incompetence and exercise 
tolerance in heart failure 
REC reference: 13/YH/0144 
IRAS project ID: 129113 
 
Thank you for your email of 08 June  2013,  responding  to  the  Committee’s  request  for  further  
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Vice-Chair.  
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so.  Publication 
will be no earlier than three months from the date of this favourable opinion letter.  Should you wish 
to provide a substitute contact point, require further information, or wish to withhold permission to 
publish, please contact the Co-ordinator Miss Diane Catterall, nrescommittee.yorkandhumber-
humberbridge@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation as 
revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Non-NHS sites 
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Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations involved in 
the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where  a  NHS  organisation’s  role  in  the  study  is  limited  to  identifying  and  referring  potential  
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version    Date    
Covering Letter    22 April 2013  
Evidence of insurance or indemnity    21 September 2012  
GP/Consultant Information Sheets  1.0  24 February 2013  
Investigator CV - Dr Klaus Witte  12 January 2012  
Investigator CV - Haqeel Jamil  25 September 2012  
Other: Certificate: Patient Consent for Clinical Trials    20 June 2012  
Other: Email from MHRA confirming non-CTIMP    04 April 2013  
Participant Consent Form  1.0  27 March 2013  
Participant Information Sheet: Atrial fibrillation  1.1  07 June 2013  
Participant Information Sheet: Sinus rhythm  1.1  07 June 2013  
Protocol  1.4  23 March 2013  
REC application  3.5  22 April 2013  
Response to Request for Further Information    07 June 2013  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After  ethical  review  – guidance  for  researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including: 
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x Notifying substantial amendments 
x Adding new sites and investigators 
x Notification of serious breaches of the protocol 
x Progress and safety reports 
x Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure.  If you wish to make your views known please use 
the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
13/YH/0144                          Please quote this number on all correspondence 
 
We  are  pleased  to  welcome  researchers  and  R  &  D  staff  at  our  NRES  committee  members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 
With  the  Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
 
Dr Lynn Cawkwell 
Chair 
 
Email:nrescommittee.yorkandhumber-humberbridge@nhs.net 
 
Enclosures:  “After  ethical  review  – guidance for researchers”   
 
Copy to:  Clare Skinner, University of Leeds 
   Mrs Amanda Burd, Research & Development LTHT 
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Appendix C GP letters and Patient Information leaflets 
 
 
Dr Klaus Witte     
Division of Cardiovascular and Diabetes Research 
Leeds Institute for Genetics, Health and Therapeutics 
The LIGHT Laboratories 
University of Leeds 
Leeds LS2 9JT 
 
Date:  
 
 
 
 
Dear Dr 
 
Re:  
 
Our joint patient has consented to participate in a study examining the influence 
of heart rate on exercise capacity in patients with pacemakers. 
The study involves two exercise tests with metabolic gas exchange on 
consecutive weeks. The tests will follow the transient reprogramming of their 
pacemaker to investigate whether increases in heart rate improve acute exercise 
capacity. The pacemaker will be reprogrammed to its usual settings after each 
exercise session.  
 
The study has no implication for the daily management of the patient, and the 
pacemaker will be returned to its original settings at the end of each visit. Any 
unexpected results achieved during the tests will be forwarded to you. 
 
If you have any additional questions please do not hesitate to contact me at 0113 
3926642. 
 
Best regards 
 
 
 
Dr Klaus Witte MRCP, FESC, FACC, MD 
 
 
 
Witte K; Chronotropy – GP letter – paced; version 1.0; date 2nd November 2009 
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Information sheet – Heart failure Opt PACE 1 
 
 
Chief Investigator:  Dr. Klaus K Witte (Tel: 0113 3923131) 
 
Title: The influence of heart rate limitation on exercise tolerance in pacemaker 
patients. 
  
You are being asked to take part in a research study.  Before agreeing to 
participate in this study, it is important that you read and understand the 
following explanation of the proposed study procedures. The following 
information describes the purpose, procedures, benefits, discomforts, risks 
and precautions associated with this study. It also describes your right to 
refuse to participate or withdraw from the study at any time. In order to decide 
whether you wish to participate in this research study, you should understand 
enough about its risks and benefits to be able to make an informed decision. 
This is known as the informed consent process. Please ask the study doctor or 
study staff to explain any words you don’t understand before signing this 
consent form. Make sure all your questions have been answered to your 
satisfaction before signing the consent form. 
 
Purpose 
During exercise, heart rate increases. In some patients with heart failure, the 
increase in heart rate during exercise might be less than normal. It is possible that 
this contributes to the symptoms of heart failure during exercise and might reduce the 
amount of exercise patients can do. It is unknown to what extent heart rate increases 
contribute to the ability to exercise. 
 
Your pacemaker has as one of its programming options, the capacity to control the 
increase in your heart rate as you exercise. We want to find out if allowing the 
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pacemaker to control your heart rate, alters the amount of exercise you can do. This 
will help establish how important heart rate increases are both in normal people and 
patients with heart problems.  
 
Why have I been invited to take part? 
We have invited you take part in this study because we know your exercise tolerance 
is limited based upon your previous exercise test and because your pacemaker has 
the capacity to be programmed in different ways. 
 
Do I have to take part? 
It is up to you to decide. Dr Witte (the principle investigator) will telephone you in a 
week to allow you the opportunity to ask questions, but there are telephone numbers 
at the end of this information sheet if you wish to call yourself. We will describe the 
study and go through this information sheet, which we will then give to you. We will 
then ask you to sign a consent form to show you have agreed to take part. You are 
free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
What will happen if I take part? 
If you agree to participate in this study, we will ask you to attend the exercise 
laboratory on two occasions. At the first visit, we might repeat the  echocardiogram 
(heart scan) if you have not had one recently (within three months). On each 
occasion, we will ask you to come having had just a light breakfast. You will perform 
two study exercise tests on the treadmill. Prior to each test we will interrogate the 
pacemaker. At one of the visits we will keep the heart rate-response program 
activated in order that your heart rate increases as you exercise. For the other test 
this function will be de-activated and your heart rate increase during the test might be 
less. The order in which we do this will be randomised and neither you nor your 
doctor will know in which order your pacemaker will be reprogrammed. This is called 
‘blinding’ and is common in studies. At the end of each test the pacemaker will be 
set back to its original setting. 
 
During each test we will sample the air you breathe in and out through a mouthpiece 
to measure the levels of oxygen and carbon dioxide. This is an accurate way to 
measure your exercise capacity. We will ask you to exercise until you can no longer 
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continue and also to score your level of breathlessness at each stage during the 
exercise. 
 
Each test will take less than one hour, and we would aim to complete all of the tests 
at your convenience, but generally at the same time of the day. 
 
Risks  
The risk of any adverse event with this level of exercise is small (less than 1 percent). 
The adverse effects could include the development of chest pain, hypotension (low 
blood pressure) or arrhythmias (irregular or abnormal heart beats). A physician will 
be present to supervise all testing. 
 
Benefits 
We want to learn about why patients fell tired and breathless during exercise. It may 
be that by examining the effects of heart rate limitation on exercise we can alter the 
way medication is prescribed to patients with heart problems. You are unlikely to 
personally benefit from participation in this study. However, information learned may 
benefit future patients with heart problems. 
  
Participation 
Your participation in this study is voluntary. You can choose not to participate or you 
may withdraw at any time without affecting your medical care. There will be 
compensation for reasonable for travel expenses. 
 
Compensation 
If you become ill or are physically injured as a result of participation in this 
study, medical treatment will be provided. In no way does signing this consent 
form waive your legal rights nor does it relieve the investigators, sponsors or 
involved institutions from their legal and professional responsibilities.  
 
Part 2 
 
What if relevant new information becomes available?  
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Sometimes we get new information about your condition, based upon the results of 
the tests. If this happens, your research doctor will tell you and discuss whether you 
should continue in the study. If you decide not to carry on, your research doctor will 
make arrangements for your care to continue. If the study is stopped for any other 
reason, we will tell you and arrange your continuing care. 
 
What if I don’t want to carry on with the study? 
You can withdraw from the study but keep in contact with us to let us know your 
progress. Information collected may still be used. Any stored blood or tissue samples 
that can still be identified as yours will be destroyed if you wish. 
 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak to Dr 
Klaus Witte who will do his best to answer your questions (0113 3923131). If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for a legal 
action for compensation against Leeds University or Leeds Teaching Hospitals NHS 
Trust but you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you. 
 
Confidentiality  
All information obtained during the study will be held in strict confidence. You will be 
identified with a study number only. No names or identifying information will be used 
in any publication or presentations. No information identifying you will be transferred 
outside the investigators in this study. During the regular monitoring of your study or 
in the event of an audit, your medical record may be reviewed by the Hospital 
Research Ethics Board. We will however make your General Practitioner aware that 
you are participating in this study. 
 
What will happen to the results of the study? 
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We will inform all participants of the results of the study and the results will be 
published in international peer-reviewed journals. 
 
Who has reviewed the study? 
All research in the NHS and the University of Leeds is looked at by independent 
group of people, called a Research Ethics Committee to protect your safety, rights, 
wellbeing and dignity. This study has been reviewed and given favourable opinion by 
Leeds West Research Ethics Committee. 
 
Questions  
If you have any further questions about the study, or would like to be included in this 
research, please call Dr Klaus K Witte’s Research Team on 0113 3923131 or his 
secretary on 0113 3926285 quoting ‘Chronotropy: The influence of heart rate 
limitation on exercise tolerance in patients with chronic heart failure’ or write to Dr 
Witte at the Cardiology Department, G-floor, Jubilee Wing, Leeds General Infirmary, 
Great George Street, Leeds, LS1 3EX. 
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Information sheet – Controls Opt PACE 1 
 
 
Chief Investigator:  Dr. Klaus K Witte (Tel: 0113 3923131)  
 
Title: The influence of heart rate limitation on exercise tolerance in 
pacemaker patients. 
  
You are being asked to take part in a research study.  Before 
agreeing to participate in this study, it is important that you read 
and understand the following explanation of the proposed study 
procedures. The following information describes the purpose, 
procedures, benefits, discomforts, risks and precautions associated 
with this study. It also describes your right to refuse to participate 
or withdraw from the study at any time. In order to decide whether 
you wish to participate in this research study, you should 
understand enough about its risks and benefits to be able to make 
an informed decision. This is known as the informed consent 
process. Please ask the study doctor or study staff to explain any 
words you don’t understand before signing this consent form. Make 
sure all your questions have been answered to your satisfaction 
before signing the consent form. 
 
Purpose 
During exercise, heart rate increases. In some patients with heart failure, 
the increase in heart rate during exercise might be less than normal. It is 
possible that this contributes to the symptoms of heart failure during 
exercise and might reduce the amount of exercise patients can do. It is 
unknown to what extent heart rate increases contribute to the ability to 
exercise. 
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Your pacemaker has as one of its programming options, the capacity to 
control the increase in your heart rate as you exercise. We want to find 
out if allowing the pacemaker to control your heart rate, alters the amount 
of exercise you can do. This will help establish how important heart rate 
increases are both in normal people and patients with heart problems.  
 
Why have I been invited to take part? 
We have invited you take part in this study because we know your 
pacemaker controls your heart rate during exercise and can be 
programmed to different modes.  
 
Do I have to take part? 
It is up to you to decide. Dr Witte (the principle investigator) will 
telephone you in a week to allow you the opportunity to ask questions, 
but there are telephone numbers at the end of this information sheet if 
you wish to call yourself. We will describe the study and go through this 
information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part. You are free 
to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
What will happen if I take part? 
If you agree to participate in this study, we will ask you to attend the 
exercise laboratory on two occasions. At the first visit, we might repeat 
the  echocardiogram (heart scan) if you have not had one recently. 
(within three months). On each occasion, we will ask you to come having 
had just a light breakfast. You will perform two study exercise tests on 
the treadmill. Prior to each test we will interrogate the pacemaker. At one 
of the visits we will keep the heart rate-response program activated in 
order that your heart rate increases as you exercise. For the other test 
this function will be de-activated and your heart rate increase during the 
test might be less. The order in which we do this will be randomised and 
neither you nor your doctor will know in which order your pacemaker will 
be reprogrammed. This is called ‘blinding’ and is common in studies. At 
the end of each test the pacemaker will be set back to its original 
setting. 
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During each test we will sample the air you breathe in and out through a 
mouthpiece to measure the levels of oxygen and carbon dioxide. This is 
an accurate way to measure your exercise capacity. We will ask you to 
exercise until you can no longer continue and also to score your level of 
breathlessness at each stage during the exercise. 
 
Each test will take less than one hour, and we would aim to complete all 
of the tests at your convenience, but generally at the same time of the 
day. 
 
Risks  
The risk of any adverse event with this level of exercise is small (less 
than 1 percent). The adverse effects could include the development of 
chest pain, hypotension (low blood pressure) or arrhythmias (irregular or 
abnormal heart beats). A physician will be present to supervise all 
testing. 
 
Benefits 
We want to learn about why patients fell tired and breathless during 
exercise. It may be that by examining the effects of heart rate limitation 
on exercise we can alter the way medication is prescribed to patients 
with heart problems. You are unlikely to benefit personally benefit from 
participation in this study. However, information learned may benefit 
future patients with heart problems.  
Participation 
Your participation in this study is voluntary. You can choose not to 
participate or you may withdraw at any time without affecting your 
medical care. There will be compensation for reasonable for travel 
expenses. 
 
Compensation 
If you become ill or are physically injured as a result of participation 
in this study, medical treatment will be provided. In no way does 
signing this consent form waive your legal rights nor does it relieve 
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the investigators, sponsors or involved institutions from their legal 
and professional responsibilities.  
 
Part 2 
 
What if relevant new information becomes available?  
Sometimes we get new information about your condition, based upon the 
results of the tests. If this happens, your research doctor will tell you and 
discuss whether you should continue in the study. If you decide not to 
carry on, your research doctor will make arrangements for your care to 
continue. If the study is stopped for any other reason, we will tell you and 
arrange your continuing care. 
 
What if I don’t want to carry on with the study? 
You can withdraw from the study but keep in contact with us to let us 
know your progress. Information collected may still be used. Any stored 
blood or tissue samples that can still be identified as yours will be 
destroyed if you wish. 
 
Complaints 
If you have a concern about any aspect of this study, you should ask to 
speak to Dr Klaus Witte who will do his best to answer your questions 
(0113 3923131). If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. Details can be 
obtained from the hospital. 
 
In the event that something does go wrong and you are harmed during 
the research and this is due to someone’s negligence then you may have 
grounds for a legal action for compensation against Leeds University or 
Leeds Teaching Hospitals NHS Trust but you may have to pay your legal 
costs. The normal National Health Service complaints mechanisms will 
still be available to you. 
 
Confidentiality  
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All information obtained during the study will be held in strict confidence. 
You will be identified with a study number only. No names or identifying 
information will be used in any publication or presentations. No 
information identifying you will be transferred outside the investigators in 
this study. During the regular monitoring of your study or in the event of 
an audit, your medical record may be reviewed by the Hospital Research 
Ethics Board. We will however make your General Practitioner aware 
that you are participating in this study. 
 
What will happen to the results of the study? 
We will inform all participants of the results of the study and the results 
will be published in international peer-reviewed journals. 
 
Who has reviewed the study? 
All research in the NHS and the University of Leeds is looked at by 
independent group of people, called a Research Ethics Committee to 
protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given favourable opinion by Leeds West Research Ethics 
Committee. 
 
Questions  
If you have any further questions about the study, or would like to be 
included in this research please call Dr Klaus K Witte’s Research Team 
on 0113 3923131 or his secretary on 0113 3926642 quoting ‘The 
influence of heart rate limitation on exercise tolerance in patients with 
chronic heart failure’ or write to Dr Witte at the Cardiology Department, 
G-floor, Jubilee Wing, Leeds General Infirmary, Great George Street, 
Leeds, LS1 3EX.  
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Information sheet – Sinus rhythm Opt PACE 2 
 
Chief Investigator:  Dr. Klaus K Witte (Tel: 0113 3923131) 
 
Title: The influence of heart rate limitation on exercise tolerance in 
pacemaker patients. 
  
You are being asked to take part in a research study.  Before agreeing 
to participate in this study, it is important that you read and understand 
the following explanation of the proposed study procedures. The 
following information describes the purpose, procedures, benefits, 
discomforts, risks and precautions associated with this study. It also 
describes your right to refuse to participate or withdraw from the study 
at any time. In order to decide whether you wish to participate in this 
research study, you should understand enough about its risks and 
benefits to be able to make an informed decision. This is known as the 
informed consent process. Please ask the study doctor or study staff 
to explain any words you don’t understand before signing this consent 
form. Make sure all your questions have been answered to your 
satisfaction before signing the consent form. 
 
Purpose 
During exercise, heart rate increases. This increase in heart rate during 
exercise might be less than normal in some patients. It is possible that this 
contributes to the symptoms during exercise and might reduce the amount of 
exercise patients can do. It is unknown to what extent heart rate increases 
contribute to the ability to exercise. 
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Many of the tablets used for angina and other heart conditions are designed 
to slow the heart down. It is thought that this might adversely affect exercise 
capacity but it is not known for sure. The presence of a pacemaker allows us 
to find out whether slowing the heart rate impairs exercise capacity at no risk 
that it will go too slowly because your pacemaker has a back up rate to 
prevent this. This therefore allows us to examine the effects of heart rate 
slowing on exercise capacity and will help establish how important heart rate 
increases are in determining exercise capacity in patients and normal 
people.  
 
Why have I been invited to take part? 
We have invited you take part in this study because you have a pacemaker.  
 
 
Do I have to take part? 
Not at all. It is up to you to decide. Dr Witte (the principle investigator) or one 
of his team will telephone you in a week to allow you the opportunity to ask 
questions, but there are telephone numbers at the end of this information 
sheet if you wish to call yourself. We will describe the study and go through 
this information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part. You are free to 
withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
What will happen if I take part? 
If you agree to participate in this study, we will ask you to attend the exercise 
laboratory at Leeds General Infirmary on two occasions a week apart for 
about two hours having had no caffeine for 16 hours before your visit. 
You can eat and drink normally before you arrive except for caffeine-
containing drinks.   
 
At the first visit, we might repeat the echocardiogram (heart scan) if you 
have not had one recently (within three months).  
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At each visit, we will also first check the pacemaker to make sure that it is 
functioning normally and set the heart rate to 60 beats per minute.  
 
Once we have done this we will ask you to take a capsule that may or may 
not contain an approved medication that slows the heart down. This 
medication is routinely used in patients with angina and heart failure. Neither 
you nor the team will know whether the capsule contains the heart slowing 
medication or a blank tablet. So you may receive the medication at the first 
visit and the blank at the second, or vice-versa. This is called blinding and is 
common in studies. It is important to reduce bias when the results are 
interpreted. Our pharmacy will know in which order you received the active 
medication and the blank and these codes can be made available to any 
team caring for you subsequently.  
 
We will ask you to then wait for 90 minutes. You are welcome to bring 
something to read while you wait and you can go to the coffee shop on B-
floor of Jubilee Wing as long as you avoid caffeine-containing drinks. The 
pacemaker will provide any back up if the medication slows your own heart 
rate, and the medication is designed specifically not to lower blood pressure 
so you should not notice anything at all.  
 
When you come back, we will ask you to perform an exercise test on the 
treadmill as described below. Prior to the test we will turn down the rate of 
the pacemaker a little to a rate of 45 beats per minute. This will allow your 
heart rate to drop gradually. At the end of each test the pacemaker will be 
set back to its original setting.  
 
The exercise tests at both visits will be on a treadmill. The speed of the 
treadmill will increase gradually during the test and we will ask you to 
exercise until you can no longer continue and also to score your level of 
breathlessness at each stage during the exercise.Throughout each test we 
will continuously sample the air you breathe in and out through a mouthpiece 
to measure the levels of oxygen and carbon dioxide. This is an accurate way 
to measure your exercise capacity.  
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Each test will take about two hours of your time, and we will aim to complete 
both of the tests at your convenience, but generally at the same time of the 
day one week apart. 
 
Risks  
The risk of any adverse event with this level of exercise is small (less than 1 
percent). The adverse effects could include the development of chest pain, 
hypotension (low blood pressure) or arrhythmias (irregular or abnormal heart 
beats). A physician will be present to supervise all testing. The heart slowing 
tablet is approved for use in people with heart failure and angina and has 
few side effects. Your pacemaker will prevent the heart from going too slow. 
We do not expect there to be any lasting effects from the single dose that 
you will take at one of the visits.  
 
Benefits 
We want to learn about why patients fell tired and breathless during 
exercise. It may be that by examining the effects of heart rate limitation on 
exercise we can alter the way medication is prescribed to patients with heart 
problems. You are unlikely to benefit personally benefit from participation in 
this study. However, information learned may benefit future patients with 
heart problems. 
  
Participation 
Your participation in this study is voluntary. You can choose not to 
participate or you may withdraw at any time without affecting your medical 
care. There will be compensation for reasonable for travel expenses. 
 
Compensation 
If you become ill or are physically injured as a result of participation in this 
study, medical treatment will be provided. In no way does signing this 
consent form waive your legal rights nor does it relieve the investigators, 
sponsors or involved institutions from their legal and professional 
responsibilities.  
 
Part 2 
 
- 287 - 
What if relevant new information becomes available?  
Sometimes we get new information about your condition, based upon the 
results of the tests. If this happens, your research doctor will tell you and 
discuss whether you should continue in the study. If you decide not to carry 
on, your research doctor will make arrangements for your care to continue. If 
the study is stopped for any other reason, we will tell you and arrange your 
continuing care. 
 
What if I don’t want to carry on with the study? 
You can withdraw from the study but keep in contact with us to let us know 
your progress. Information collected may still be used.  
 
Complaints 
If you have a concern about any aspect of this study, you should ask to 
speak to Dr Klaus Witte who will do his best to answer your questions (0113 
3928106). If you remain unhappy and wish to complain formally, you can do 
this through the NHS Complaints Procedure. Details can be obtained from 
the hospital. 
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have 
grounds for a legal action for compensation against Leeds University or 
Leeds Teaching Hospitals NHS Trust but you may have to pay your legal 
costs. The normal National Health Service complaints mechanisms will still 
be available to you. 
 
Confidentiality  
All information obtained during the study will be held in strict confidence. You 
will be identified with a study number only. No names or identifying 
information will be used in any publication or presentations. No information 
identifying you will be transferred outside the investigators in this study. 
During the regular monitoring of your study or in the event of an audit, your 
medical record may be reviewed by the Hospital Research Ethics Board. We 
will make your General Practitioner aware that you are participating in this 
study. 
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What will happen to the results of the study? 
We will inform all participants of the results of the study and the results will 
be published in international peer-reviewed journals. 
 
Who has reviewed the study? 
All research in the NHS and the University of Leeds is looked at by 
independent group of people, called a Research Ethics Committee to protect 
your safety, rights, wellbeing and dignity. This study has been reviewed and 
given a favourable opinion by NRES Committee Yorkshire and Humber – 
Humber Bridge REC. 
 
Questions  
If you have any further questions about the study, or would like to be 
included in this research, please call Dr Klaus K Witte on 0113 3923131 
quoting ‘The influence of heart rate limitation on exercise tolerance in 
patients with chronic heart failure’ or write to Dr Witte at the Cardiology 
Department, G-floor, Jubilee Wing, Leeds General Infirmary, Great George 
Street, Leeds, LS1 3EX. 
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Dr Klaus Witte    
Academic Unit of Cardiovascular Medicine  
Leeds Institute for Genetics, Health and Therapeutics 
The LIGHT Laboratories 
University of Leeds 
Leeds LS2 9JT 
 
Information sheet – Atrial fibrillation Opt PACE 2 
 
Chief Investigator:  Dr. Klaus K Witte (Tel: 0113 3926642) 
 
Title: The influence of heart rate limitation on exercise tolerance in 
pacemaker patients. 
  
You are being asked to take part in a research study.  Before agreeing 
to participate in this study, it is important that you read and understand 
the following explanation of the proposed study procedures. The 
following information describes the purpose, procedures, benefits, 
discomforts, risks and precautions associated with this study. It also 
describes your right to refuse to participate or withdraw from the study 
at any time. In order to decide whether you wish to participate in this 
research study, you should understand enough about its risks and 
benefits to be able to make an informed decision. This is known as the 
informed consent process. Please ask the study doctor or study staff 
to explain any words you don’t understand before signing this consent 
form. Make sure all your questions have been answered to your 
satisfaction before signing the consent form. 
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Purpose 
During exercise, heart rate increases. This increase in heart rate during 
exercise might be less than normal in some patients. It is possible that this 
contributes to the symptoms during exercise and might reduce the amount of 
exercise patients can do. It is unknown to what extent heart rate increases 
contribute to the ability to exercise. 
 
Many of the tablets used for angina and other heart conditions are designed 
to slow the heart down. It is thought that this might adversely affect exercise 
capacity but it is not known for sure. The presence of a pacemaker allows us 
to find out whether slowing the heart rate impairs exercise capacity at no risk 
that it will go too slowly because your pacemaker has a back up rate to 
prevent this. This therefore allows us to examine the effects of heart rate 
slowing on exercise capacity and will help establish how important heart rate 
increases are in determining exercise capacity in patients and normal 
people.  
 
Why have I been invited to take part? 
We have invited you take part in this study because you have a pacemaker.  
 
Do I have to take part? 
Not at all. It is up to you to decide. Dr Witte (the principle investigator) or one 
of his team will telephone you in a week to allow you the opportunity to ask 
questions, but there are telephone numbers at the end of this information 
sheet if you wish to call yourself. We will describe the study and go through 
this information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part. You are free to 
withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive. 
 
What will happen if I take part? 
If you agree to participate in this study, we will ask you to attend the exercise 
laboratory at Leeds General Infirmary on two occasions a week apart for 
about one hour. having had no caffeine for 16 hours before your visit. 
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You can eat and drink normally before you arrive except for caffeine-
containing drinks.   
 
At the first visit, we might repeat the echocardiogram (heart scan) if you 
have not had one recently (within three months).  
 
At each visit, we will also first check the pacemaker to make sure that it is 
functioning normally. We will then slowly reduce the rate setting of the 
pacemaker to 45 beats per minute. This will allow your heart rate to drop 
gradually.  
 
At one of the visits we will keep the heart rate-response program activated in 
order that your pacemaker makes the heart beat faster as you exercise. For 
the other test this function will be de-activated and your heart rate will 
increase less during this test. The order in which we do this will be 
randomised and neither you nor your doctor will know in which order your 
pacemaker will be reprogrammed. This is called ‘blinding’ and is common in 
studies. At the end of each test the pacemaker will be set back to its 
original setting.   
 
The exercise tests at both visits will be on a treadmill. The speed of the 
treadmill will increase gradually during the test and we will ask you to 
exercise until you can no longer continue and also to score your level of 
breathlessness at each stage during the exercise.Throughout each test we 
will continuously sample the air you breathe in and out through a mouthpiece 
to measure the levels of oxygen and carbon dioxide. This is an accurate way 
to measure your exercise capacity.  
 
Each visit will take about one hour of your time, and we will aim to complete 
both of the tests at your convenience, but generally at the same time of the 
day, one week apart. 
Risks  
The risk of any adverse event with this level of exercise is small (less than 1 
percent). The adverse effects could include the development of chest pain, 
hypotension (low blood pressure) or arrhythmias (irregular or abnormal heart 
beats). A physician will be present to supervise all testing. Your pacemaker 
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will prevent the heart from going too slow. We do not expect there to be any 
lasting effects from participation in this study.  
 
Benefits 
We want to learn about why patients feel tired and breathless during 
exercise. It may be that by examining the effects of heart rate on exercise 
we can alter the way medication is prescribed to patients with heart 
problems. You are unlikely to benefit personally benefit from participation in 
this study. However, information learned may benefit future patients with 
heart problems. 
  
Participation 
Your participation in this study is voluntary. You can choose not to 
participate or you may withdraw at any time without affecting your medical 
care. There will be compensation for reasonable for travel expenses. 
 
Compensation 
If you become ill or are physically injured as a result of participation in this 
study, medical treatment will be provided. In no way does signing this 
consent form waive your legal rights nor does it relieve the investigators, 
sponsors or involved institutions from their legal and professional 
responsibilities.  
 
Part 2 
 
What if relevant new information becomes available?  
Sometimes we get new information about your condition, based upon the 
results of the tests. If this happens, your research doctor will tell you and 
discuss whether you should continue in the study. If you decide not to carry 
on, your research doctor will make arrangements for your care to continue. If 
the study is stopped for any other reason, we will tell you and arrange your 
continuing care. 
 
What if I don’t want to carry on with the study? 
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You can withdraw from the study but keep in contact with us to let us know 
your progress. Information collected may still be used.  
 
Complaints 
If you have a concern about any aspect of this study, you should ask to 
speak to Dr Klaus Witte who will do his best to answer your questions (0113 
3928106). If you remain unhappy and wish to complain formally, you can do 
this through the NHS Complaints Procedure. Details can be obtained from 
the hospital. 
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have 
grounds for a legal action for compensation against Leeds University or 
Leeds Teaching Hospitals NHS Trust but you may have to pay your legal 
costs. The normal National Health Service complaints mechanisms will still 
be available to you. 
 
Confidentiality  
All information obtained during the study will be held in strict confidence. You 
will be identified with a study number only. No names or identifying 
information will be used in any publication or presentations. No information 
identifying you will be transferred outside the investigators in this study. 
During the regular monitoring of your study or in the event of an audit, your 
medical record may be reviewed by the Hospital Research Ethics Board. We 
will make your General Practitioner aware that you are participating in this 
study. 
 
What will happen to the results of the study? 
We will inform all participants of the results of the study and the results will 
be published in international peer-reviewed journals. 
 
Who has reviewed the study? 
All research in the NHS and the University of Leeds is looked at by 
independent group of people, called a Research Ethics Committee to protect 
your safety, rights, wellbeing and dignity. This study has been reviewed and 
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given a favourable opinion by NRES Committee Yorkshire and Humber – 
Humber Bridge REC.  
. 
Questions  
If you have any further questions about the study, or would like to be 
included in this research, please call Dr Klaus K Witte on 0113 3923131 
quoting ‘The influence of heart rate limitation on exercise tolerance in 
patients with chronic heart failure’ or write to Dr Witte at the Cardiology 
Department, G-floor, Jubilee Wing, Leeds General Infirmary, Great George 
Street, Leeds, LS1 3EX. 
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Dr Klaus Witte     
Division of Cardiovascular and Diabetes Research 
Leeds Institute for Genetics, Health and Therapeutics 
The LIGHT Laboratories 
University of Leeds 
Leeds LS2 9JT 
 
5th September 2011 
 
 
 
 
Dear Dr 
 
Re:  
 
Our joint patient has consented to participate in a study exploring cardiac 
contractility. 
 
The study will involve two or three extra visits to the cardiology department 
where the patient will undergo echocardiography with the increased heart 
rate being stimulated by  their pacemaker. There are unlikely to be any 
consequences, but if you have any questions, please feel free to contact me 
through the hospital switchboard, or my secretary on 01133926642. 
 
Best regards 
 
 
Dr Klaus Witte MRCP, FESC, MD 
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Dr Klaus Witte       
Academic Unit of Cardiovascular Medicine  
Leeds Institute for Genetics, Health and Therapeutics 
The LIGHT Laboratories 
University of Leeds 
Leeds LS2 9JT 
 
Information sheet – Controls Opt PACE 3 
 
 
Chief Investigator:  Dr. Klaus K Witte (Tel: 0113 3926642) 
 
Title: Defining the optimal heart rate in chronic heart failure 
 
You are being asked to take part in a research study.  Before agreeing to 
participate in this study, it is important that you read and understand the 
following explanation of the proposed study procedures. The following 
information describes the purpose, procedures, benefits, discomforts, risks 
and precautions associated with this study. It also describes your right to 
refuse to participate or withdraw from the study at any time. In order to 
decide whether you wish to participate in this research study, you should 
understand enough about its risks and benefits to be able to make an 
informed decision. This is known as the informed consent process. Please 
ask the study doctor or study staff to explain any words you don’t 
understand before signing this consent form. Make sure all your questions 
have been answered to your satisfaction before signing the consent form. 
 
Purpose 
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We have invited you to take part in this study as a ‘control subject’. In other words 
information we get from you will be compared with information from patients with 
heart failure in order to know what is normal and what is abnormal.  
 
Chronic heart failure is a condition most people associate with a weakened heart. 
However, most patients are comfortable at rest, but develop symptoms of 
breathlessness and fatigue during activity. This might be due to the fact that in 
people with heart failure, as the heart rate increases, the power (contractility) of 
each beat, rather than increasing, as is normal, is reduced. This causes a reversal 
of the normal response to exercise, where, as activity intensifies cardiac contractile 
function reduces. This can have a major effect on patients’ ability to exercise, but 
might also contribute to long term deterioration in heart function.  
 
It is possible therefore that conventional wisdom suggesting we need to make sure 
that the heart rate goes up more in people with heart failure is wrong. It might be 
better for people with heart failure to have a lower than usual heart rate to maintain 
optimal heart contraction. 
 
We want to examine in detail the heart’s contraction in response to increases in 
heart rate. In order to do this we would like to do an echocardiogram (ultrasound of 
the heart) during three further visits to the cardiology department while your heart is 
beating faster. We will make your heart speed up either by asking you to exercise 
while lying down, during the infusion of a stimulant or while we program the 
pacemaker to beat faster. 
 
Why have I been invited to take part? 
We have invited you take part in this study because you do not have heart failure. 
 
Do I have to take part? 
It is up to you to decide. Dr Witte (the principle investigator) will telephone you in a 
week to allow you the opportunity to ask questions, but there are telephone 
numbers at the end of this information sheet if you wish to call yourself. We will 
describe the study and go through this information sheet, which we will then give to 
you. We will then ask you to sign a consent form to show you have agreed to take 
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part. You are free to withdraw at any time, without giving a reason. This would not 
affect the standard of care you receive. 
 
What will happen if I take part? 
If you agree to participate in this study, we will invite you to come to the 
Cardiology Department at Leeds General Infirmary. 
  
We will program the pacemaker to faster heart rates while we take heart 
images. The pacemaker will be reprogrammed to its usual settings once this 
visit is completed.   
 
The visit should take less than 45 minutes to complete.  
 
Risks  
The risk of any adverse event with this project is very small. You will be able to stop 
each of the tests if you develop shortness of breath or angina. An echocardiogram 
is a very safe test done routinely in the NHS.  
 
 
Benefits 
We want to learn about why patients with heart failure feel tired and breathless 
during exercise. It may be that by examining the effects of heart rate on heart 
contraction that we can tailor patients’ heart rates to them as an individual. You are 
unlikely to benefit personally benefit from participation in this study. However, 
information learned may benefit future patients with heart problems. 
 
Participation 
Your participation in this study is voluntary. You can choose not to participate or 
you may withdraw at any time without affecting your medical care. There will be 
compensation for reasonable for travel expenses. 
 
Compensation 
If you become ill or are physically injured as a result of participation in this 
study, medical treatment will be provided. In no way does signing this 
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consent form waive your legal rights nor does it relieve the investigators, 
sponsors or involved institutions from their legal and professional 
responsibilities.  
 
Part 2 
 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak to Dr 
Klaus Witte who will do his best to answer your questions (0113 3926642). If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital. 
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have grounds for a 
legal action for compensation against Leeds University or Leeds Teaching 
Hospitals NHS Trust but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you. 
 
Confidentiality  
All information obtained during the study will be held in strict confidence. You will 
be identified with a study number only. No names or identifying information will be 
used in any publication or presentations. No information identifying you will be 
transferred outside the investigators in this study. During the regular monitoring of 
your study or in the event of an audit, your medical record may be reviewed by the 
Hospital Research Ethics Board. We will however make your General Practitioner 
aware that you are participating in this study and of any important information that 
comes out of it. 
 
What will happen to the results of the study? 
We will inform all participants of the results of the study and the results will be 
published in international peer-reviewed journals. 
 
Who has reviewed the study? 
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All research in the NHS and the University of Leeds is looked at by independent 
group of people, called a Research Ethics Committee to protect your safety, rights, 
wellbeing and dignity. This study has been reviewed and given favourable opinion 
by Bradford Research Ethics Committee. 
 
Questions  
If you have any further questions about the study, or would like to be included in 
this research, please call Dr Klaus K Witte on 0113 3926642 or write to Dr Witte at 
the Cardiology Department, G-floor, Jubilee Wing, Leeds General Infirmary, Great 
George Street, Leeds, LS1 3EX. 
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Dr Klaus Witte    
Academic Unit of Cardiovascular Medicine  
Leeds Institute for Genetics, Health and Therapeutics 
The LIGHT Laboratories 
University of Leeds 
Leeds LS2 9JT 
 
Information sheet – Heart failure Opt PACE 3 
 
 
Chief Investigator: Dr. Klaus K Witte (Tel: 0113 3926642; 0113 3926285; 0113 
3923131) 
 
Title: Defining the optimal heart rate in chronic heart failure. 
 
You are being asked to take part in a research study.  Before agreeing to 
participate in this study, it is important that you read and understand the 
following explanation of the proposed study procedures. The following 
information describes the purpose, procedures, benefits, discomforts, risks 
and precautions associated with this study. It also describes your right to 
refuse to participate or withdraw from the study at any time. In order to 
decide whether you wish to participate in this research study, you should 
understand enough about its risks and benefits to be able to make an 
informed decision. This is known as the informed consent process. Please 
ask the study doctor or study staff to explain any words you don’t 
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understand before signing this consent form. Make sure all your questions 
have been answered to your satisfaction before signing the consent form. 
 
Purpose 
Chronic heart failure is a condition most people associate with a weakened heart. 
However, most patients are comfortable at rest, but develop symptoms of 
breathlessness and fatigue during activity. This might be due to the fact that in 
people with heart failure, as the heart rate increases, the power (contractility) of 
each beat, rather than increasing, as is normal, is reduced. This causes a reversal 
of the normal response to exercise, where, as activity intensifies cardiac contractile 
function reduces. This can have a major effect on patients’ ability to exercise, but 
might also contribute to long term deterioration in heart function.  
 
It is possible therefore that conventional wisdom suggesting we need to make sure 
that the heart rate goes up more in people with heart failure is wrong. It might be 
better for people with heart failure to have a lower than usual heart rate to maintain 
optimal heart contraction. 
 
We want to examine in detail the heart’s contraction in response to increases in 
heart rate. In order to do this we would like to do an echocardiogram (ultrasound of 
the heart) during two (or three) further visits to the cardiology department while your 
heart is beating faster. We will make your heart speed up either by asking you to 
exercise while lying down, during the infusion of a stimulant or (if you have a 
pacemaker) while we program the pacemaker to beat faster. 
 
Why have I been invited to take part? 
We have invited you take part in this study because you have heart failure. 
 
Do I have to take part? 
It is up to you to decide. Dr Witte (the principle investigator) will telephone you in a 
week to allow you the opportunity to ask questions, but there are telephone 
numbers at the end of this information sheet if you wish to call yourself. We will 
describe the study and go through this information sheet, which we will then give to 
you. We will then ask you to sign a consent form to show you have agreed to take 
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part. You are free to withdraw at any time, without giving a reason. This would not 
affect the standard of care you receive. 
 
What will happen if I take part? 
 
If you agree to participate in this study, we will invite you to come to the 
Cardiology Department at Leeds General Infirmary. 
  
We will program the pacemaker to faster heart rates while we take heart 
images. The pacemaker will be reprogrammed to its usual settings once this 
visit is completed.   
 
The visit should take less than 45 minutes to complete.  
 
Risks  
The risk of any adverse event with this project is very small. You will be able to stop 
each of the tests if you develop shortness of breath or angina. An echocardiogram 
is a very safe test done routinely in the NHS.  
 
 
Benefits 
We want to learn about why patients with heart failure feel tired and breathless 
during exercise. It may be that by examining the effects of heart rate on heart 
contraction that we can tailor patients’ heart rates to them as an individual. You are 
unlikely to benefit personally benefit from participation in this study. However, 
information learned may benefit future patients with heart problems. 
  
Participation 
Your participation in this study is voluntary. You can choose not to participate or 
you may withdraw at any time without affecting your medical care. There will be 
compensation for reasonable for travel expenses. 
 
Compensation 
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If you become ill or are physically injured as a result of participation in this 
study, medical treatment will be provided. In no way does signing this 
consent form waive your legal rights nor does it relieve the investigators, 
sponsors or involved institutions from their legal and professional 
responsibilities.  
 
Part 2 
 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak to Dr 
Klaus Witte who will do his best to answer your questions (0113 3926642; 0113 
3926285). If you remain unhappy and wish to complain formally, you can do this 
through the NHS Complaints Procedure. Details can be obtained from the hospital. 
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence then you may have grounds for a 
legal action for compensation against Leeds University or Leeds Teaching 
Hospitals NHS Trust but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you. 
 
Confidentiality  
All information obtained during the study will be held in strict confidence. You will 
be identified with a study number only. No names or identifying information will be 
used in any publication or presentations. No information identifying you will be 
transferred outside the investigators in this study. During the regular monitoring of 
your study or in the event of an audit, your medical record may be reviewed by the 
Hospital Research Ethics Board. We will however make your General Practitioner 
aware that you are participating in this study and of any important information that 
comes out of it. 
 
What will happen to the results of the study? 
We will inform all participants of the results of the study and the results will be 
published in international peer-reviewed journals. 
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Who has reviewed the study? 
All research in the NHS and the University of Leeds is looked at by independent 
group of people, called a Research Ethics Committee to protect your safety, rights, 
wellbeing and dignity. This study has been reviewed and given favourable opinion 
by Bradford Research Ethics Committee. 
 
Questions  
If you have any further questions about the study, or would like to be included in 
this research, please call Dr Klaus K Witte on 0113 3926642 (Research office 
numbers: 0113 3926285; 0113 3923131), or write to Dr Witte at the Cardiology 
Department, G-floor, Jubilee Wing, Leeds General Infirmary, Great George Street, 
Leeds, LS1 3EX. 
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